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Chapter 1
 
General Introduction
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The phenotype of the polycystic ovary syndrome
Polycystic ovary syndrome (PCOS) is the most common endocrine disorder among women of 
reproductive age. It has an estimated prevalence of 5-15% worldwide [1-3]. PCOS represents 
the major cause of anovulatory infertility and is associated with distressing cutaneous 
manifestations of androgen excess, such as hirsutism and acne [4,5]. Moreover, obesity as 
well as insulin resistance co-occur with the syndrome [6,7]. Hence, it is a life-long condition 
with adverse reproductive as well as metabolic implications in affected women [8]. The 
pathogenesis of PCOS is multifactorial and far from being fully understood [9,10].
Historical (dis)agreement on the definition of PCOS
PCOS was first described in 1935 by Dr. Irving F. Stein and Dr. Michael L. Leventhal, who 
evaluated seven obese patients suffering from anovulation and having enlarged ovaries [11]. 
Since their observation, several diagnostic criteria have been proposed to define PCOS (Table 1). 
In 1990, the National Institutes of Health (NIH) provided the first set of diagnostic criteria and 
defined PCOS as the co-existence of ovulatory dysfunction and hyperandrogenism [12]. The 
Rotterdam consensus meeting in 2003 recognized PCOS as a syndrome that encompasses 
a broad spectrum of signs and symptoms, including at least two of the following: ovulatory 
dysfunction, hyperandrogenism and polycystic ovarian morphology (PCOM) [4,5]. Other 
causes that mimic these features, such as congenital adrenal hyperplasia, Cushing syndrome, 
androgen-producing tumours and hyperprolactinemia, should be excluded. In 2006, the 
Androgen Excess and PCOS Society (AES) proposed the AE-PCOS criteria emphasizing that 
hyperandrogenism should be considered as the key-feature of PCOS [13]. 
 Obviously, this continuous debate regarding the definition has challenged clinical care and 
hampered research in this field because of lack of consensus. Therefore, in December 2012, 
the NIH organized the Evidence-based Methodology Workshop on PCOS [14]. During this 
meeting the PCOS definition was critically reappraised. An independent panel recommended 
maintaining the broad diagnostic criteria as formulated during the consensus meeting held in 
2003 in Rotterdam [4,5]. 
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Table 1 | Diagnostic criteria for PCOS and accompanying component phenotypes (1-2-3) and 
phenotype groups (A-B-C-D).
Phenotype groups NIH 1990 Rotterdam 2003 AE-PCOS 2006
A
1. Oligo-anovulation
+ + +2. Hyperandrogenism and/or hirsutism
3. Polycystic ovarian morphology
B
1. Oligo-anovulation
+ + +
2. Hyperandrogenism and/or hirsutism
C
2. Hyperandrogenism and/or hirsutism
+ +
3. Polycystic ovarian morphology
D
1. Oligo-anovulation
+
3. Polycystic ovarian morphology
NIH, National Institute of Health; AE-PCOS, Society of Androgen Excess and Polycystic Ovary Syndrome. Modified from Azziz 
et al. The Androgen Excess and PCOS Society criteria for the polycystic ovary syndrome: the complete task force report [15].
Variability within the PCOS phenotype
PCOS is usually diagnosed during the early reproductive years. It is a life-long lasting condition 
with substantial variation of symptomatology regarding reproductive, metabolic and 
cardiovascular health throughout a woman’s life (Figure 1) [8]. During their reproductive years, 
patients with PCOS suffer from oligo-ovulation or anovulation resulting in decreased fertility 
[16,17]. Moreover, PCOS seems to be associated with an increased risk of complications during 
pregnancy, such as gestational diabetes, pregnancy-induced hypertension and preeclampsia 
[18]. Ovarian and/or adrenal hyperandrogenism is present in 50-80% of all patients, depending 
on which diagnostic criteria are used [19,20]. Hirsutism is the most common clinical sign of 
hyperandrogenemia. Acne and alopecia androgenetica are present to a lesser extent [21]. 
 The metabolic disturbances become more pronounced with increasing age. Insulin 
resistance and hyperinsulinemia occur in 50-70% of all patients with PCOS [7,22]. Subsequently, 
patients are at increased risk of developing impaired glucose tolerance and type 2 diabetes 
mellitus [23]. Moreover, PCOS is associated with dyslipidemia, increased carotid intima-media 
thickness, increased coronary artery calcification and subclinical cardiovascular disease 
[24-27]. Overweight or obesity is present in up to 80% of all patients [6]. It aggravates the 
metabolic co-morbidities associated with PCOS [28]. Lifestyle interventions and weight-
loss not only improve the metabolic disturbances, but also ameliorate the reproductive 
phenotype [29]. However, obesity does not fully account for the burden of these long-term 
health complications. Patients with PCOS also experience these complications independently 
of their BMI levels [30]. Adequately powered long-term follow-up studies of PCOS patients 
monitoring hard endpoints of cardiovascular risk, such as stroke, myocardial infarction, and 
mortality, have not been conducted yet. Hence, although suggested by surrogate makers, 
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it is still unclear whether or not patients with PCOS encounter a substantially increased risk 
of developing cardiovascular events. Moreover, these increased risks might be limited to 
patients with certain phenotypic characteristics. Therefore, after the diagnosis PCOS has 
been established, considerable differences amongst these patients might be present in terms 
of treatment-outcome, associated co-morbidities and the impact of the long-term health 
sequelae.
Figure 1 | The phenotype of PCOS varies throughout life.
Cycle irregularities
Hirsutism, acne
Pregnancy complications
Infertility
Obesity
Type 2 Diabetes Mellitus
Cardiovascular Disease
REPRODUCTIVE DISORDERS
CARDIOMETABOLIC DISEASE
increasing age
Modified from Fauser and Balen ESHRE/ASRM PCOS Consensus meeting [8].
Pathogenesis of PCOS
The following paragraph provides a global overview of the dynamic processes occurring 
during an ovulatory menstrual cycle [31,32]. Moreover, it describes the potential underlying 
mechanisms of PCOS. However, these mechanisms are far from fully understood. Schematic 
representation of these processes is displayed in Figure 2.
Ovarian physiology
The menstrual cycle is an orderly sequence of events regulated by hypothalamic, pituitary and 
gonadal hormones. Normal reproductive function involves monthly follicular development, 
ovulation and preparation of the endometrium for implantation. The neurons of one of the 
basal nuclei in the hypothalamus control the pulsatile release of gonadotropin-releasing 
hormone (GnRH). In response to a slow GnRH pulse frequency, the anterior pituitary 
produces follicle-stimulating hormone (FSH). During the follicular phase, i.e. the first part of 
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the menstrual cycle, FSH gradually increases and is responsible for follicular development in 
the ovary. FSH stimulates the secretion of inhibin B from the granulosa cells. In response to 
luteinizing hormone (LH), the theca cells are stimulated to produce androgens that can then 
be converted, through FSH-induced aromatization, to estrogens in the granulosa cells. The 
secretion of inhibin B and estrogens rises with increasing diameter of follicles and suppresses 
further release of FSH by the pituitary via a negative feedback mechanism. The influence of 
estrogens on LH release varies with concentration and duration of exposure. At low levels, 
estrogens have a negative feedback on LH release. However, when estrogen levels reach a 
certain threshold, this negative feedback changes into a positive feedback triggering an 
increase in GnRH pulse frequency resulting in the LH surge. LH initiates luteinisation of the 
granulosa cells and synthesis of progesterone. Subsequently, the follicle ruptures, ovulation 
occurs and the corpus luteum is formed. The corpus luteum produces progesterone, inhibin A 
and estrogens. Elevated progesterone levels inhibit LH secretion through negative feedback 
at both the hypothalamic as well as the pituitary level. Inhibin A suppresses FSH production 
from the pituitary during the early and mid-luteal phase. In early pregnancy, human chorionic 
gonadotropin (hCG) rescues the corpus luteum. However, when a pregnancy does not occur, 
LH levels fall giving rise to the demise of the corpus luteum. This in turn results in a decrease in 
progesterone, inhibin A and estrogen levels. The decrease in inhibin A removes a suppressing 
influence on FSH secretion in the pituitary. The decrease in estrogen and progesterone results 
in an increase in GnRH pulse frequency. This increase in pulse frequency in combination with 
the removal of the suppressing influence on the pituitary leads to an increase in FSH levels 
allowing a new cohort follicles to be recruited. 
 Granulosa cells of primary and small antral follicles produce Anti Müllerian Hormone (AMH) 
[33]. AMH inhibits initial recruitment of primordial follicles and attenuates follicle sensitivity 
to FSH, thereby affecting folliculogenesis [33]. AMH production steadily declines as follicles 
grow. This decline appears to be an important requirement for dominant follicle selection and 
progression to ovulation [34]. 
 The ovaries as well as the adrenal glands contribute to the androgen production in 
women. Dehydroepiandrosterone (DHEAS) is almost exclusively produced by the adrenal 
gland. DHEAS can be converted to dehydroepiandrosterone (DHEA), which is the precursor for 
biologically active androgens and estrogens [35]. One of these biologically active androgens 
is testosterone. The ovary is responsible for approximately half of the circulating testosterone, 
whereas the remaining part is produced by the adrenal gland. In the circulation testosterone is 
bound to albumin and sex-hormone binding globulin (SHBG), only around 1% of testosterone 
circulates freely and is biologically active in women. 
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Figure 2 | Schematic presentation of the processes and accompanying fluctuations of hormone levels 
during a regular ovulatory menstrual cycle (on the left) and a anovulatory cycle in PCOS (on the right).
The arrows represent a stimulus, unless otherwise indicated (-). The thicker arrows in the right figure represent an increase in 
production in PCOS compared to the production during an ovulatory menstrual cycle, whereas the dotted arrows indicate 
a decrease in hormone production. GnRH, Gonadotropin Releasing Hormone; FSH, Follicle Stimulating Hormone; LH, 
Luteinizing Hormone; AMH, Anti Müllerian Hormone; SHBG, Sex Hormone Binding Globulin; DHEAS, Dehydroepiandosterone-
sulphate. The processes are described in more detail in the text.
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Pathophysiology of PCOS
The pathophysiology of PCOS is far from fully understood. However, over the last decades 
potential underlying mechanisms have been proposed. An increased GnRH pulse frequency 
resulting in LH hypersecretion has been reported [36-38]. As stated, LH stimulates the 
ovarian theca cells to produce androgens, such as testosterone. Because of a relative FSH 
deficiency, testosterone is incompletely aromatized by the granulosa cells, resulting in 
hyperandrogenemia. There seems also to be an increase in the activity of steroidogenic 
enzymes in polycystic ovaries, which further adds to the androgen excess [39]. Moreover, 
although the ovaries are the main source of androgen excess in PCOS, also the adrenal glands 
contribute to the existing hyperandrogenism. Up to 50% of the patients with PCOS also have 
elevated DHEAS levels [40]. These elevated androgen levels can lead to symptoms of androgen 
excess such as hirsutism, acne and alopecia. 
 In PCOS, hyperandrogenism, hyperinsulinemia and altered intraovarian paracrine 
signalling can disrupt follicle growth [9,41]. The gonadotropin-independent development of 
preantral follicles seems disordered in PCOS [41]. Moreover, FSH does not seem to increase to 
the threshold levels which are required to stimulate normal follicular maturation resulting in 
follicular arrest [41,42]. The accumulation of small antral follicles result in elevated AMH levels 
[34,43,44]. These increased AMH levels seem to add to the anovulation in PCOS by reducing 
both primordial follicle growth and follicle sensitivity to FSH [34]. 
 Hyperinsulinemia aggravates the androgen excess and ovarian follicular arrest. Insulin 
acts synergistically with LH on theca cells to stimulate ovarian androgen production [45,46]. 
Moreover insulin suppresses hepatic production of SHBG, resulting in higher levels of 
bioavailable testosterone [47]. In turn, androgens can produce insulin resistance by directly 
influencing insulin action in skeletal muscle and adipocytes, by altering adipokine secretion 
and by increasing visceral adiposity. However, these androgen effects on insulin action are 
modest [7].
Genetics of PCOS
PCOS is considered to be a so-called complex genetic disorder. Complex genetic disorders 
are diseases of which the etiology is explained by the effects of genetic and environmental 
factors. PCOS as well as its associated co-morbidities cluster within families. Approximately 
20-40% of the first-degree female family members of patients with PCOS are also diagnosed 
with the syndrome [48,49]. Moreover, associated co-morbidities, such as hyperandrogenemia, 
hyperinsulinemia and disturbed insulin secretion, also cluster within these families of patients 
with PCOS [50-53]. Finally, PCOS seems to be more common amongst sisters of monozygotic 
twin pairs compared to dizygotic twins indicating a high degree of heritability in patients 
with PCOS [54]. Heritability (h2) is the proportion of the total phenotypic variation that can be 
attributed to additive genetic effects. For PCOS the heritability is estimated to be around 65% 
[54], indicating that genetic factors largely determine PCOS susceptibility.
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Genetic variation in humans
The human genome is made up of Deoxyribo Nucleic Acid (DNA), which consists of a long 
sequence of four types of nucleotide bases, i.e. adenine (A), cytosine (C), guanine (G), and 
thymine (T) typically intertwined with each other [55] (Figure 3A). These nucleotides bind in 
pairs, i.e. A with T and C with G, resulting in so-called double-stranded helices. The complete 
DNA sequence of the human genome consists of about 3,3 billion base pairs. Approximately 
3% of the genome consists of coding sequences [56]. It is estimated that approximately 30,000 
to 40,000 protein-coding genes exist [57-59]. DNA is transcribed into messenger Ribo Nucleic 
Acid (mRNA), which encodes for amino acids that can built up a protein. This process is called 
translation. Changes in the DNA sequences can result in alterations in protein function and 
thereby affecting disease risk [56]. 
Figure 3 | Single Nucleotide Polymorphisms and genetic association studies. 
controlscases
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Nucleotide
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Panel A shows DNA which is packed into chromosomes as two long twisted strands. Panel B shows an a G to T SNP. Panel C 
represent the principle used in genetic association studies: the SNP is considered to be associated with the disease, when it is 
more frequently present in individuals with the disease (cases) compared to individuals without the disease (controls). DNA, 
Deoxyribo Nucleic Acid; A, adenine; C, cytosine; G, guanine; T, thymine; SNP, Single Nucleotide Polymorphism.
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The genome of any two unrelated individuals is for 99.9% identical. Consequently, the remaining 
0.1% of the genome is responsible for differences between two unrelated individuals. If the 
DNA sequence at a given locus, i.e. an unique chromosomal location defining the position of a 
gene or DNA sequence, varies in the population, each different version is called an allele [60]. If 
there are two alleles at a given locus, the allele that is less common in the population is the minor 
allele. Many types of DNA sequence variations exist (56). The most common DNA variation is 
the Single Nucleotide Polymorphism (SNP), which constitutes a single base variation (Figure 
3B). A SNP is defined as a locus at which two alleles are present, both at a frequency of at least 
1% [61]. It is estimated that > 50 million SNPs are present across the human genome [62]. SNPs 
in protein-coding regions are either non-synonymous or synonymous, depending on whether 
they do or do not have a modifying effect on the amino acid sequence of the gene’s protein 
product [57,60]. Intronic and intergenic SNPs lie in the non-coding regions of the genome. All 
types of SNPs can contribute to susceptibility of disease [60]. 
Genetic association studies
Candidate-gene studies versus genome-wide approach
Genetic association studies aim to detect the association of a disease with a SNP. If a certain 
SNP is more frequently present in individuals with the disease compared to individuals without 
the disease, the SNP is considered to be associated with the disease (Figure 3C). Two types of 
methods to study such associations exist: the candidate gene study and the genome-wide 
association study (GWAS). Using candidate gene analysis, SNPs in genes are selected based 
on prior knowledge of biological mechanisms underlying the disease. In case of a GWAS 
the association of a trait or disease with over 500,000 SNPs is tested using a hypothesis-free 
approach. The level of statistical significance required to establish association for a common 
variant in GWASs is < 5 × 10-8, applying Bonferroni correction for approximately 1,000,000 
independent genomic markers (0.05/1 million; genome-wide significant, gws). GWAS has 
proven its value for implicating novel biological pathways in disease pathogenesis [63].
Correlation of genetic variants
The identified SNP may be the causal variant, but is more likely to be highly correlated to the 
actual causal variant due to lack of genetic recombination between the two. This concept of 
non-random association of alleles at 2 or more loci due to infrequent recombination events, is 
called linkage disequilibrium (LD). Using LD it is possible to select optimized subsets of SNPs, 
in such a way that all preferred variants are either directly genotyped or are strongly correlated 
with the genotyped SNP [57]. Indirect association mapping relies on LD in the sense that the 
functional variant needs not to be studied at all, as long as one measures a variant that is in LD 
with this functional variant [64]. The index r2 is used as a measurement of LD and is the square 
of the conventional correlation coefficient of the relationship between the allele at the typed 
16 | Chapter 1
locus and the allele at the causal locus. A high r2, i.e. r2 = 1, indicates that the alleles can predict 
each other completely [65]. Using the concept of r2 it is possible to predict genotypes that are 
not directly measured. The term for this process is genotype imputation [66]. Imputing against 
a reference genotype dataset, such as HapMap or 1000Genomes, increases the number of 
SNPs that can be tested for association. 
Meta-analysing genetic data
Meta-analysis combines the results of different studies investigating the same research 
question in order to identify patterns among the study results. The aim of the meta-analysis 
in genetic epidemiology is to evaluate the diversity, i.e. so-called heterogeneity, among the 
results of the different studies and estimating a pooled effect of the trait-associated SNP [67]. 
Moreover, by meta-analysing data a more robust indication of whether or not a certain genetic 
variant is really of importance in the disease under study might be achieved. Depending on 
the amount of heterogeneity, either a fixed or random effects meta-analysis is used. A fixed 
effects meta-analysis assumes that the genetic effects are similar across the combined studies 
and that all observed differences are due to chance [68]. Random effects calculations assume 
that due to true differences because of various reasons, the estimates of the genetic effects 
may vary across different studies [67]. The between-studies heterogeneity can be measured 
by the metric I2, which is the percentage of total variation across studies due to heterogeneity 
beyond chance [67,69]. The I2 ranges from 0 to 100%. An I2 exceeding 25% is considered 
to indicate moderate to large heterogeneity [67]. Therefore, when an I2 > 25% is present, a 
random effects meta-analysis is used in this thesis to combine data from different studies. 
PCOS as a complex genetic disorder
Candidate gene studies
Hitherto, candidate gene studies have been the predominant approach used in PCOS genetics 
(for review see [9,70-73]). In these studies over a hundred candidate genes have been studied, 
mainly focussing on candidate genes selected from logical pathways involved in or regulating 
gonadotropin secretion, steroid synthesis and insulin signalling [70]. Varying diagnostic 
criteria, small sample sizes in many studies, and more importantly, the lack of positive 
replication studies along with the broad phenotype of PCOS have hindered progress in this 
field [9,72]. Although, in general, this candidate gene approach has not been tremendously 
successful, some very promising candidate genes have been identified. The most thoroughly 
investigated functional candidates for PCOS susceptibility are the fibrillin (FBN3) gene, which is 
involved in TGF-β signalling; genes involved in insulin signalling and type 2 diabetes mellitus; 
and obesity genes [71]. 
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Genome-wide association studies
Obviously, candidate gene selection is also limited by our incomplete knowledge of the 
pathophysiology of PCOS [70]. Three GWASs of PCOS have been published: two in Han-
Chinese patients and one in Korean patients with PCOS (74-76). The results of these GWASs are 
presented in Figure 4 and Table 2.
Figure 4 | Manhattan plot of the results of the association analysis of the GWASs in the Han-Chinese 
PCOS patients.
Results of the studies by Chen et al. [74] and Shi et al. [76]. On the Y-axis the logarithm of the P value is plotted. The 
chromosomes are plotted on the X-axis. Every dot represents a SNP.
The LHCGR and FSHR gene are plausible PCOS candidate genes due to their role in follicular 
development and ovarian physiology. SNPs mapping to the FSHR gene has been previously 
reported to be associated with PCOS [77]. In addition, the GWASs also provided new directions 
to further unravel underlying biological mechanisms of PCOS. GTF2A1L is highly expressed 
in adult testis and may play a role in spermatogenesis [78]. The THADA (thyroid adenoma 
associated) region has previously been associated with type 2 diabetes mellitus in Europeans 
[79]. Genetic variants mapping to the DENND1A (DENN domain-containing protein 1A) locus 
might influence the pathogenesis of PCOS through misregulation of endoplasmic reticulum 
aminopeptidase 1 (ERAP1) [74]. The other identified PCOS association signals were mapping 
to genes related to insulin signalling, sexual hormone function, type 2 diabetes calcium 
signalling and endocytosis. The GWAS in Korean patients with PCOS did not reveal genome-
wide significant hits [75].
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Table 2 | Results of GWASs in PCOS.
Discovery set (n) Replication set (n) chr Nearby genes Ethnic origin
Cases Controls Cases Controls
Chen et al.1 744 895 3338 5792 2 GTF2A1L 
LHCGR
Han-Chinese
THADA
9 DENND1A
Shi et al.2 2254 2911 8226 7578 2 FSHR Han-Chinese
9 C9orf3
11 YAP1
12 RAB5B, 
SUOX
HMGA2
16 TOX3
19 INSR
20 SUMO1P1 
ZNF217
Hwang et al.3 1741 967 - - no SNP with p-value < 5 x 10-8 Korean
GWAS, Genome Wide Association Study; n, number; Chr, chromosome; SNP, single Nucleotide Polymorphism. 
1 Chen ZJ, Zhao H, He L, et al. Genome-wide association study identifies susceptibility loci for polycystic ovary syndrome on 
chromosome 2p16.3, 2p21 and 9q33.3. Nature genetics. 2011; Jan; 43: 55-9.
2 Shi Y, Zhao H, Cao Y, et al. Genome-wide association study identifies eight new risk loci for polycystic ovary syndrome. 
Nature genetics. 2012; Sep; 44: 1020-5.
3 Hwang JY, Lee EJ, Jin Go M, et al. Genome-wide association study identifies GYS2 as a novel genetic factor for polycystic 
ovary syndrome through obesity-related condition. J Hum Genet. 2012; Oct; 57: 660-4.
Large phenotypic differences are present among patients with PCOS from various ethnicities 
[80,81]. Therefore, genetic variants might act differently in PCOS patients of various ethnic 
groups. The association of SNPs mapping to the THADA, DENND1A and FSHR susceptibility 
loci in Chinese patients with PCOS have been replicated in patients from Northern European 
descent (82-84). However, more studies are needed to further determine the role of genetic 
factors in explaining ethnic differences in PCOS [8].
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Aims of the thesis
The variety of phenotypic characteristics accompanying PCOS might be partly reflected by 
the influence of genetic factors, environmental factors and ethnic origin. Subsequently, not all 
patients with PCOS encounter similar health risks.
The aims of this thesis were: 
1. to determine which patients, based on specific characteristics within the broad PCOS 
phenotype, have the highest risk of developing long-term health complications,
2. to identify genetic variants associated with PCOS based on candidate-gene analysis as well 
as on hypothesis-free approach using GWAS
 
The first part in this thesis focusses on identification of patients with a high risk of developing 
adverse long-term health implications. The second part focusses on identification of additional 
PCOS-loci using the candidate gene and genome-wide association approach to obtain novel 
biological insights into the pathogenesis of PCOS and the mechanisms of its phenotypic 
heterogeneity. Moreover, the studies in this thesis address the cross-ethnic effect of genetic 
variants and the influence of genetic ancestry on phenotypic characteristics of PCOS.
Outline of the thesis
Chapter two defines the risk of cardiometabolic complications in patients with PCOS based on 
the presence of hyperandrogenism. Chapter three determines the mortality risk of parents of 
patients with PCOS, especially of parents with type 2 diabetes mellitus. Chapter four includes 
the results of three candidate-gene studies for PCOS. Chapter five describes the preliminary 
results of a genome-wide association study in patients with PCOS of European descent. 
 Chapter six assesses the effects of genetic variants identified in Chinese patients with 
PCOS in patients from Northern European descent. Chapter seven compares the self-reported 
ethnicity of patients with PCOS to their genetic ancestry based on genome-wide genetic data. 
Moreover, it determines which of these two is the best predictor for phenotypic characteristics 
of the syndrome. 
 Chapter eight summarizes the results of this thesis, places them in broader context and 
discusses the implications for clinical practice as well as the directions for future research.
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Abstract
Context: Different sub-phenotypes within Polycystic Ovary Syndrome (PCOS) are associated 
with differences in cardiometabolic presentation.
Objective: To compare the known markers for cardiometabolic disease and cardiovascular 
risk factor (CVRF) distribution of patients with hyperandrogenic PCOS, with patients having 
ovulatory dysfunction and polycystic ovarian morphology (PCOM).
Setting: Specialized reproductive outpatient clinics of the Erasmus Medical Centre Rotterdam 
and the University Medical Centre Utrecht, the Netherlands. 
Patients or Other Participants: 2288 distinctly phenotyped reproductive-aged patients with 
PCOS were included.
Intervention(s): Women with a suspicion of oligo- or anovulation underwent a standardized 
screening consisting of a systematic general medical, reproductive and family history taking, 
anthropometric measurements, transvaginal ultrasonography, extensive endocrine and 
metabolic laboratory assessment.
Main Outcome Measure(s): Differences in cardiometabolic profile and CVRF prevalence 
between different PCOS sub-phenotypes, i.e. obesity and overweight, hypertension, 
hyperglycemia, insulin resistance, dyslipidemia and the metabolic syndrome (MetS). 
Results: Patients with hyperandrogenic PCOS presented with a poor cardiometabolic profile 
upon screening, resulting in a higher prevalence of CVRFs such as obesity and overweight 
(P <0.001), insulin resistance (P <0.001) and MetS (P <0.001), compared with patients with 
non-hyperandrogenic PCOS. No significant differences in cardiometabolic risk factors, except 
for overweight or obesity, were observed amongst the different hyperandrogenic PCOS 
characteristics.
Conclusions: Patients with hyperandrogenic PCOS have an unfavourable cardiometabolic 
profile and higher prevalence of cardiovascular risk factors compared to patients with 
ovulatory dysfunction and PCOM. Whether these risk factors result in cardiovascular disease 
and actual cardiovascular events should be determined in prospective follow-up studies. 
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Introduction
The Polycystic Ovary Syndrome (PCOS) is the most common endocrinopathy in women of 
reproductive age. The prevalence of PCOS has been estimated to be up to 12% depending on 
which diagnostic criteria are used [1]. Ever since Stein and Leventhal first described a series 
of women with oligmenorrhea or amenorrhea and polycystic ovaries in 1935 [2], there has 
been an ongoing international debate about the legitimacy of various criteria which are used 
to diagnose PCOS. In the absence of an universally accepted definition the 1990 National 
Institute of Health (NIH) criteria were introduced, delineating PCOS as a syndrome of both 
chronic anovulation and clinical/biochemical signs of hyperandrogenism (with exclusion of 
other etiologies) [3].
 During the years thereafter the broad clinical expression of PCOS gave rise to the 
perception that no single criterion was mandatory in diagnosing PCOS resulting in the 2003 
Rotterdam consensus criteria [4,5]. According to these criteria, PCOS is diagnosed when at 
least two of the following criteria are present: ovulatory dysfunction (oligo- or amenorrhea), 
hyperandrogenism (either biochemical or clinical being hirsutism) and/or polycystic ovarian 
morphology (PCOM). With the introduction of these broadened criteria, the prevalence of 
PCOS amongst women with normogonadotropic normo-oestrogenic anovulation as well as 
amongst women in the general population, increased considerably [6].
 Over the years evidence has accumulated that the presence of hyperandrogenism is 
associated with an increased prevalence of metabolic disturbances in patients with PCOS [7-11]. 
Therefore, in response to the introduction of the Rotterdam criteria, it has been postulated 
that PCOS should indeed be primarily considered a disorder of hyperandrogenemia [12]. It 
may even be justified to distinguish the hyperandrogenic PCOS phenotype as a separate 
entity given its profound metabolic implications, and assign this phenotype with a new name 
since the current denomination is unsatisfying for both clinicians and patients [13].
 It remains to be elucidated to what extent women with ovarian dysfunction and polycystic 
ovarian morphology, face the same long term health implications as “classic” hyperandrogenic 
patients with PCOS. At the NIH Evidence-based Methodology Workshop on PCOS in December 
2012 an independent expert panel recommended maintaining the broad diagnostic 
Rotterdam criteria, along with the usage of distinct phenotyping in PCOS [14]. Furthermore, 
the panel underlined several future research priorities, one of which is the determination of 
the prevalence of cardiometabolic implications of the individual PCOS phenotypes, as was 
also stressed at the previous ESHRE-ASRM endorsed, third consensus meeting [15].
 The aim of the current large cohort study was to compare the known markers for 
cardiometabolic disease as well as the cardiovascular risk factor (CVRF) distribution, amongst 
women with the hyperandrogenic PCOS sub-phenotypes and those with the ovulatory 
dysfunction and polycystic ovarian morphology (PCOM) phenotype. 
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Materials and Methods
Study population
Women diagnosed with PCOS according to the Rotterdam criteria, who were screened at the 
outpatient clinics of either the Erasmus Medical Centre Rotterdam or the University Medical 
Centre Utrecht between January 1st 2004 and May 1st 2013, were eligible for inclusion in this 
study. This screening was performed by trained professionals according to a standardized 
protocol that has been previously described in great detail [6,9]. The screening procedure 
started with a thorough general medical, reproductive and family history taking, which was 
followed by anthropometric measurements including height, weight, body mass index (BMI), 
systolic and diastolic blood pressure (BP), waist circumference (WC), hip circumference and the 
measurement of hirsutism using the Ferriman-Gallwey (FG) score. Furthermore, a systematic 
transvaginal ultrasonography was performed assessing double endometrial thickness, ovarian 
volume and the total number of antral follicles, measuring 2-10 mm. Finally, an extensive 
fasting endocrine and metabolic profile was assessed. 
 PCOS was diagnosed according to the Rotterdam criteria; i.e. requiring the presence of at 
least two out of the following three criteria: ovulatory dysfunction, androgen excess and/or 
polycystic ovarian morphology [4,5]. Ovulatory dysfunction was defined as oligomenorrhea, 
i.e. mean bleeding interval between 35 days – 182 days, or amenorrhea, i.e. absence of 
menstrual bleeding for more than 182 days. We defined androgen excess as a FG score 
≥ 9, and/or a free androgen index > 4.5 [FAI: (Testosterone / SHBG) x 100)] [16]. An ovary was 
designated as polycystic if the volume exceeded 10 cm³ and/or the follicle count (2-10 mm) 
was ≥ 12 [17].
 Normogonadotropic normoestrogenic patients who underwent the aforementioned 
standardized screening and were diagnosed with PCOS, were classified into one of the four 
potential PCOS phenotypes:
1. Androgen Excess + Ovulatory Dysfunction (AE + OD)
2. Androgen Excess + Polycystic Ovarian Morphology (AE + PCOM)
3. Ovulatory Dysfunction + Polycystic Ovarian Morphology (OD + PCOM)
4. Androgen Excess + Ovulatory Dysfunction + Polycystic Ovarian Morphology (AE + OD + 
PCOM).
Patients had to be aged between 18-45 years upon the moment of screening. Patients were 
excluded if they were not fasting at the time of the blood withdrawal.
Endocrine and metabolic assessment
With respect to cardiometabolic presentation we collected information on BMI, WC, systolic 
and diastolic BP. Furthermore, we selected the following endocrine and metabolic laboratory 
parameters for comparative analysis between PCOS sub-phenotype groups: FSH, LH, estradiol, 
testosterone, dehydroepiandrosterone sulphate (DHEAS), SHBG, insulin, glucose, total 
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cholesterol (TC), triglycerides (TG), high-density lipoprotein cholesterol (HDL-C). Low-density 
lipoprotein cholesterol (LDL-C) was calculated using the Friedewald formula [LDL-C = TC − 
HDL-C − (TG/5)] [18]. Insulin resistance was assessed using the homeostasis model assessment 
(HOMA-IR): fasting glucose(mmol/L) x fasting insulin(mU/L) / 22.5 [19]. During the study period 
both centres used various assays to measure these parameters. Details about the used assays 
and their mutual comparability are available in Supplementary Table 1. Uniformity between 
different assays was assured by using annual calibration data from the Dutch Foundation for 
quality assessment in clinical laboratories (SKML) , which allowed combined interpretation of 
laboratory results from both centres. All data were recalculated accordingly. 
Assessment of cardiometabolic profile
We compared the presence of the following CVRFs between different PCOS sub-phenotype 
groups: obesity (BMI ≥ 30 kg/m2), overweight (BMI 25-29.9 kg/m2), hypertension 
(BP ≥ 140/90 mmHg), increased WC (WC ≥ 88 cm), hyperglycemia (fasting glucose 
> 6.0 mmol/L), insulin resistance (1/HOMA-IR < 0.47), dyslipidemia (TC ≥ 5.0 mmol/L, 
TG > 1.7 mmol/L, LDL-C ≥ 3.0 mmol/L, HDL-C < 1.2 mmol/L) and presence of the metabolic 
syndrome (MetS) (≥ 3 of any of these clinical features; WC ≥ 88 cm, fasting glucose ≥ 5.6 mmol/L, 
BP ≥ 130/85 mmHg, HDL < 1.3 mmol/L, TG ≥ 1.7 mmol/L) [20-23].
Statistical analyses
Lipid profile assessment was only performed in a subset of the patients screened at the 
Erasmus Medical Centre. To avoid any potential bias that may occur in complete-case analysis, 
multiple imputations (10×) were applied using observed patient characteristics [24]. Missing 
data were imputed using a logistic regression model. Baseline variables were expressed as 
means with standard deviation or numbers with percentage. Multiple imputation and other 
statistical analyses were performed using SPSS statistics version 20.0.
 For the first analyses, we compared the hyperandrogenic patients with PCOS (phenotypes: 
AE + OD, AE + PCOM and AE + OD + PCOM) to the non-hyperandrogenic patients with PCOS 
(phenotype OD + PCOM) for potential variations in ethnic distribution and differences in 
CVRF prevalence. Univariate logistic regression was used to compare the endocrine and 
cardiometabolic characteristics of hyperandrogenic to those of non-hyperandrogenic patients 
with PCOS. Subsequently, multivariate logistic regression analyses were performed to correct 
for potential confounders including age, BMI, smoking and ethnicity. A P value of < 0.05 was 
considered to be statistically significant. Moreover, in a subgroup analysis we compared 
the three individual hyperandrogenic sub-phenotype groups to detect differences in CVRF 
prevalence. In pairwise comparisons between any two hyperandrogenic sub-phenotype 
groups, a Bonferroni corrected P value for multiple testing < 0.0167 (0.05/3) was considered 
statistically significant.
30 | Chapter 2
Ethical approval
This study was reviewed by the local Institutional Review Board (IRB) Committee of both the 
Erasmus Medical Centre Rotterdam and the University Medical Centre Utrecht. Since the study 
neither implied that patients would receive a particular treatment, nor imposed on their 
behaviour as described in the Medical Research Involving Human Subjects Act (WMO), the IRB 
officially stated that the WMO did not apply. 
Results 
In total, 2510 patients diagnosed with PCOS were eligible for inclusion in this study. Of these, 
222 (8.9%) patients could not be assigned to a PCOS sub-phenotype group because of missing 
data: 13 women were excluded because of uncertainty about their (current) menstrual cycle 
pattern, 99 women had incomplete or inconclusive ultrasonography data, of one patient data 
on androgen levels was missing, 71 women were excluded since they were not fasting at the 
time of blood withdrawal and 38 women were excluded because they were under 18 years of 
age at time of screening. Hence, 2288 patients with PCOS were included in our final analyses, 
of which 1437 patients were diagnosed with PCOS at the Erasmus Medical Centre Rotterdam 
and 851 patients at the University Medical Centre Utrecht.
 In our study population 1219 (53.3%) women exhibited a hyperandrogenic form of PCOS 
(AE +OD, AE + PCOM, AE + OD + PCOM). The 1069 (46.7%) remaining patients with PCOS, 
solely had signs of ovulatory dysfunction and polycystic ovarian morphology (OD + PCOM) as 
is depicted in Figure 1.
 The majority (69.7%) of included patients were from Northern European descent 
which is shown in Table 1. The distribution of the various ethnicities differed significantly 
between patients with hyperandrogenic PCOS and patients with non-hyperandrogenic 
PCOS. The proportion of women from Northern European descent was significantly lower 
in hyperandrogenic patients with PCOS than in non-hyperandrogenic patients with PCOS 
(58.0% vs. 82.8% respectively; P <0.001). Furthermore each one of the other ethnicities was 
more prevalent amongst patients with hyperandrogenic PCOS compared to patients with 
non-hyperandrogenic PCOS.
 Patients with hyperandrogenic PCOS differed significantly from patients with non-
hyperandrogenic PCOS as far as the majority of endocrine and cardiometabolic parameters 
were concerned (Table 1). Patients with hyperandrogenic PCOS had a more unfavourable 
cardiometabolic profile, including higher BMI, WC, systolic and diastolic BP, and fasting 
insulin, LDL-C, and lower HDL-C levels. Moreover, a higher prevalence of CVRFs in patients 
with hyperandrogenic PCOS, compared to patients with non-hyperandrogenic PCOS was 
observed (Table 2). In patients with hyperandrogenic PCOS the most prevalent CVRFs were 
overweight or obesity (67.9%), raised LDL-C (61.8%) and elevated waist circumference (53.5%). 
This CVRF distribution was dissimilar to the distribution seen in non-hyperandrogenic PCOS 
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patients. In the latter raised LDL-C was the most prevalent risk factor (52.2%) followed by 
raised Total-C (47.4%) and overweight or obesity (28.5%). When the prevalence of individual 
CVRFs were compared between the hyperandrogenic and non-hyperandrogenic PCOS group, 
we observed that hyperandrogenic patients were significantly more often overweight/obese, 
hyperglycemic, insulin resistant and hypertensive. Furthermore, lipid profiles of these patients 
were significantly more disturbed, and the MetS was more prevalent in the hyperandrogenic 
PCOS group (25.8% vs 6.5%, P < 0.001) compared to the non-hyperandrogenic PCOS sub-
phenotype.
 Multiple logistic regression analysis, correcting for age, BMI, smoking and ethnicity, 
revealed that the differences in the incidence of CVRF between hyperandrogenic and non-
hyperandrogenic patients attenuated, but did not disappear. However, the difference in the 
incidence of hypertension between patients with hyperandrogenic and patients with non-
hyperandrogenic PCOS was no longer significant. Also, differences in lipid profile were less 
pronounced after this correction, except for HDL-C levels (P = 0.006). Differences in prevalence 
of MetS and insulin resistance remained significant (P = 0.025 and P < 0.001, respectively).
 When comparing the individual hyperandrogenic sub-phenotypes (AE+OD, AE + PCOM, 
AE+OD+PCOM) for CVRF incidence (Table 3), we observed no significant differences between 
these sub-phenotypes after correction for multiple testing (P < 0.0167), except for overweight/
obesity between the OD + AE phenotype and the OD + AE + PCOM phenotype (P = 0.010).
Figure 1 | Distribution of PCOS phenotypes.
Androgen Excess and Ovulatory Dysfunction (n=91)
Ovulatory Dysfunction and Polycytic Ovarian Morphology (n=1069)
Androgen Excess and Polycystic Ovarian Morphology (n=80)
Androgen Excess, Ovulatory Dysfunction and Polycystic Ovarian Morphology (n=1048)
4.0%
46.7%45.8%
3.5%
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Table 1 | Comparison of the baseline and endocrine characteristics of the hyperandrogenic and the 
non-hyperandrogenic patients with PCOS.
Parameters HA – PCOS
(n=1219)
non HA – PCOS
(n=1069)
P values Adjusted  
P values
Age (years) 27.5 (5.1) 29.1 (4.5) < 0.001 -
Ethnicity < 0.001 -
Northern European 707 (58.0) 886 (82.8)
Turkish / Moroccan 123 (10.1) 69 (6.5)
Negroid 206 (16.9) 41 (3.8)
Hindustani 80 (6.6) 22 (2.1)
Asian 57 (4.7) 29 (2.7)
Other 46 (3.7) 22 (2.1)
BMI (kg/m2) 28.8 (6.5) 23.6 (4.7) < 0.001 < 0.001*
WC (cm) 90.5 (16.3) 77.6 (14.0) < 0.001 < 0.001
BP systolic 120.6 (14.1) 117.2 (12.7) < 0.001 0.053
BP diastolic 78.3 (10.4) 74.7 (9.7) < 0.001 0.010
LH (U/L) 11.4 (9.7) 9.0 (8.6) < 0.001 < 0.001
FSH (U/L) 6.2 (2.2) 6.2 (2.6) 0.604 < 0.001
Estradiol (pmol/L) 223.6 (198.0) 226.1 (205.3) 0.768 0.414
Testosterone (nmol/L) 2.2 (0.9) 1.5 (0.6) < 0.001 < 0.001
DHEAS (µmol/L) 5.8 (9.7) 4.3 (1.8) < 0.001 < 0.001
Androstenedione (nmol/L) 6.9 (2.7) 4.9 (1.8) < 0.001 < 0.001
SHBG (nmol/L) 32.2 (17.2) 62.9 (29.4) < 0.001 < 0.001
FAI 8.6 (6.5) 2.7 (1.1) < 0.001 < 0.001
Glucose (mmol/L) 4.9 (0.8) 4.9 (2.0) 0.174 0.117
Insulin (mIU/L) 11.6 (10.6) 6.0 (4.9) < 0.001 < 0.001
TG (mmol/L) 1.2 (0.9) 1.0 (4.1) 0.171 0.954
Total-C (nmol/L) 5.2 (1.5) 5.1 (1.6) 0.236 0.719
LDL-C (nmol/L) 3.4 (1.3) 3.2 (1.3) < 0.001 0.356
HDL-C (nmol/L) 1.4 (0.5) 1.7 (0.5) < 0.001 0.002
Values are means (standard deviations) or numbers (percentages). Adjusted P values are adjusted for age, smoking, BMI and 
ethnicity. *Corrected for age, smoking and ethnicity only. HA, Hyperandrogenic; BMI, body mass index; BP, blood pressure; 
WC, waist circumference, FAI, free androgen index; TG, triglycerides; Total-C, total cholesterol; LDL-C, LDL-cholesterol; HDL-C, 
HDL-cholesterol.
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Table 2 | Prevalence of cardiovascular risk factors in hyperandrogenic and non-hyperandrogenic 
patients with PCOS.
Parameters HA – PCOS
(n=1219)
non HA – PCOS
( n=1069)
unadjusted 
P value
adjusted 
P value
Obesity (BMI ≥ 30 kg/m2) 498 (40.9) 113 (10.6) < 0.001 < 0.001*
Overweight or Obesity (BMI ≥ 25 kg/m2) 828 (67.9) 305 (28.5) < 0.001 < 0.001*
Hyperglycemia  
(fasting glucose > 6.0 mmol/L)
49 (4.0) 22 (2.1) 0.010 0.831
1/HOMA – IR < 0.47 528 (43.3) 150 (14.0) < 0.001 < 0.001
BP ≥ 140 systolic and/or  
90 diastolic mmHg
214 (17.6) 126 (11.8) < 0.001 0.912
WC ≥ 88 cm 652 (53.5) 188 (18.8) < 0.001 0.009
TG > 1.7 mmol/L 191 (15.6) 78 (7.3) < 0.001 0.485
Total-C ≥ 5.0 mmol/L 588 (48.2) 507 (47.4) 0.696 0.957
LDL-C ≥ 3.0 mmol/L 753 (61.8) 558 (52.2) < 0.001 0.233
HDL-C <1.2 mmol/L 498 (40.9) 193 (18.1) < 0.001 0.006
MetS 314 (25.8) 70 (6.5) < 0.001 0.025
Values are numbers of patients (percentages). Adjusted P values; adjusted for smoking, ethnicity, age and BMI. *Corrected 
for smoking and ethnicity only. BMI, body mass index; BP, blood pressure; WC, waist circumference; TG, triglycerides; Total-C, 
total cholesterol; LDL-C, LDL-cholesterol; HDL-C, HDL-cholesterol; MetS, metabolic syndrome. 
Table 3 | Prevalence of cardiovascular risk factors in different hyperandrogenic PCOS phenotypes.
Parameters Phenotype 1
AE + OD
(n=91)
Phenotype 2
AE + PCOM
(n=80)
Phenotype 3
AE+ OD + PCOM
(n=1048)
Obesity (BMI ≥ 30 kg/m2) 48 (52.7) 29 (36.3) 422 (40.3)
Overweight or Obesity (BMI ≥ 25 kg/m2) 73 (80.2) a 57 (71.3) 698 (66.6) a
Hyperglycemia (fasting glucose > 6.0 mmol/L) 7 (7.7) 2 (2.5) 39 (3.7)
1/HOMA – IR < 0.47 46 (50.5) 32 (40.0) 450 (42.9)
BP ≥ 140 systolic and/or 90 diastolic mmHg 20 (22.0) 16 (20.0 177 (16.9)
WC ≥ 88 cm 59 (64.8) 37 (46.3) 557 (53.1)
TG > 1.7 mmol/L 18 (19.8) 11 (13.8) 162 (15.5)
Total-C ≥ 5.0 mmol/L 42 (46.2) 33 (41.3) 513 (49.0)
LDL-C ≥ 3.0 mmol/L 55 (60.4) 48 (60.0) 651 (62.1)
HDL-C < 1.2 mmol/L 49 (53.8) 33 (41.3) 417 (39.8)
MetS 32 (35.2) 22 (27.5) 260 (24.8)
Differences were considered significant when P < 0.0167 (Bonferroni correction). a Significant difference (P 0.010) between 
phenotype 1 and 3, all other differences were not significant. AE, androgen excess; OD, ovulatory dysfunction; PCOM, 
polycystic ovarian morphology; BMI body mass index; BP, blood pressure; WC, waist circumference; TG triglycerides, Total-C, 
total cholesterol; LDL-C, LDL-cholesterol; HDL-C HDL-cholesterol; MetS, metabolic syndrome.
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Discussion
In this study we have observed that the hyperandrogenic sub-phenotype in patients with 
PCOS is clearly associated with an unfavourable cardiometabolic profile compared to patients 
who exhibit the non-hyperandrogenic PCOS sub-phenotype. In our study population, i.e. 
women with PCOS within their fertile years, about half of all patients were categorised into 
the hyperandrogenic PCOS sub-phenotype whereas the other half suffered from ovulatory 
dysfunction in combination with PCOM, i.e. the non-hyperandrogenic PCOS sub-phenotype. 
Hyperandrogenic patients with PCOS had a higher prevalence of nearly all studied CVRFs 
compared to the women with the non-hyperandrogenic PCOS sub-phenotype. This 
unfavourable profile remained even after correction for BMI, age, smoking and ethnic origin. 
Thereby, we have confirmed results from previously published studies including considerably 
smaller sample sizes, that the so-called hyperandrogenic PCOS phenotype encompasses the 
patients with the most unfavourable cardiometabolic phenotype [7,25]. Overall, the presence 
of CVRFs within the different sub-phenotypes of hyperandrogenic patients with PCOS were 
similar. However, patients with androgen excess and ovulatory dysfunction were more often 
overweight or obese compared to patients with hyperandrogenism, ovulatory dysfunction 
and PCOM. 
 This study provides further insight in the prevalence of MetS in different PCOS sub-
phenotypes. Our results yielded a 25.8% prevalence of MetS in women with hyperandrogenic 
PCOS which is in line with previous reported prevalences of MetS (ATP III criteria) varying 
between 20-46% in women with PCOS defined according to the former (1992) NIH criteria 
[8]. The significantly lower prevalence of MetS (6.5%) in non-hyperandrogenic PCOS women 
within our population, seems to resemble the prevalence of MetS as it is seen in the normal 
(non – PCOS) population of women of similar age, BMI and ethnic background , although 
studies reporting on this matter are limited. This might be explained by the fact that the non-
hyperandrogenic PCOS sub-phenotype consists of women who merely exhibit symptoms 
of ovulatory dysfunction and PCOM on ultrasound. Previous studies have indicated that 
the combination of current advanced ultrasound techniques and maintenance of a follicle 
threshold at 12 follicles to determine PCOM, results in a high prevalence of PCOM amongst 
asymptomatic women of reproductive age [26,27]. This has led some authors to conclude that 
PCOM itself is not associated with metabolic abnormalities [26]. At the same time others have 
advocated to raise the antral follicle count (AFC) threshold in the ultrasonographic diagnosis 
of PCOM, or even replace the ultrasound as a diagnostic tool with determination of AMH levels 
being a more precise marker in AFC assessment [27,28]. 
 According to these views some of the young women with non-hyperandrogenic PCOS 
in our study population, should not have been diagnosed with PCOM and consequently 
therefore not would be assigned as having PCOS. The PCOM trait in ovulatory women does not 
necessarily seem to result in the development of PCOS later in life [29]. Nonetheless, PCOM in 
ovulatory women has been associated with significantly higher circulating serum testosterone 
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levels compared to ovulatory women without PCOM [30].This suggests that PCOM might be a 
predisposing factor for the evolvement of PCOS in some women, and therefore should not be 
entirely disregarded as such.
 Furthermore, we have demonstrated that the distribution of ethnic origin between 
non-hyperandrogenic and hyperandrogenic PCOS women was different stressing the 
importance of taking ethnicity into consideration when addressing PCOS and its long-term 
health implications. Patients with PCOS of non-Northern European descent were more often 
attributed to the hyperandrogenic phenotype group, consistent with the higher prevalence of 
hyperandrogenism in patients of Middle Eastern and Mediterranean origin [31,32]. Moreover, 
it has been demonstrated previously in community based mixed population studies in the USA 
that there are not only variations in prevalence of PCOS amongst women of different ethnic 
descent, but also significant in differences in associated CVRF prevalence such as dyslipidemia, 
hypertension, insulin resistance and diabetes between various ethnic groups [33,34]. These 
differences observed in patients with PCOS might also reflect variation in androgen levels in 
the general population of different ethnic descent [35]. Therefore, the use of ethnic-specific 
appropriate thresholds for determining presence of hyperandrogenism as well as identifying 
adverse cardiometabolic implications has been proposed [15,36]. To overcome the potential 
bias associated with differences in ethnicity in the current study, we have adjusted the analyses 
for ethnic origin of the patients.
 We are well aware that the lack of (inter)national assay standardization, as well as the 
limitations of current clinical methods used to assess hyperandrogenism, make diagnosing 
hyperandrogenism in PCOS and non-PCOS women an utterly precarious matter [37,38]. A 
potential limitation of the study is that due to the extensive period of screening we were faced 
with various changes in endocrine and metabolic laboratory assays over time. Fortunately we 
were able to apply well established conversion factors when necessary to correct for potential 
variations due to these assay alterations, also facilitating between-centre assay comparisons. By 
doing so we feel that we have corrected for potential variations due to these assay alterations. 
Moreover, it has been shown that RIA’s are comparable to liquid chromatography tandem 
mass spectrometry (LC-MS/MS) in accuracy and precision of testosterone measurements 
in patients with PCOS [39]. At low testosterone levels, poor precision with all assays and 
significant variability between different LC-MS/MS assays remain problematic [40]. Hence, it is 
implausible that overestimation of testosterone levels has interfered with our results.
 Although, the current study underlines disturbances in the cardiometabolic 
profile of hyperandrogenic patients with PCOS, it has to be noted that patients with 
the non-hyperandrogenic PCOS sub-phenotype also encountered derangements in 
their cardiometabolic profile at this relatively young age. According to the treatment 
recommendations of both the American Heart Association and European Society of 
Cardiology, intervention for cardiovascular risk factor reduction is required for some of these 
patients [23,41].
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The high prevalence of CVRFs suggests that patients with PCOS, especially in patients with 
hyperandrogenic PCOS, are at a higher risk of developing cardiovascular disease and events 
later in life. These complications might also affect their life expectancy. Available studies 
reporting on this matter either lack numbers of well phenotyped PCOS patients, or have 
limited time to follow up [42-44]. Recognizing this necessity, we are currently embarking on 
a prospective long term follow-up study in PCOS women using a standardized screening for 
cardiovascular and metabolic risk factors. Furthermore, in older PCOS patients the incidence 
of cardiovascular events will be assessed. Hopefully this will be of help to improve the ability 
of both patient and physician to improve the health of PCOS patients and their offspring 
throughout life.
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Abstract
Context: Because of the heritable nature of Polycystic Ovary Syndrome (PCOS), parents of 
these patients are also prone to develop type 2 diabetes mellitus, which might influence their 
life-expectancy.
Objective: All-cause mortality of parents of patients with PCOS was determined. Parents with 
diabetes were compared to controls, whose diabetes was not related to PCOS.
Design: Reverse parent-offspring study.
Setting: University hospital and general community.
Participants: The medical history of mothers (n=946) and fathers (n=902) was primarily 
obtained during the initial screening of the patient and updated via questionnaires. The 
control-population consisted of 1353 men and women diagnosed with type 2 diabetes 
mellitus. 
Main outcome measures: Standardized mortality ratio (SMR) was calculated as the ratio of the 
observed mortality of the parents to the expected mortality in the Dutch general population. 
The mortality of parents with type 2 diabetes mellitus relative to controls with diabetes 
not related to PCOS was standardized for age, gender and calendar period using Poisson 
regression. 
Results: 302 parents deceased in 62,693 person-years. Mothers above age 60 had significant 
excess mortality of 1.50 (95% CI 1.15 to 1.92). Moreover, mothers with diabetes had two-times 
higher mortality risk compared to control women with diabetes (RR 2.0, 95% CI 1.19 to 3.41). 
No excess mortality among fathers was observed. 
Conclusions: Type 2 diabetes among mothers of PCOS patients resulted in severe excess 
mortality compared to women with diabetes from the general population. We strongly advise 
screening of these mothers to ensure that timely preventive and therapeutic measures are 
taken.
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Introduction
Polycystic ovary syndrome (PCOS) is the most common endocrine disorder in women of 
reproductive age with a prevalence of 6-10% in an unselected population [1]. PCOS is a life-
long condition with considerable variation of symptomatology between and within patients 
over time [2]. The syndrome is characterized by ovulatory dysfunction, hyperandrogenism and 
polycystic appearance of the ovaries [3]. Insulin resistance is a prominent feature of PCOS [4]. 
Also, a higher rate of impaired glucose tolerance, gestational diabetes and type 2 diabetes 
mellitus was found in patients with PCOS compared with controls [5,6]. Obesity is present 
in up to 60% of all patients with PCOS and is an exacerbating factor for the development of 
insulin resistance, impaired glucose tolerance and type 2 diabetes mellitus [7]. Type 2 diabetes 
mellitus increases the risk of cardiovascular and reduces lifetime expectancy [8]. Studies 
assessing mortality rates of patients with PCOS and their family members are scarce due to 
small sample sizes and limited follow-up time of the patients [9-12].
 Genetic factors play an important role in the etiology of PCOS as suggested by the estimated 
heritability of 65% [13]. The syndrome itself and notably the associated co-morbidities cluster 
both in families. Parents of patients with PCOS have more often insulin resistance compared 
with age and BMI matched controls with a healthy daughter [14,15]. Consequently, they 
seem to be at increased familial risk of developing cardiometabolic problems [16]. A previous 
study indicated that fathers of patients with PCOS had a high prevalence of heart attacks and 
strokes compared to a reference population [17]. Moreover, an increase has been observed 
of premature cardiovascular events among mothers of patients with PCOS [18]. Whether 
presence of diabetes plays a role in this increased cardiovascular risk is insufficiently known. 
 We hypothesized that the susceptibility to type 2 diabetes mellitus explains an important 
part of the complications among the patients with PCOS and their parents. Long-term follow-
up studies with adequate sample size and well-phenotyped patients with PCOS assessing 
mortality, the most indisputable outcome, are ongoing but still require approximately three 
decades of follow-up. Because of the high heritability and to overcome the lack of appropriate 
follow-up data, we determined all-cause mortality in parents of patients with PCOS compared 
with the mortality in the general Dutch population. Moreover, we determined all-cause 
mortality of parents with type 2 diabetes mellitus compared to the mortality of men and 
women with type 2 diabetes, who were recruited without selection for PCOS. 
Methods
PCOS diagnosis and assessment
Women with oligomenorrhea (interval of menstrual periods of at least 35 days) or amenorrhea 
(absence of vaginal bleeding for over 6 months) were examined at the outpatient clinic for 
cycle disturbances of the ErasmusMC University Medical Center Rotterdam. Medical history 
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was obtained. Extensive clinical and endocrine examination was performed as described 
previously [19]. Diagnosis of PCOS was based on the Rotterdam criteria [3]. According to 
these criteria, two of the following symptoms need to be present: oligo- or anovulation, 
clinical or biochemical hyperandrogenism, and polycystic ovarian morphology. Clinical 
hyperandrogenism was defined as a modified Ferriman-Gallwey score of at least 8 [20]. 
Biochemical hyperandrogenism was determined by the calculation of the Free Androgen 
Index (FAI): 100 x T in nmol/L / SHBG in nmol/L. A cut-off level of 4.5 was used to define 
biochemical hyperandrogenism. Polycystic ovarian morphology was assessed by transvaginal 
ultrasound and a cut-off of 12 or more follicles in at least one ovary and/or an ovarian volume 
of at least 10 ml was used to define polycystic ovarian morphology [21]. Informed consent 
from every patient who visited the outpatient clinic was obtained, according to international 
review board standards of the ErasmusMC University Medical Center Rotterdam. This protocol 
has been approved by the medical ethical review board of the ErasmusMC University Medical 
Center Rotterdam according to the Declaration of Helsinki.
Parental life years and parental medical history
Birthdates and mortality dates of the parents were obtained from a nationwide web-based 
municipal record database (Dutch name: Gemeentelijke Basisadministratie Persoons-
gegevens). This nationwide municipal database contains official records of births, marriages, 
and deaths of all government registered people living in the Netherlands and the Netherlands 
Antilles. Parental person-years were calculated by using dates of birth, death, and censoring 
(end of follow-up: January 1, 2007). In case this information was untraceable for both parents, 
the patient was excluded from further analyses. The parental medical history was primarily 
obtained during the initial screening of the patient. To complete and update the information 
about the prevalence of type 2 diabetes in their parents, a questionnaire was sent to all 
screened patients with PCOS. 
Population-based cohort of patients diagnosed with type 2 diabetes mellitus
Mortality rates of men and women diagnosed with type 2 diabetes mellitus were collected 
from the Zwolle Outpatient Diabetes Project Integrating Available Care (ZODIAC) study. This 
large diabetes project was initiated in 1998 in the Zwolle region of the Netherlands. In its 
first phase, general practitioners were assisted by hospital-based diabetes specialist nurses 
in providing care for patients with type 2 diabetes. Patients with a very short life expectancy 
and patients with insufficient cognitive abilities were excluded. A total of 1,353 (90%) patients 
agreed to participate in the study. The details of this study have been published previously 
[22]. The ZODIAC study was approved by the local medical ethics committee and all included 
subjects provided informed consent.
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Statistical analysis
Baseline characteristics of the patients with PCOS were evaluated using a commercially 
available statistical package (IBM Statistical Package of the Social Science/Predictive Analytic 
Software version 20). Man-Whitney-U tests and Chi-square tests, if necessary with continuity 
correction, were performed to compare baseline characteristics of the patients.
 The all-cause mortality of the parents of the patients with PCOS was compared to the all-
cause mortality of men and women from the general Dutch population standardized for age, 
gender, and calendar period, as previously described [23,24]. The ratio of the observed to the 
expected numbers of deaths is the standardized mortality ratio (SMR). The expected mortality 
was calculated by multiplying the total number of years lived by the study population until 
January 1, 2007 in each calendar period, with the age and gender specific mortality rates in 
the Dutch general population for each calendar period. These data are available at Statistics 
Netherlands using software of the World Health Organization [23].
 Statistics Netherlands is responsible for collecting and processing data of a multitude 
of societal aspects including mortality rates. The parental years before birth of the patient 
with PCOS were excluded from the analyses. Including these years would lead to selecting 
years without deaths resulting in underestimation of the mortality risk. Calendar periods 
were divided into five-year intervals, and to each of these intervals we applied the population 
mortality rates. We also calculated the SMR in different age-groups. The 95% Confidence 
Interval (CI) of the SMR was calculated assuming a Poisson distribution of the observed 
number of deaths and by using exact limits [24]. The SMR of the diabetic patients, who were 
recruited from the general population, was calculated after excluding the years of life before 
entering the ZODIAC study. 
 Finally, we used Poisson regression to compare the mortality in the parents of the patients 
with PCOS with the mortality in the patients with diabetes who were recruited from the 
general population by calculating the relative risk (RR) standardized for age, gender and 
calendar period. A p-value < 0.05 was considered to be statistically significant.
Results
In total 1088 patients diagnosed with PCOS were eligible. Of these, the address of 130 patients 
could not be traced. They were therefore considered as lost to follow-up. Dates of birth, death, 
and censoring of at least one parent were available for the remaining 958 (88.1%), patients 
with PCOS who were included for further analyses. Baseline characteristics of included and 
excluded patients with PCOS are shown in Table 1. PCOS features and associated characteristics 
were very similar in both groups.
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Table 1 | Baseline characteristics of the patients with PCOS. 
Included patients  
(n=958)
Excluded patients  
(n= 130)
P value
Age (years) 28.7 (6.4) 27.5 (6.1) 0.06
BMI (kg/m2) 25.6 (9.0) 27.0 (9.0) 0.24
Waist circumference (cm) 86 (23) 88 (22) 0.52
Polycystic Ovaries (%) 90.1 % 84.7% 0.09
Hyperandrogenism (%) 61.4 % 66.9 % 0.26
Amenorrhea (%) 27.6 % 22.3 % 0.25
FSH (IU/L) 4.6 (2.3) 4.30 (2.4) 0.07
LH (IU/L) 7.1 (5.9) 6.5 (6.3) 0.49
SHBG (nmol/L) 40.1 (36.3) 36.9 (30.5) 0.21
Testosterone (nmol/L) 2.0 (1.3) 2.0 (1.3) 0.47
FAI 4.9 (5.4) 5.3 (5.4) 0.49
Androstenedione (nmol/L) 12.4 (6.8) 11.8 (7.6) 0.86
Glucose (mmol/L) 4.1 (0.8) 4.20 (0.7) 0.03
Insulin (pmol/L) 71 (66) 72 (67) 0.46
Baseline characteristics are shown as median and interquartile ranges (IQR), unless indicated otherwise. BMI, Body mass 
index; FSH, Follicle Stimulating Hormone; LH, Luteinizing Hormone, SHBG, Sex Hormone Binding Globulin, FAI, Free Androgen 
Index.
First, we evaluated whether having a daughter with PCOS influenced all-cause mortality. 
Information on birth and mortality dates was available of 1848 (96.5%) of the 1916 parents, i.e. 
946 (98.7%) of the mothers and 902 (94.1%) of the fathers. A total of 302 deaths were observed 
in 62,693 person years (Table 2). The overall life expectancy of the parents independent of 
their medical history was not influenced by the fact that their daughters were diagnosed with 
PCOS (SMR 1.04; 95% CI 0.98 to 1.23), nor was the life expectancy of mothers (SMR 1.13; 95% CI 
0.93 to 1.37) and fathers (SMR 0.99; 95% CI 0.86 to 1.14) separately affected. As predefined in 
the SMR method, data were also analyzed in different age categories. Figure 1 summarizes 
the SMR of mothers and fathers in different age ranges standardized for gender and calendar 
period. The SMR of the mothers above 60 years of age was 1.50 (95% CI 1.15 to 1.92).
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Table 2 | Standardized Mortality Ratio of parents of patients with PCOS compared to the general Dutch 
population and of patients with diabetes compared to the general Dutch population. 
Person  
years
Observed 
deaths
Expected 
deaths
SMR 95% CI P value
All parents 62693.54 302 291.44 1.04 0.98-1.23 0.276
All mothers 32785.34 106 93.69 1.13 0.93-1.37 0.113
All fathers 29908.19 196 197.75 0.99 0.86-1.14 0.559
Mothers with type 2 diabetes* 3169.83 22 9.91 2.22 1.39-3.36 0.001
Fathers with type 2 diabetes* 3204.14 25 21.40 1.17 0.76-1.72 0.245
Female diabetic patients† 6063.67 326 219.94 1.48 1.33-1.65 < 0.001
Male diabetic patients† 4369.25 244 174.01 1.40 1.23-1.59 < 0.001
* Mothers and fathers diagnosed with type 2 diabetes mellitus and having a daughter diagnosed with PCOS. † Females and 
males diagnosed with type 2 diabetes mellitus and recruited from a population-based cohort study. DM2, type 2 diabetes 
mellitus; SMR, standardized mortality ratio; CI, confidence interval.
In total, 586 patients with PCOS replied to the questionnaires, resulting in a response rate of 
61.2% (586 out of 958). The overall SMRs were similar between parents, whose information on 
medical health was available, and parents, whose information was missing. Type 2 diabetes 
was present in 15.6% (95% CI 13.5-17.6%) of the parents (mothers n=90; fathers n=98), while 
it was 8.1% in an age-matched samples of the Dutch population (difference 7.5%; 95% CI 
5.4-9.5%; P value = < 0.001) [25]. Mothers with type 2 diabetes mellitus had excess mortality 
(SMR 2.22; 95% CI 1.39 to 3.36) compared to the general Dutch population (Table 2). Moreover, 
the mothers with diabetes had a two-fold excess mortality compared to the diabetic female 
patients who were recruited from the general population (RR 2.0: 95% CI 1.19 to 3.41; 
P value 0.009) standardized for age and calendar period. The fathers with type 2 diabetes 
mellitus (SMR 1.17; 95% CI 0.76-1.72) exhibited a shorter lifespan; however this difference was 
not significant. No differences in mortality were observed between fathers with diabetes and 
male patients with diabetes, who were recruited from the general population (RR 0.96; 95% CI 
0.59 to 1.57; P value = 0.87).
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Figure 1 | Standardized mortality ratio, number of deaths and person years of mothers (panel A) and 
fathers (panel B) compared to the general population divided by age categories. 
SMR, Standardized Mortality Ratio; PYRS, Person Years.
Discussion
Our study has shown that mothers above age 60 years with a daughter diagnosed with 
PCOS do have an increased mortality risk. Moreover, severe excess mortality was observed in 
mothers with type 2 diabetes mellitus, being twice as high as in female controls with diabetes. 
 The familial and heritable nature of PCOS has been well established [13]. Not only PCOS 
itself, but also associated co-morbidities of the syndrome evidently affect family members of 
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patients with PCOS. Our findings support the notion that parents of patients diagnosed with 
PCOS develop type 2 diabetes mellitus more often than age-matched subjects in the general 
population [25]. In the Dutch population 73% (95% CI 72.1-74.7%) of the patients had onset 
of type 2 diabetes mellitus above age 60 years [25]. We observed excess mortality in mothers 
above age 60 years relative to the general Dutch population, fully in line with the expected 
age of onset of chronic diseases. The presence of type 2 diabetes mellitus is associated with 
increased risk of early cardiovascular as well as all-cause mortality: it has been postulated 
that patients with type 2 diabetes mellitus should be immediately treated as if they had prior 
coronary disease [8].
 Over the last few decades the prevalence of type 2 diabetes mellitus started to increase in the 
Netherlands [26]. Implementation of strict treatment guidelines and improvement of quality 
of diabetes care in shared care settings have introduced a trend towards mortality more similar 
to the general population [27]. Nonetheless, we even observed a two-fold increased mortality 
of diabetic mothers of patients with PCOS relative to female patients with diabetes recruited 
from the general population. Notably, a greater mortality risk has been observed in females 
than males with diabetes [28-30]. Although mechanisms underlying these gender differences 
are not fully understood, it has been shown that surrogate markers for cardiovascular disease, 
such as elevated blood pressure, dyslipidemia and increased carotid intima-media thickness, 
were more prominently present in females than in males with diabetes [31]. These risk markers 
are also well-known co-morbidities of PCOS [32-34]. Although we did not assess presence of 
PCOS in the post-menopausal mothers, previous studies have shown that mothers of PCOS 
patients do share clinical characteristics in at least half of all cases. Hence, they suffer more 
often from irregular menstrual cycles and hirsutism compared to mothers with daughters 
without PCOS [16]. Moreover, menstrual cycle irregularity, elevated androgen levels as well as 
presence of diabetes predispose to cardiovascular disease and events [35-37]. Therefore it can 
be hypothesized that the higher mortality in mothers with type 2 diabetes mellitus might be 
related to reproductive disorders, such as PCOS. Current efforts to obtain endpoint data based 
on large prospective follow-up studies of patients with PCOS and their family members will 
provide more profound insight in the coming decades. 
 The presented reverse parent-offspring analysis overcomes the problem of lacking 
adequate follow-up data and, because of high heritability of the syndrome, may serve as a 
warning for the future risk of the PCOS daughters. More importantly, the excess of mortality 
observed in diabetic mothers of patients with PCOS relative to the patients with diabetes 
recruited from the general population suggests that this specific high-risk group is either 
not sufficiently recognized limiting the use of preventive measures. Therefore, we feel that 
early and active screening as well as aggressive treatment for type 2 diabetes mellitus 
amongst these mothers of daughters suffering from PCOS is justified. We realize that we 
observed a limited number of deaths. However, the SMR method uses person-years and the 
corresponding population-based expected deaths. Therefore, power problems hardly occur 
and small numbers of deaths can be used to estimate differences with high confidence as long 
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as the number of person-years is large, which is the case in our study. The increased mortality 
of the mothers with type 2 diabetes mellitus is within the range of mortality caused by severe 
inherited cardiovascular disorders like familial hypercholesterolemia [38]. Early identification 
and treatment of cardiovascular risk factors may be of major importance in this specific high 
risk group, also in the light of the fact that the incidence of cardiovascular disease in women 
with diabetes begins to increase at least 15 years before diabetes is clinically diagnosed [39]. 
Moreover, it is also known that type 2 diabetes is much more common in patients with PCOS 
and about 20% of these develop diabetes as early as during their forth decade of life [40]. 
In case of such a double burden, early diagnosis of diabetes will hopefully lead to early and 
aggressive treatment of risk factors, which in turn will have its effects on primary outcome.
 This is the first study assessing this excess risk in parents of patients diagnosed having 
PCOS, the most common endocrine disease in women of reproductive age. One could argue 
that we excluded severe cases from the population-based diabetic cohort. Excluding subjects 
with a very short life expectancy during the first months of a population-based cohort study 
is performed to avoid effects of severe, prevalent diseases on the follow-up of the cohort 
limiting the observations to truly incident cases. If this approach had introduced a bias, we 
would have expected excess mortality in the mothers below 60 years of age. However, this 
was not the case, implying that type 2 diabetes mellitus is indeed a disease of the elderly in 
our population. Questionnaires were used to get insight in the co-morbidities of the parents, 
and unfortunately we did not get a maximum response. Although this may have influenced 
our study, we did not observe any differences in mortality rates between the parents of the 
patients, who responded to the questionnaire, compared to those, who did not respond. 
The questionnaires may also have introduced recall bias for family history. However, this was 
previously demonstrated to be minimal for long-term chronic diseases [41]. Moreover, the 
high prevalence of type 2 diabetes mellitus in the parents of our patients is in agreement 
with earlier studies [12, 14]. We were not able to assess potential risk factors, including obesity 
hypertension or dyslipidemia, in the studied parents, which might shed some light on the 
potential mechanisms underlying the high mortality of the diabetic mothers. Future studies 
are needed to identify these potential additional risk factors. 
 In conclusion, we observed severe excess mortality above the age of 60 years in mothers 
of patients with PCOS, most likely as a result of type 2 diabetes mellitus. Mothers with type 2 
diabetes mellitus had a two-fold excess mortality compared to females with diabetes recruited 
from the general population without selection on PCOS. Our findings justify screening for type 
2 diabetes mellitus among the mothers with a daughter suffering from PCOS to ensure that 
good preventive and therapeutic measures according to the appropriate guidelines can be 
taken timely.
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Abstract
Objective: To evaluate association with polycystic ovary syndrome (PCOS) of 295 variants in 
39 genes central to metabolic insulin signaling and glycogen synthase kinase 3b (GSK-3b) 
regulation, followed by replication efforts.
Design: Case-control association study, with discovery and replication cohorts.
Setting: Subjects were recruited from reproductive endocrinology clinics, and controls were 
recruited from communities surrounding the University of Alabama at Birmingham and 
Erasmus Medical Center, Rotterdam.
Patient(s): A total of 273 cases with PCOS and 173 control subjects in the discovery cohort; 
and 526 cases and 3,585 control subjects in the replication cohort. All subjects were Caucasian.
Intervention(s): Phenotypic and genotypic assessment.
Main Outcome Measure(s): Detection of 295 single-nucleotide polymorphisms (SNPs), PCOS 
status.
Result(s): Several SNPs were associated with PCOS in the discovery cohort. Four insulin 
receptor (INSR) SNPs and three insulin receptor substrate 2 (IRS2) SNPs associated with PCOS 
were genotyped in the replication cohort. One INSR SNP (rs2252673) replicated association 
with PCOS. The minor allele conferred increased odds of PCOS in both cohorts, independent 
of body mass index.
Conclusion(s): A pathway-based tagging SNP approach allowed us to identify novel INSR SNPs 
associated with PCOS, one of which confirmed association in a large replication cohort.
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Introduction
Insulin resistance and compensatory hyperinsulinemia are frequent findings in polycystic 
ovary syndrome (PCOS), affecting 70% of cases [1]. The fact that insulin-sensitizing agents 
ameliorate features of PCOS points to insulin resistance as a key pathophysiologic factor [2].
 Not only is PCOS itself heritable, but within PCOS, insulin resistance is under significant 
genetic control [3]. First-degree relatives of women with PCOS exhibit an increased prevalence 
of insulin resistance whether or not they have PCOS [4]. For these reasons, some of the earliest 
candidate genes examined for PCOS were components of the insulin-signaling pathway [5]. 
However, insulin signaling, which starts with insulin binding to the insulin receptor (INSR) on 
the cell surface, is a complex system that interacts with other signaling pathways [6]. INSR 
initiates metabolic effects (e.g., stimulation of glucose uptake and glycogen synthesis) via two 
main pathways, the phosphatidylinositol-3 (PI3) kinase cascade and the CAP/Cbl pathway [7]; 
it also promotes cell proliferation via the mitogen-activated protein kinase cascade. These 
are the best- understood immediate systems activated by the INSR. Given the considerable 
number of components of these systems, insulin-signaling pathways have been incompletely 
examined to date. Examples of studied genes include AKT2, INSR, IRS1, IRS2, GSK3B, PTP1B, 
PPP1R3, and SORBS1 [8].
 What has been needed is an analysis that considers all of the key components of the insulin 
signaling pathway by using a tagging SNP approach to encompass the majority of genetic 
variation across the target regions. Advances in high-throughput genotyping have made this 
possible. Therefore, to fully interrogate the insulin signaling pathway for susceptibility loci for 
PCOS, we genotyped the INSR gene plus 27 genes coding for pathway components related to 
metabolic effects (PI3 kinase and CAP/Cbl pathways; Figure 1). We also genotyped 11 genes 
that have been described as regulators of glycogen synthase kinase 3b [9], given our earlier 
genetic and physiologic results implicating this factor and its upstream regulator AKT2 in PCOS 
[10-12]. The genes with the most significant SNPs associated with PCOS in the discovery phase 
were INSR and IRS2. Therefore, four SNPs in INSR and three SNPs in IRS2 were genotyped and 
analyzed in a larger replication cohort. One of the INSR SNPs replicated association with PCOS.
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Figure 1 | Metabolic insulin-signaling pathway genes genotyped in the discovery cohort. 
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The protein products of the 39 genes that were genotyped in the discovery cohort are indicated. Names containing a slash 
indicate two isoforms encoded by two different genes. p, phosphate group; PIP3, phosphatidylinositol (3,4,5)-triphosphate. 
Full gene names are listed in Supplementary Table 2.
Materials and Methods
Subjects and phenotyping
Discovery cohort
We studied 275 unrelated White PCOS patients and 173 White control women recruited at 
the University of Alabama at Birmingham (UAB). Study subjects were premenopausal, non-
pregnant, and on no hormonal therapy, including oral contraceptives or insulin-sensitizing 
agents for > 3 months, and they met 1990 National Institutes of Health (NIH) criteria for PCOS 
[13]. Parameters for defining hirsutism, hyperandrogenemia, ovulatory dysfunction, and 
exclusion of related disorders were previously reported [14]. Supplementary Table 1 presents 
clinical characteristics.
 Control subjects were healthy women, with regular menstrual cycles and no evidence of 
hirsutism, acne, alopecia, or endocrine dysfunction and who had not taken hormonal therapy 
(including oral contraceptives) for > 3 months. Controls were recruited by word of mouth 
and advertisements calling for ‘‘healthy women.’’ Each of the subjects gave written informed 
consent. The study was performed according to the guidelines of the Institutional Review 
Boards of UAB and Cedars-Sinai Medical Center.
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Replication cohort
Replication efforts were carried out in an independent cohort consisting of 526 Caucasian 
PCOS women and 3,585 unselected control subjects from the general population. The 
replication cohort included patients with oligomenorrhea (menstrual cycle > 35 days) 
or amenorrhea (absence of vaginal bleeding for > 6 months), serum FSH levels within the 
normal limits (1-10 U/L), i.e. normogonadotropic anovulation (classification according to the 
World Health Organization), and PCOS. PCOS was diagnosed according to the 2003 revised 
Rotterdam criteria [15]. Patients with non-Caucasian ethnic background were excluded.
 Control subjects were drawn from the Rotterdam Study, of which the design was described 
previously [16]. In brief, this is a large population- based study of elderly subjects from a specific 
area near Rotterdam (Ommoord). All women with age of menopause > 45 years and available 
DNA were included in the present analysis, providing a reference group of allele frequencies 
reflective of the local general Caucasian population (rather than a control group wherein PCOS 
was specifically excluded). The study was approved by the Institutional Review Board at the 
Erasmus Medical Center, Rotterdam, and informed consent was obtained from each of the 
patients as well as control subjects.
Genotyping
SNPs were selected by using data from the Caucasian (CEU) subjects in the International 
HapMap database (release 24; http://hapmap.ncbi.nlm.nih.gov) with the aim of exploiting 
linkage disequilibrium (LD) for the study of each gene. For all 39 genes, we selected SNPs to 
tag (r2 > 0.8) the majority of variation in each gene plus 10 kb upstream and 3 kb downstream 
or 5% upstream and 5% downstream (depending on gene size), resulting in a total of 341 SNPs. 
Supplementary Table 2 displays gene statistics; Supplementary Table 3 displays SNP statistics. 
The average SNP coverage was 74%. 338 of the 341 SNPs were genotyped by using the 
oligoligation assay (GoldenGate Chemistry) on an Illumina (San Diego, CA) BeadStation [17]. 
Six of the SNPs were not polymorphic, and one failed Hardy-Weinberg equilibrium (P < .001); 
these SNPs were not considered further. SNPs were clustered in a single project that included 
all samples and used Illumina’s BeadStudio clustering algorithm. Each SNP was then manually 
reviewed to remove individual samples from each cluster plot that were not clearly assigned 
to one cluster (major or minor allele homozygotes or heterozygotes). SNPs that did not clearly 
form three clusters for each genotype group were removed from the analysis. Thirty-nine SNPs 
were removed because they failed this quality control. Therefore, 292 SNPs were ultimately 
analyzed of the 338 genotyped on this platform. The genotyping success rate for these 292 
SNPs was 93.6%. Duplicate genotyping of ten subjects yielded 100% concordance.
 The remaining three of the 341 SNPs (from the IRS1 gene) were genotyped by using Applied 
Biosystems Taqman Assays-On-Demand (Applied Biosystems, Foster City, CA) according to the 
manufacturer’s instructions. The overall genotyping success rate was 93.4%. Four INSR and 
three IRS2 SNPs were genotyped in the replication study.
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For the PCOS cases, Taqman Allelic Discrimination (Applied Biosystems) was used for the INSR 
SNPs. For the Rotterdam Study control subjects, genotypes from two INSR SNPs (rs12459488 
and rs12971499) were extracted from the Genome-Wide Association Study (GWAS) imputed 
genotypes data- base, and INSR SNPs rs2252673 and rs10401628 were genotyped by using 
Taqman Allelic Discrimination. The IRS2 SNPs (rs7997595, rs7987237, rs1865434) were 
extracted from the GWAS imputed genotypes database. We also genotyped 127 ancestry 
informative markers [18] (listed in Supplementary Table 4) in the discovery cohort and 
examined the cohort for population structure by generating principal components in 
Eigenstrat implemented in Golden Helix (Bozeman, MT). Plotting the first and second most 
informative principal components revealed that the case and control subjects were of similar 
ancestry (Supplementary Figure 1), with the exception of two control subjects, who were 
excluded from analysis. None of the principal components were associated with PCOS status.
Statistical Analysis
Unpaired t tests and chi-square tests were used to compare clinical characteristics between case 
and control subjects; quantitative traits were log or square root transformed as appropriate to 
reduce non-normality. Data are presented as median (interquartile range).
 In the discovery cohort, allelic analyses were conducted using chi-square tests to compare 
allele frequencies between case and control subjects for 295 SNPs. The same allelic analyses 
were carried out in the replication cohort (seven SNPs). We targeted for replication seven SNPs 
in the genes with the most SNPs associated with PCOS at P < 0.05. In the replication stage, 
SNPs were considered to be significantly associated with PCOS if the P value was < 0.007 
(0.05/7=0.007).
 To assess whether the effects of the seven associated SNPs were independent of body 
mass index (BMI), adjusted analyses were conducted with logistic regression; the dependent 
variable was PCOS status, and the independent variables were genotype (dominant model) 
and BMI. Furthermore, we directly evaluated the seven SNPs for an effect on BMI by conducting 
linear regression wherein BMI was the dependent variable. Meta-analyses were conducted 
on the logistic regression results of the discovery and replication cohorts by using the Metal 
program (http://www.sph.umich.edu/csg/abecasis/metal/). The discovery cohort sample size 
had good power (≥ 80%) to detect association of risk alleles of frequency ≥ 0.2 with PCOS at 
odds ratio (OR) ≥ 1.75 and moderate power (40%-60%) to detect association at OR 1.5; the 
power to detect association of rare risk alleles (frequency ≤ 0.1) with PCOS at OR ≤1.5 is limited 
[19].
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Table 1 | Allelic association results in the discovery cohort.
Name Gene Chr Alleles 
(major/minor)
Associated 
Allele
Case 
Frequency
Control 
Frequency
Chi-square 
value
P value
rs7997595a IRS2a 13 C:G C 0.881 0.795 11.281 0.001
rs10401628a INSRa 19 G:A G 0.919 0.856 8.298 0.004
rs2274490 SORBS1 10 T:C C 0.430 0.334 7.428 0.006
rs7987237a IRS2a 13 C:T C 0.884 0.817 7.398 0.007
rs12459488a INSRa 19 C:G C 0.760 0.674 7.335 0.007
rs12971499a INSRa 19 T:C T 0.635 0.543 6.932 0.009
rs2252673a INSRa 19 C:G G 0.178 0.112 6.479 0.011
rs1865434a IRS2a 13 A:G A 0.875 0.814 5.875 0.015
rs4952834 RHOQ 2 G:C C 0.338 0.261 5.500 0.019
rs3753242 PRKCZ 1 C:T C 0.953 0.913 5.432 0.020
rs2267922 PIK3R2 19 C:G C 0.539 0.460 5.002 0.025
rs3736328 PIK3R2 19 C:G G 0.523 0.444 4.978 0.026
rs7207345 PRKCA 17 T:C C 0.281 0.212 4.902 0.027
rs6510949 INSR 19 G:T T 0.070 0.034 4.858 0.028
rs7641983 PIK3CA 3 C:T C 0.832 0.772 4.610 0.032
rs7646409 PIK3CA 3 T:C T 0.833 0.774 4.527 0.033
rs3094127 FLOT1 6 T:C C 0.262 0.199 4.328 0.038
rs6020608 PTPN1 20 C:T C 0.764 0.702 3.923 0.048
rs13420857 RHOQ 2 C:G G 0.391 0.323 3.905 0.048
rs6443624 PIK3CA 3 C:A C 0.771 0.711 3.848 0.050
rs7651265 PIK3CA 3 A:G A 0.906 0.862 3.832 0.050
Single-nucleotide polymorphisms (SNPs) are displayed in order of significance. P values are for allelic association with 
polycystic ovary syndrome (no covariate adjustment). Chr Chromosome.
a INSR and IRS2 SNPs that were selected for genotyping in the replication cohort.
Results
In the discovery cohort (275 case subjects and 171 control subjects [2 control subjects 
excluded based on principal component analysis]), we analyzed 295 SNPs for association with 
PCOS (Supplementary Table 3). SNPs with allelic association with PCOS (P < 0.05) are listed in 
Table 1. The gene with the largest number of SNPs significantly associated with PCOS in the 
discovery phase was INSR. IRS2 also contained several associated SNPs at the top of the list. 
These observations, and the key importance of INSR and IRS2 in the initial steps of insulin 
signaling, prompted us to attempt replication of the four INSR SNPs (rs12459488, rs12971499, 
rs2252673, rs10401628) and three IRS2 SNPs (rs7997595, rs7987237, rs1865434) most 
associated with PCOS in the discovery cohort. These seven SNPs were not associated with BMI, 
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either in the entire discovery cohort (linear regression, adjusted for age and diagnosis) or in 
the PCOS women only (adjusted for age).
Table 2 | Allelic association of four INSR and three IRS2 SNPs with PCOS in the replication cohort.
SNP Gene Case MAF Control MAF Chi-square value P value
rs12459488 INSR 0.292 0.288 0.58 0.81
rs12971499 INSR 0.432 0.412 1.38 0.24
rs2252673 INSR 0.209 0.170 9.56 0.002
rs10401628 INSR 0.127 0.125 0.02 0.89
rs7997595 IRS2 0.173 0.166 0.186 0.666
rs7987237 IRS2 0.151 0.153 0.039 0.842
rs1865434 IRS2 0.153 0.153 0.014 0.907
Allelic P values are derived from chi-square testing. MAF, minor allele frequency; PCOS, polycystic ovary syndrome; SNP, single 
nucleotide polymorphism.
These seven SNPs were genotyped in the replication cohort consisting of 526 Caucasian 
PCOS women and 3,585 control subjects. Association results are presented in Table 2. SNP 
rs2252673 replicated association with PCOS (P = 0.002). Logistic regression analyses revealed 
that the association of rs2252673 was independent of BMI (Table 3). Carriers of the minor G 
allele at rs2252673 had increased odds of PCOS in both the discovery cohort (BMI-adjusted 
OR 2.06, 95% confidence interval [CI] 1.21-3.52; P < 0.008) and the replication cohort (BMI-
adjusted OR 1.32, 95% CI 1.08-1.60; P = 0.006). P value meta-analysis of the two cohorts for 
this SNP revealed a combined P = 0.00058 (Table 3). The significant associations using the 
dominant model (Table 3) exhibited significance similar to the additive model. We also 
analyzed the association of the INSR SNP in the replication cohort with inclusion of only the 
286 cases meeting the NIH 1990 definition of PCOS. With the halving of the number of cases 
in this analysis, statistical significance was diminished, but the odds of association with PCOS 
for rs2252673 (BMI-adjusted OR 1.34, 95% CI 1.03-1.74; P = 0.03) were identical to that in the 
entire replication cohort.
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Table 3 | Logistic regression association of four INSR and three IRS2 SNPs in the discovery and replication 
cohorts.
Discovery cohort Replication cohort Meta-analysis
SNP Gene OR 95% CI P value OR 95% CI P value P value
rs12459488 INSR 0.62 0.39-0.98 0.04 1.11 0.92-1.34 0.30 0.71
rs12971499 INSR 0.68 0.42-1.11 0.12 1.05 0.86-1.28 0.067 0.21
rs2252673 INSR 2.06 1.21-3.52 0.008 1.32 1.08-1.60 0.006 0.00058
rs10401628 INSR 0.45 0.25-0.79 0.006 1.00 0.80-1.25 0.99 0.40
rs7997595 IRS2 0.54 0.33-0.89 0.015 1.09 0.81-1.41 0.54 0.84
rs7987237 IRS2 0.54 0.33-0.90 0.019 1.03 0.79-1.35 0.84 0.58
rs1865434 IRS2 0.58 0.35-0.95 0.032 1.05 0.80-1.37 0.73 0.72
Logistic regression models included PCOS status as the dependent variable, and genotype (dominant model) and body mass 
index as independent variables. The P value meta-analysis was conducted on logistic regression models in the discovery and 
replication cohorts. CI, confidence interval; OR, odds ratio; MAF, minor allele frequency; PCOS, polycystic ovary syndrome; 
SNP, single nucleotide polymorphism.
Discussion
We have replicated association with PCOS of an INSR variant that predisposes to the syndrome. 
This result sheds light on the origins of PCOS as an inherited condition characterized by insulin 
resistance in many affected individuals.
 Genetic variation in INSR may affect PCOS risk via an effect on insulin signaling. This was 
recognized as a possibility early in the field of PCOS genetics. Initial studies screening exons 
of the INSR gene (typically by polymerase chain reaction and single-stranded conformational 
polymorphisms) found missense/nonsense mutations in only isolated cases of women with 
PCOS-like phenotypes [5]. Such screens commonly identified only a silent C/T variation in 
codon His1058, leading many to conclude that INSR variation was not a major factor in PCOS.
 In subsequent years, several genetic association studies of INSR in PCOS case-control 
cohorts were published, most of which focused on His1058 C/T variant; a recent meta-analysis 
of these studies revealed a non-significant trend (OR 1.28, 95% CI 0.88-1.85) for association 
of this silent variant with PCOS [5]. In Chinese subjects, a Cys1008Arg variant in exon 17 was 
associated with PCOS and lower insulin sensitivity index [20]; however, the frequency of this 
variant in other populations has not been determined (not available in the Single-Nucleotide 
Polymorphism Database [dbSNP]; http:// www.ncbi.nlm.nih.gov/SNP/). A Korean study that 
genotyped nine variants (initially found by sequencing) found association of a novel intron 
21 variant with PCOS; this is another variant not yet listed in dSNP [21]. Therefore, we cannot 
determine whether our replicated INSR SNP is in linkage disequilibrium (LD) with either of 
these variants. The microsatellite D19S884, a replicated PCOS locus, was initially selected 
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based on proximity to INSR; however, it resides in a different gene (FBN3) > 850 kb from INSR 
and therefore likely represents an independent susceptibility locus [22].
 The Korean study genotyped rs2252673 and found that carriers of the G allele (major allele 
in Koreans, minor allele in Caucasians) exhibited a trend to increased PCOS (OR 1.18, 95% CI 
0.53-2.26) [21], consistent with our findings for this SNP. This suggests that this variant might 
influence PCOS risk across three continents (North America, Europe, Asia). If PCOS is an ancient 
disorder, as recently proposed, one would predict shared susceptibility variants across the 
globe [23]. Further studies of this variant are needed to establish whether rs2252673 is such a 
universal risk factor for PCOS.
 How the replicated variant affects INSR function and/or expression is unknown. SNP 
rs2252673 is not in LD (r2 < 0.8) with any other SNP in the INSR gene in the HapMap Caucasian 
database [24]. As an intronic variant, it may be in LD with unknown functional (or not yet 
genotyped in HapMap) variants elsewhere in the gene. Sequencing may identify coding 
variants in LD with the associated variant. Alternatively, the variant itself may influence INSR 
transcription or mRNA splicing. In the Transcription Element Search System database (http://
www.cbil.upenn.edu/tess/), rs2252673 results in alternative possible transcription factor-
binding sites. Two forms of the insulin receptor arise from alternative splicing of exon 11 
(excluded from the A isoform and included in the B isoform). The A isoform, expressed mainly 
during fetal development and the adult brain, has low affinity for insulin but high affinity 
for insulin-like growth factor 2; the B isoform has high affinity for insulin and is expressed in 
insulin-responsive tissues such as muscle, liver, and adipose [25]. Whether the replicated INSR 
SNP affects INSR splicing and/or transcription must be determined by biochemical studies. 
Tissue-specific effects (e.g., muscle, liver, ovary) could also be evaluated.
 The large size of the INSR gene (> 180 kb) has made its investigation as a candidate 
gene challenging. Earlier studies only looked at one or a few variants in the gene, leading to 
incomplete coverage of its genetic variation. This is the first study that tagged the entire INSR 
region using information from HapMap [24]. This was critical to allow the discovery phase to 
detect INSR variants potentially associated with PCOS. Efforts to replicate genetic association 
results have been infrequent in the field of PCOS genetics. Examples include replication 
studies of HSD17B5 [26], HSD17B6 [27], CYP11A1 [28], the insulin gene [29], and others [22,30]. 
A key factor in our successful replication was that the replication cohort was substantially 
larger than the discovery cohort. Genetic effect size is typically overestimated in initial studies, 
a phenomenon known as the ‘‘winner’s curse’’ [31].
 Therefore, replication cohorts should be larger than discovery cohorts to have sufficient 
power to detect the association at a lower effect size. This proved to be true in the present 
study, wherein the odds for association with PCOS were higher in the discovery cohort 
than in the replication cohort. Another possible explanation for the different effect sizes is 
that PCOS was excluded from the discovery cohort control subjects (increasing power for 
discovery), whereas the replication cohort control subjects consisted of an unselected sample 
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representative of the general population. The latter large (> 3,500 subjects) population-based 
sample may indicate broad generalizability of our findings.
 Ideally, both the discovery cohort and replication cohort PCOS cases would have been 
diagnosed by using the same criteria. This was not the case, because these were preexisting 
cohorts. Fortunately, this did not hinder our ability to replicate at least one SNP association 
with PCOS. We ruled out BMI disparity between case and control subjects as a cause of spurious 
SNP association with PCOS by directly ruling out SNP association with BMI and by adjusting for 
BMI as a covariate.
 We did not adjust the results in the discovery cohort for multiple testing (e.g., Bonferroni 
correction), because we planned to follow-up with a replication effort. Replication is the 
optimal solution to multiple testing. We corrected for multiple testing in the replication 
phase. Given their central roles in insulin signaling and preponderance of significant SNPs in 
the discovery phase (Table 1), we first attempted to replicate variants in INSR and IRS2. In the 
future, we will attempt to replicate SNPs in other loci associated with PCOS in the discovery 
cohort. We hope that this publication inspires other investigators to also examine these loci in 
their cohorts.
 In conclusion, in a survey of 39 genes coding for the central components of metabolic 
insulin-signaling pathways, we identified SNPs in the INSR and IRS2 genes that were associated 
with PCOS. One of these SNPs replicated association with PCOS in a larger independent cohort. 
These data should reinvigorate interest in INSR as a genetic susceptibility factor for PCOS.
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Supplementary Table 1 | Clinical characteristics of the discovery cohort.
Control 
n=171
PCOS 
n=275
Age (yr) 34.0 (15.0) 27.6 (11.5)a
BMI (kg/m2) 24.3 (6.3) 34.7 (13.0)a
WHR 0.78 (0.08) 0.83 (0.11)a
mFG score 0 (0) 7.0 (5.8)a
Hirsute (%) 0 74.2a
Total testosterone (ng/dl) 42.0 (27.3) 80.0 (31.0)a
Free testosterone (pg/ml) 0.36 (0.26) 0.84 (0.46)a
DHEAS (ng/ml) 966 (723) 2094 (1702)a
SHBG (nmol/l)b 210.0 (120.0) 150.0 (62.5)a
Insulin (µIU/ml) 6.9 (6.3) 18.0 (18.0)a
Glucose (mg/dl) 86.0 (10.8) 86.0 (12.8)
HOMA-IR 0.95 (0.81) 2.25 (1.92)a
HOMA-%B 106.6 (61.1) 175.0 (99.6)a
Data are presented as median (interquartile range). BMI, body mass index; WHR, waist-to-hip ratio; mFG, modified Ferriman- 
Gallwey hirsutism score; HOMA-IR, insulin resistance estimated by homeostatic model assessment; HOMA-%B, beta-cell 
function estimated by homeostatic model assessment; PCOS, polycystic ovary syndrome. 
a P < .001 compared with control group. 
b SHBG activity was measured by competitive binding analysis using Sephadex G-25 and [3H]T as the ligand; this assay gives 
values of ~100-300 nmol/L in normal adult women.
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Supplementary Table 4 | Ancestry informative markers genotyped in the discovery cohort.
rs2986742 rs10007810 rs12544346 rs946918
rs6541030 rs1369093 rs7844723 rs200354
rs647325 rs385194 rs2001907 rs3784230
rs4908343 rs7657799 rs1408801 rs12439433
rs1325502 rs2702414 rs10511828 rs2899826
rs12130799 rs316598 rs3793451 rs8035124
rs3118378 rs870347 rs2306040 rs4984913
rs3737576 rs37369 rs10513300 rs4781011
rs7554936 rs6451722 rs2073821 rs2269793
rs1040404 rs12657828 rs3793791 rs818386
rs1407434 rs6556352 rs4746136 rs2966849
rs4951629 rs1500127 rs4918842 rs1879488
rs316873 rs6422347 rs4880436 rs2033111
rs798443 rs1040045 rs10839880 rs11652805
rs7421394 rs2504853 rs1837606 rs10512572
rs4666200 rs7745461 rs2946788 rs2125345
rs4670767 rs192655 rs11227699 rs4798812
rs13400937 rs4463276 rs948028 rs4800105
rs260690 rs4458655 rs2416791 rs7238445
rs10496971 rs1871428 rs1513056 rs881728
rs2627037 rs731257 rs214678 rs4891825
rs1569175 rs32314 rs772262 rs874299
rs10510228 rs2330442 rs2070586 rs8113143
rs4955316 rs4717865 rs1503767 rs3745099
rs9809104 rs10954737 rs9319336 rs2532060
rs6548616 rs705308 rs7997709 rs6104567
rs12629908 rs7803075 rs9530435 rs3907047
rs9845457 rs10236187 rs9522149 rs2835370
rs734873 rs6464211 rs1760921 rs1296819
rs2030763 rs10108270 rs2357442 rs4821004
rs1513181 rs3943253 rs1950993 rs5768007
rs9291090 rs1471939 rs8021730
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Supplementary Figure 1 | Principal component plot of the discovery cohort. The plot confirms that the 
cases and controls are well matched, except for two controls who were excluded from further analysis.
CPC Common Principal Component
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Abstract 
Context: Because of the elevated dehydroepiandrosterone sulfate (DHEAS) levels in polycystic 
ovary syndrome (PCOS) and the heritability of DHEAS serum levels, genes encoding the 
enzymes that control the sulfation of dehydroepiandrosterone (DHEA) to DHEAS and vice 
versa are obvious candidate genes to explain part of the heritability of PCOS.
Objective: The objective of the study was to determine the role of genetic variants in 
sulfotransferase (SULT2A1), 3-phosphoadenosine 5-phosphosulfate synthase isoform 2 (PAPSS2) 
and steroid sulfatase (STS) in PCOS and in hormone levels related to the hyperandrogenic 
phenotype of PCOS.
Design: This was a candidate-gene study.
Patients: The discovery set consisted of 582 patients and 2017 controls.
Main outcome measures: A pruned subset of 28 single nucleotide polymorphisms (SNPs) in 
SULT2A1, PAPSS2 and STS was generated based on pairwise genotypic correlation. Association 
with PCOS was tested and we studied whether the SNPs modulate DHEAS levels, DHEA levels 
and their ratio in PCOS. Significant SNPs were replicated in an independent sample of patients.
Results: None of the SNPs in SULT2A1, PAPSS2 and STS constituted risk alleles for PCOS. SNP 
rs2910397 in SULT2A1 decreased the DHEAS to DHEA ratio in PCOS by 5% in the discovery 
sample. Meta-analysis of discovery and replication sample resulted in a combined effect of 
-0.095 (P = 0.027). However, carrying the minor T-allele did not contribute to differences in 
hyperandrogenic phenotype, including levels of T and androstenedione, of PCOS patients.
Conclusions: Genetic variants in SULT2A1, PAPSS2 and STS do not predispose to PCOS. Although 
a variant in SULT2A1 decreased the DHEAS to DHEA ratio, no changes in other androgenic 
hormone levels were observed. 
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Introduction
Hyperandrogenism is one of the cardinal features of the polycystic ovary syndrome (PCOS). 
Overall prevalence of hyperandrogenism in PCOS patients amounts up to 75%, and increased 
levels of androgens persist in postmenopausal PCOS patients [1,2]. Not only PCOS itself, 
but also hyperandrogenemia within PCOS appears to be under genetic control. Familial 
aggregation of androgen excess in both brothers and sisters of patients with PCOS suggests 
that hyperandrogenemia is a highly heritable trait [3,4].
 The ovaries are considered to be the main source of androgen production in PCOS. 
Nevertheless, in most patients the adrenal glands contribute to the hyperandrogenism as well, 
and adrenal androgen production remains high until menopause as reflected by elevated levels 
of dehydroepiandrosterone sulfate (DHEAS) [5,6]. Heritability of DHEAS levels in twin studies 
was estimated to be approximately 60% [7]. DHEAS is almost exclusively of adrenocortical 
origin, and its serum concentration is the most abundant of the steroids secreted by the 
adrenal glands [8]. Moreover, it is relatively stable throughout the day and the menstrual cycle 
[9,10]. Elevated DHEAS levels have been reported in up to 50% of the PCOS patients [11-13]. 
The biologically inactive DHEAS can be converted to dehydroepiandrosterone (DHEA), which 
is a principal precursor for the production of biologically active androgens and estrogens [14].
 An increase in circulating DHEA would lead to an increase of the androgens downstream 
of DHEA leading to excess of active androgens, which is one of the key features of PCOS. 
As illustrated in Figure 1, conversion of DHEA to DHEAS and vice versa is controlled by the 
enzymes sulfotransferase 2A1 (SULT2A1) and steroid sulfatase (STS). The activity of the SULT2A1 
enzyme depends on the sulfate donor 3’-phosphoadenosine 5’-phosphosulfate (PAPS), which 
is synthesized by PAPS synthatase (PAPSS). Of the 2 isoforms PAPSS1 and PAPSS2, PAPSS2 
is highly expressed in the major sites of DHEA sulfation, ie, the liver and the adrenal glands 
[15,16].
Figure 1 | (De) sulfation of DHEA to DHEAS and vice versa. 
DHEAS DHEA
STS
SULT2A1
active androgens
PA
PS
S2
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The sulfation of DHEA takes place through the action of DHEA sulfotransferase (SULT2A1). The 
activity of the SULT2A1 enzyme depends on the sulfate donor PAPS, produced by the enzyme 
PAPSS2. In turn, the sulfate group in DHEAS is removed by steroid sulfatase (STS) regenerating 
DHEA that can then be metabolized to active androgens, such as androstenedione and T.
 Genetic variants in genes encoding these enzymes might influence their activity and 
as such might contribute to the higher levels of androgens in patients with PCOS. Unlike 
genetic variants in STS, a potential role of the single nucleotide polymorphism (SNP) rs182420 
in the SULT2A1 gene contributing to the adrenal androgen excess among PCOS patients 
has previously been proposed [17]. However, no replication studies have been conducted 
to validate this finding. Mutations in the PAPSS2 gene have been recently suggested to be 
a monogenic adrenocortical cause of androgen excess in a girl with premature adrenarche, 
which might be an early manifestation of PCOS [18,19]. Genetic variants in PAPSS2 have never 
been studied in association with PCOS before.
 The aim of this study was to test genetic variations in SULT2A1, PAPSS2 and STS for 
association with PCOS. Moreover, we studied whether these genetic variants modulate DHEAS 
levels, DHEA levels and DHEAS to DHEA ratio, as a marker for DHEA sulfation capacity, in PCOS. 
Finally, we studied whether carrying these genetic variants would result in differences in 
phenotypic characteristics, including levels of T and androstenedione, in PCOS patients.
Materials and Methods
Study population 
Discovery sample
A total of 582 Caucasian PCOS patients and 2017 Caucasian controls from the general 
population were included in the discovery cohort. All PCOS patients underwent a standardized 
physical examination and hormonal evaluation. Clinical work-up included menstrual history 
as well as current cycle length, anthropometric measurements (height and weight), and 
calculation of body mass index (BMI) as weight in kilograms divided by the squared height 
in meters. Transvaginal ultrasonography was performed to assess ovarian volume and total 
number of follicles in both ovaries. The diagnosis PCOS was established on the basis of the 
2003 European Society for Human Reproduction and Embryology/American Society for 
Reproductive Medicine Rotterdam criteria [20,21].
 Controls were derived from the Rotterdam Study, which is a large population based study 
of elderly men and women from Ommoord, a defined area in Rotterdam, The Netherlands. 
The design of the study has been described in detail previously [22]. All women of whom DNA 
was available, who were proven to be fertile, with an age of menopause > 45 years and age of 
menarche between 10-17 years and available BMI measurements were included as controls. 
These controls provide a reference group of the local general Caucasian population rather 
than a control group in which PCOS was specifically excluded. The study was approved by the 
Medical Ethical Review Board of the Erasmus Medical Center, Rotterdam, and written informed 
consent was obtained from all patients as well as from control subjects.
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Replication sample
Replication efforts were carried out in an independent sample consisting of 412 Caucasian 
PCOS patients from the area near Utrecht, The Netherlands. PCOS was diagnosed according 
to the 2003 revised Rotterdam criteria [20,21]. These patients were screened according to 
the same protocol as the PCOS patients in the discovery sample including anthropometric 
measurements, transvaginal ultrasonography and extensive endocrine evaluation. The study 
was approved by the Institutional Review Board of the University Medical Center Utrecht and 
all patients gave written informed consent.
Hormone assays
Blood samples of all patients were drawn after an overnight fast before 10.00 am on the day 
of clinical examination and processed within 2h after withdrawal. Until assayed, serum was 
stored at -20°C. In Rotterdam serum levels of SHBG, androstenedione, insulin and DHEAS were 
measured by immunoluminometric assay (Immulite® platform, Siemens Diagnostic Products 
Corporation (DPC), Los Angeles, CA). Testosterone was determined by radioimmunoassay 
(RIA) (Siemens DPC, Los Angeles, CA). DHEA was measured using RIA (Diagnostic Systems 
Laboratories, Webster, TX). Glucose levels were measured using a Hitachi 917 analyzer (Roche 
Diagnostics, Almere, The Netherlands). Intra- and interassay coefficients of variation (CV) were 
less than 4 and 5% for SHBG, less than 8 and 11% for androstenedione, less than 6 and 8% for 
insulin, less than 9 and 11% DHEAS, less than 3 and 5% for testosterone, and, less than 5 and 
15% for DHEA, respectively. The ratio of DHEAS to DHEA was calculated.
 In Utrecht, SHBG and insulin levels were quantified using an immunoluminometric assay 
(Immulite® platform, Siemens Diagnostic Products Corporation). Androstenedione was 
measured after hexane-toluene extraction using an in-house RIA (with extraction). DHEAS 
was measured using the Coat-A-Count DHEA-SO4 RIA (TKDS2, Siemens Diagnostics, Breda, 
Netherlands). Testosterone measurement was performed using an in-house extraction RIA. 
DHEA was measured after diethylether extraction and Celite chromatography using an in-
house RIA (with extraction). Glucose levels were measured using a VITROS Chemistry System 
(Ortho-Clinical Diagnostics, Strasbourg, France) and from November 2006 on the Beckman 
Coulter UniCell DxC 800 chemistry analyser (Beckman Coulter, Woerden, the Netherlands).
 Intra- and interassay CVs were less than 10% and 6% for SHBG, less than 4% and 12% for 
androstenedione, less than 3% and 8% for insulin, less than 5% and 8% for DHEAS, less than 
11%, for testosterone, less than 9% and 14% for DHEA, and less than 4% and 4% for glucose, 
respectively. The ratio of DHEAS to DHEA was calculated.
Genotyping and quality control
Genomic DNA was extracted from peripheral venous blood samples according to standard 
procedures. For the discovery cohort genotypes were extracted from our Genome Wide 
Associated imputed genotypes database. Genotyping was performed using the Illumina 
HumanHap 610K bead array (Illumina). Imputation of the genome-wide genotyped data 
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on all autosomes was performed using the MACH algorithm (http://www.sph.umich.edu/
csg/abecasis/MACH/). Imputation of the X-chromosome was performed using IMPUTE 
(http://mathgen.stats.ox.ac.uk/impute/impute.html). SNPs in SULT2A1, PAPSS2 and STS plus 
50kb upstream and 50 kb downstream of the genes were selected using data from the 
Caucasian (CEU) subjects in the International HapMap database (release 24; http://hapmap.
ncbi.nlm.nih.gov). Of the total 594 SNPs, i.e. 129 SNPs in SULT2A1, 303 SNPs in PAPSS2 and 
162 SNPs in STS, 335 SNPs passed the quality thresholds of an imputation quality score of 
at least 0.90 and a minor allele frequency of 0.01 or greater. Based on pair-wise genotypic 
correlation with an r2 threshold of 0.2, a pruned subset of SNPs in SULT2A1, PAPSS2 and STS 
was generated using PLINK version 1.07 (http://pngu.mgh.harvard.edu/purcell/plink/) [23]. 
This pair-wise genotypic correlation resulted in a subset consisting of 28 independent SNPs: 
9 SNPs in SULT2A1, 11 SNPs in PAPSS2 and 8 SNPs in STS. Replication genotyping was done 
using Taqman Allelic Discrimination (Applied Biosystems) according to the manufacturer’s 
instructions.
Statistical analysis
Baseline characteristics of the PCOS patients from the discovery and replication set are 
presented as medians with interquartile ranges and percentages. In case of non-normality, 
parameters were log transformed to obtain a normal distribution. The statistical analyses were 
carried out using the IBM Statistical Package for the Social Sciences version 20 for Windows 
(IBM SPSS Inc).
 First, to determine association of the SNPs in SULT2A1, PAPSS2 and STS with PCOS, a case-
control analysis was carried out in the discovery set using logistic regression in MACH2DAT 
[24] for the SNPs in SULT2A1 and PAPSS2 and in SNPTEST [25] for the SNPs in STS. These analyses 
were adjusted for the first four principal components obtained from multidimensional scaling 
to correct for population stratification. Secondly, SNPs in SULT2A1, PAPSS2 and STS were tested 
in relation to DHEAS levels, DHEA levels and DHEAS to DHEA ratio in PCOS patients from the 
discovery set using MACHQTL [24] and SNPTEST [25]. Because the DHEAS and DHEA levels 
as well as the ratio were non-normally distributed we used the log transformed data in the 
analyses.
 Analyses within the PCOS set were first only adjusted for age and the first four principal 
components. In a second run the analyses were adjusted for principle components, age, 
BMI and insulin levels. The threshold for significance was set to a P ≤ 8.9e-4 [0.05/(28 SNPs*2 
independent analyses)].
 The discovery sample had power greater than 80% to detect an association of a risk allele 
with a frequency of 0.25 at an odds ratio of 1.5 with an alpha of 8.9e-4. SNPs reaching this 
threshold for significance were validated in the independent replication set of PCOS patients 
from Utrecht, the Netherlands using adjusted linear regression analysis. Replication analyses 
were carried out using SPSS. In the replication analysis Bonferroni adjustment was applied for 
the number of SNPs tested. Combined effect of the significant SNPs was tested using random 
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effects meta-analysis in R, statistical software for data analysis (http://www.R-project.org) [26]. 
To provide some insight in the role of the identified variants in SULT2A1, STS and PAPSS2 in 
the general population, association of significant SNPs with DHEAS levels, DHEA levels and 
their ratio will be tested in women from the Rotterdam Study. These data is only available in a 
subset of women included in the Rotterdam study, ie, for DHEAS levels n=852; for DHEA levels, 
n=303; and for their ratio, n=290. However, because there is only little overlap (n=95) between 
the subset of women with known DHEAS and DHEA levels in the Rotterdam Study and the 
women who were included as controls in the current study, and because a large age difference 
is present between PCOS cases (mean age 29.2 years) and controls (mean age 71.4 years), no 
direct comparisons will be made (Supplementary Note).
 Finally, to determine the influence of the replicated SNPs on the hyperandrogenic phenotype 
of PCOS, including testosterone and androstenedione levels, we compared phenotypic 
characteristics of PCOS patients who carried one of both minor allele of the significantly 
associated SNP with phenotypic characteristics of the patients who were homozygous for the 
major allele. These data were presented as median and interquartile range, and a regression 
analysis was performed to calculate differences between the carriers and noncarriers using 
SPSS. Analyses were adjusted for age, BMI, and insulin levels as indicated.
Results
Baseline characteristics of the PCOS patients from Rotterdam and Utrecht are listed in Table 1. 
The PCOS patients from Rotterdam had a more severe PCOS phenotype, indicated by a higher 
percentage of amenorrhea, a higher follicle count, higher BMI levels, higher insulin levels and 
higher androstenedione levels compared to patients from Utrecht. First, we determined the 
association of SNPs in SULT2A1, PAPSS2 and STS with PCOS. None of the SNPs in the genes 
constituted risk alleles for PCOS (Table 2).
 As indicated in Table 3, none of the SNPs in SULT2A1, PAPSS2 and STS were associated with 
logtransformed DHEAS levels in PCOS. SNP rs12011936 mapping STS showed a trend towards 
significance in relation to log-transformed DHEA levels as well as the ratio between DHEAS 
and DHEA. However, these variants did not reach the threshold for significance.
 Carriers of the minor T-allele of SNP rs2910397 in SULT2A1, had a decreased log-transformed 
DHEAS to DHEA ratio compared to noncarriers (effect -0.052, se 0.014, P = 1.24e-4). Each extra 
copy of the T-allele at rs2910397 decreased the log-transformed DHEAS to DHEA ratio with 
0.052, resulting in a 5.1% decrease in this ratio in patients suffering from PCOS. Additional 
adjustment of the association of rs2910397 for BMI and insulin levels did not change our 
results.
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Table 1 | Phenotypic characteristics of the PCOS patients in the discovery and replication sample.
Discovery sample Replication sample
n=582 n=412
Age, years 29.2 (25.5-32.0) 28.7 (25.0-31.9)
BMI, kg/m2 24.7 (21.4-30.1) 23.4 (20.7-28.4)
Amenorrhea 32.5% 27.6%
Oligomenorrhea 66.2% 70.9%
Regular cycle 1.4% 1.5%
Total follicle count, n 36 (26-50) 30 (24-39)
PCOM, % 93.4% 90.8%
DHEA, nmol/l 13.0 (9.2-19.0) 17.0 (13.0-24.0)
DHEAS, µmol/l 5.0 (3.5-6.7) 4.7 (3.3-6.5)
DHEAS/DHEA ratio, µmol/nmol 0.36 (0.26-0.50) 0.26 (0.2-0.35)
Adione, nmol/l 10.5 (8.1-13.4) 6.7 (5.1-8.8)
T, nmol/l 1.8 (1.3-2.3) 2.0 (1.5-2.4)
SHBG, nmol/l 43.3 (29.6-63.5) 52 (35-72)
FAI 4.1 (2.2-6.8) 3.7 (2.3-6.0)
Insulin, pmol/l 50 (34-82) 35 (21-63)
Glucose, mmol/l 4.2 (3.8-4.6) 5.0 (4.8-5.3)
Adione, androstenedione; FAI, free androgen index [(T/SHBG)100]; PCOM, polycystic ovarian morphology. Data are presented 
as median (interquartile range: 25th to 75th percentile), unless otherwise indicated.
Similar to the results in the discovery set, replication of the rs2910397 SNP in the independent 
set of PCOS patients from Utrecht was highly significantly associated with the log-transformed 
DHEAS to DHEA ratio after correction for age (effect -0.138, se 0.013, P = 0.005) and nominally 
significantly associated with the log-transformed DHEAS levels (effect -0.090, se 0.015, 
P = 0.05). Random effect meta-analysis of the discovery and replication sample resulted in 
a combined effect of -0.095 (P = 0.027) of rs2910397 on the ratio. In the general population, 
SNP rs2910397 was associated with neither the DHEAS levels nor the DHEA levels (P = 0.212 
and P = 0.373, respectively), however, the SNP was nominally significantly associated with the 
DHEAS to DHEA ratio (effect = -0.036, P = 0.04, see also supplementary note). Table 4 depicts 
the effect of carrying the minor T-allele of rs2910397 on several phenotypic characteristics of 
PCOS. We aimed to determine whether carrying this minor allele would result in differences 
in phenotype within PCOS. Obviously, the DHEAS to DHEA ratio was significantly decreased in 
the carriers of one or both minor T-alleles at rs2910397 compared to the noncarriers. However, 
all other parameters were similar in the carriers compared with the noncarriers.
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Table 2 | Case-control association analysis of genetic variants in SULT2A1, PAPSS2 and STS in PCOS cases 
versus controls from the general population.
Gene Chr SNP Position Alleles OR (95% CI) SE P value
SULT2A1 19 rs10410589 53016534 C,A 1.06 (0.92-1.23) 0.075 0.43
rs17272610 53020551 T,A 0.96 (0.83-1.12) 0.077 0.58
rs3760818 53028770 A,T 1.00 (0.88-1.14) 0.068 0.99
rs8100405 53034176 C,G 0.97 (0.85-1.11) 0.069 0.68
rs12462534 53036382 A,G 1.08 (0.95-1.24) 0.069 0.28
rs4802397 53053724 T,C 1.07 (0.88-1.30) 0.099 0.46
rs3936308 53078612 C,T 0.83 (0.47-1.49) 0.296 0.54
rs2932766 53082236 T,G 1.05 (0.91-1.21) 0.073 0.52
rs2910397 53089929 T,C 1.02 (0.88-1.18) 0.074 0.83
PAPSS2 10 rs10887732 89362213 T,G 1.00 (0.87-1.14) 0.068 0.99
rs17110864 89364066 C,T 1.03 (0.82-1.29) 0.114 0.80
rs1555433 89408867 G,A 0.93 (0.78-1.10) 0.086 0.38
rs17430359 89418502 T,G 0.87 (0.66-1.15) 0.142 0.33
rs17774221 89421320 G,A 1.17 (0.81-1.71) 0.191 0.40
rs7903516 89431082 T,C 1.09 (0.95-1.24) 0.068 0.22
rs12570024 89432677 C,T 1.08 (0.79-1.48) 0.160 0.62
rs941830 89447141 G,A 0.96 (0.84-1.09) 0.068 0.50
rs7919607 89459569 T,C 0.99 (0.86-1.13) 0.069 0.86
rs2302404 89464052 C,T 1.04 (0.69-1.58) 0.212 0.84
rs1321934 89485344 A,G 1.01 (0.88-1.16) 0.070 0.92
STS X rs17331438 7012290 G,A 1.59 (1.14-2.20) 0.168 0.006
rs12011936 7177230 G,T 1.04 (0.89-1.22) 0.079 0.59
rs5934670 6982708 A,G 0.87 (0.75-1.02) 0.078 0.08
rs4830732 7140734 C,T 1.23 (1.04-1.47) 0.090 0.02
rs802891 6959714 G,A 0.69 (0.49-0.97) 0.173 0.03
rs5934937 7100818 C,G 1.00 (0.87-1.14) 0.069 0.94
rs5933907 7176576 G,A 1.02 (0.86-1.22) 0.090 0.79
rs802901 6947743 G,A 1.00 (0.88-1.15) 0.069 0.96
Chr, chromosome; CI, confidence interval; OR, odds ratio; SE, standard error. The first mentioned allele is the effect allele.
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Discussion
None of the investigated SNPs in SULT2A1, PAPSS2, and STS were associated with PCOS. We did 
identify and replicate one SNP in SULT2A1 associated with the DHEAS to DHEA ratio in patients 
with PCOS. Although the minor allele of this SNP was associated with lower ratios, it did not 
affect the hyperandrogenic phenotype of PCOS.
 Because of the elevated DHEAS levels in PCOS patients [11] and given the evidence 
that adrenal hyperandrogenism is an inherited phenotype in PCOS [3,4], genes involved 
in the interconversion between DHEAS and DHEA are obvious candidate genes for PCOS. 
Remarkably, literature evaluating these genes in PCOS is scarce. Previously, only Goodarzi et al. 
[17] studied SULT2A1 and STS in relation to PCOS. They found no association of genetic variants 
in SULT2A1 and STS with PCOS. However, no replication cohort was included to validate the 
findings, and the study was only adequately powered to detect risk alleles with large effects. In 
our sample, which was twice as large and adequately powered, we could confirm that indeed 
both SULT2A1 and STS do not seem to be associated with PCOS. To our knowledge the present 
study is the first evaluating the role of PAPSS2 as a risk gene for PCOS. Availability of the sulfate 
donor PAPS regulates the activity of SULT2A1 [16]. Impaired sulfation of DHEA would result 
in elevated DHEA levels and thus increase levels of active androgens, which is an important 
feature of PCOS [18,19]. However, we found no association of SNPs in PAPSS2 with PCOS 
suggesting that PAPSS2 as well as SULT2A1 and STS, do not constitute risk genes for PCOS.
 PCOS encompasses a broad spectrum of signs and symptoms. Phenotypic characteristics, 
such as DHEAS and DHEA levels, vary largely between patients diagnosed with PCOS. Only 
half of the PCOS patients encounter elevated DHEAS levels [11-13]. Identification of modifiers 
of these characteristics can provide insight in the etiology of PCOS. Genetic variants mapping 
to SULT2A have been identified previously to be associated with lower DHEAS levels in PCOS 
patients [17]. We found that genetic variants in SULT2A1, PAPSS2 and STS were neither associated 
with DHEAS nor with DHEA levels in PCOS patients. However, one variant, ie, rs2910397, was 
highly associated with the DHEAS to DHEA ratio in PCOS patients from Rotterdam as well as 
with the ratio in the independent sample of PCOS patients from Utrecht. This genetic variant 
rs2910397 is mapping to SULT2A1. Previous studies have shown that the action of SULT2A1 is 
the rate-limiting step regulating the equilibrium between DHEAS and DHEA. In other words, 
sulfation appears to be the predominant direction of the interconversion between DHEAS and 
DHEA [27,28].
 To further explore the role of rs2910397 as a potential disease modifier in PCOS, we 
compared the phenotype of carriers of one or two minor alleles with the phenotype of patients 
who carried both copies of the major allele. Carriers of this genetic variant in SULT2A1 however, 
demonstrated no change in levels of active androgens or ovarian morphology compared to 
noncarriers. It is possible that SNP rs2910397 might only be an enhancing factor for PCOS 
or its phenotypic characteristics in association with other genetic variants. A genetic variant 
identified in Chinese PCOS patients was associated with hyperandrogenism in PCOS patients 
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from Northern European ancestry [29,30]. Interestingly, the variant was not related to a specific 
androgen level. The authors suggested it might be reflected a more complex relationship with 
serum androgen levels or the clinical features of hyperandrogenism [30].
 Because PCOS is a complex genetic disorder, interaction of several genetic variants in 
genes encoding enzymes in the steroidogenesis might contribute to the variation in adrenal 
androgen levels in PCOS. Increased expression of 3β-hydroxysteroid dehydrogenase (3β-HSD) 
type 1 and type 2 in adipose tissue has been observed in PCOS patients [31]. These enzymes 
are responsible for the conversion of DHEA to androstenedione in peripheral and adrenal 
tissue respectively. Increased expression of 3β-HSD 1 and 2 might lead to an increase of the 
conversion of DHEA to androstenedione and, subsequently, an elevation of the DHEAS to 
DHEA ratio [32]. In addition, an increased 5α-reductase activity as well as dysregulation of 
11β-HSD has been described in PCOS patients [33-36]. Both enzymes are involved in cortisol 
metabolism: 5α-reductase is responsible for 5alpha-reduction of cortisol to 5α-hydrocortisol 
in liver and 11β-HSD catalyzes the conversions of cortisone in cortisol and vice versa. Increased 
peripheral cortisol metabolism caused by either an increased 5α-reductase activity or 
dysregulation of 11β-HSD leads to a compensatory increase of ACTH secretion via a decrease 
in the negative feedback signal. As a result adrenal androgen levels will increase. Genetic 
variation in the 11β-HSD1 gene was observed to enhance cortisol clearance, and resulted 
in, increased DHEAS levels independently of BMI in PCOS patients [37]. On the contrary, a 
decrease in DHEAS levels was observed in PCOS patients carrying CYP3A7*1C variants [38]. The 
enzyme CYP3A7 metabolizes DHEA and DHEAS, facilitating their elimination [39]. Decreased 
levels of DHEAS levels were found in individuals carrying the CYP3A7*1C variant [40], which 
causes CYP3A7 expression to persist after birth [41]. Amongst all these factors, SNP rs2910397 
in SULT2A1 might contribute to the variation in adrenal androgens in PCOS.
 Because we also observed an association of rs2910397 in SULT2A1 with the DHEAS to 
DHEA ratio in controls, this SNP might be related to the genetic basis of steroidogenesis in 
general. Ideally, we would have also evaluated the effect of the genetic variants on DHEAS, 
DHEA levels as well as their ratio in PCOS patients compared with the effect in controls, but 
unfortunately a large age-matched control group with DHEAS as well as DHEA levels was not 
available. Therefore, whether the effect size of rs2910397 on the DHEAS/DHEA ratio is larger in 
PCOS cases compared to controls remains to be revealed.
 Genetic variants in SULT2A1, including rs2910397, have been found to be associated 
with serum DHEAS in a large meta-analysis of female Caucasian subjects from the general 
population [42]. Probably due to lack of power, we did not observe an association with DHEAS 
levels in our PCOS patients.
 In conclusion, genetic variants in SULT2A1, PAPSS2 and STS may not predispose to PCOS. 
One genetic variant in SULT2A1 was associated with an increase in the DHEAS to DHEA ratio 
in PCOS. However, clinical implications of this finding for PCOS diagnosis and etiology seem 
limited, since this SNP did not modulate the hyperandrogenic phenotype in PCOS and was 
also found be related to the DHEAS to DHEA ratio in the general population.
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Supplementary note
To provide some insight in the role of the identified variants in SULT2A1, STS and PAPSS2 in the 
general population, association of significant SNPs with DHEAS levels, DHEA levels and their 
ratio will be tested in women from the general population.
Methods
Study population
The Rotterdam Study is a large population-based study of elderly men and women from a 
defined area in Rotterdam the Netherlands. Data on DHEAS and DHEA levels were available in 
a randomly selected subset of women included in the Rotterdam Study, i.e. for DHEAS levels 
n=852; for DHEA levels, n=303; and for their ratio, n=290. DHEA and DHEAS were measured 
by double-antibody radioimmunoassays (RIA), Diagnostic Systems Laboratories, Webster, TX, 
USA. The ratio of DHEAS to DHEA was calculated.
Statistical analysis
SNPs mapping to the SULT2A1, STS and PAPSS2 genes that were significantly associated with 
DHEAS, DHEA levels or their ratio in PCOS patients, were also tested in controls for association 
with DHEAS, DHEA levels or their ratio in subject from the general population. Linear regression 
analysis was carried out to determine the association of these SNPs in relation to DHEAS, DHEA 
levels and their ratio in control women from the Rotterdam Study. Bonferroni adjustment was 
applied for the number of SNPs tested. The statistical analyses were carried out using the IBM 
Statistical Package for the Social Sciences version 20 for Windows (IBM SPSS Inc.). Because 
there was only little overlap (n=95) between the subset of women with known DHEAS and 
DHEA levels in the Rotterdam Study and the women who were included as controls in the 
current study, and because a large age difference is present between PCOS cases (mean age 
29.2 years) and controls (mean age 71.4 years) no direct comparisons will be made.
Results
In the controls from the general population mean levels of DHEAS were 2.7 µmol/l (± 2.1), 
DHEA 11.2 nmol/l (± 7.0) and the DHEAS to DHEA ratio was 0.30 (± 0.18). Of these women, 
n=95 were included as controls in the current study. In this set mean levels of DHEAS were 
2.6 µmol/l (± 2.0), DHEA 11.4 nmol/l (± 6.4) and the DHEAS to DHEA ratio was 0.29 (± 0.19). SNP 
rs2910397 was highly significantly associated with the DHEAS to DHEA ratio in PCOS patients 
and was therefore the role of rs2910397 in controls from the general population was tested. 
These association results are depicted in Table 1 and 2. 
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Table 1 | Association of rs2910397 in SULT2A1 in relation to DHEAS, DHEA and their ratio in controls 
form a population-based cohort.
DHEAS (n=852) DHEA (n=303) DHEAS to DHEA ratio (n=290)
Effect SE P value Effect SE P value Effect SE P value
rs2910397 -0.14 0.11 0.21 0.584 1.0 0.37 -0.04 0.02 0.04
DHEA, dehydroepiandrosterone; DHEAS, dehydroepiandrosterone sulfate; SE, standard error.
Table 2 | Association of rs2910397 in SULT2A1 in relation to DHEAS, DHEA and their ratio in controls 
included in the current study.
DHEAS (n=298) DHEA (n=98) DHEAS to DHEA ratio (n=95)
Effect SE P value effect SE P value Effect SE P value
rs2910397 -0.04 0.18 0.84 -0.06 1.0 0.95 -0.04 0.03 0.25
DHEA, dehydroepiandrosterone; DHEAS, dehydroepiandrosterone sulfate; SE, standard error.
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Abstract
Introduction: Polycystic Ovary Syndrome (PCOS) has a strong genetic background and the 
majority of patients with PCOS have elevated BMI levels. The aim of this study was to determine 
to which extent BMI-increasing alleles contribute to risk of PCOS when contemporaneous BMI 
is taken into consideration.
Methods: Patients with PCOS and controls were recruited from the United Kingdom (563 cases 
and 791 controls) and The Netherlands (510 cases and 2720 controls). Cases and controls were 
of similar BMI. SNPs mapping to 12 BMI-associated loci which have been extensively replicated 
across different ethnicities, i.e. BDNF, FAIM2, ETV5, FTO, GNPDA2, KCTD15, MC4R, MTCH2, NEGR1, 
SEC16B, SH2B1, and TMEM18, were studied in association with PCOS within each cohort using 
the additive genetic model followed by a combined analysis. A genetic allelic count risk score 
model was used to determine the risk of PCOS for individuals carrying increasing numbers of 
BMI-increasing alleles.
Results: None of the genetic variants, including FTO and MC4R, was associated with PCOS 
independent of BMI in the meta-analysis. Moreover, no differences were observed between 
cases and controls in the number of BMI-risk alleles present and no overall trend across the 
risk score groups was observed.
Conclusion: In this combined analysis of over 4,000 BMI-matched individuals from the United 
Kingdom and the Netherlands, we observed no association of BMI risk alleles with PCOS 
independent of BMI. 
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Introduction
Polycystic ovary syndrome (PCOS) is the most common endocrine disorder affecting up to 10% 
of females of reproductive age [1]. PCOS itself as well as its separate phenotypic characteristics 
demonstrate familial aggregation [2,3] and its heritability has been estimated as high as 
65% [4]. Key features of the syndrome include ovulatory dysfunction, hyperandrogenism 
and polycystic ovarian morphology. Moreover, the majority of patients with PCOS have 
overweight or obesity [5]. It has been well established that obesity worsens the phenotype 
of PCOS. Lifestyle interventions and weight-loss not only improve body composition and 
insulin resistance in patients with PCOS, they also ameliorate the reproductive phenotype 
[6-8]. Although this close relationship between PCOS and obesity clearly exists, underlying 
mechanisms are far from being understood.
 Obesity is also known to be a highly heritable trait [9,10] and its genetics have been widely 
and successfully investigated using genome wide association studies (GWAS) [11-15]. Since 
patients with PCOS have increased BMI levels compared to controls, genetic variants influencing 
PCOS might well include BMI risk alleles such that GWAS signals identified influencing PCOS 
might in fact be driven by primary effects on BMI. Therefore, it is of importance to evaluate 
whether adjustment or matching for BMI would eradicate the potential for variants influencing 
BMI to have an apparent effect on PCOS risk. If these effects remain after taking case-control 
differences in BMI into consideration, it might suggest either that a single BMI measurement is 
not an adequate proxy for lifelong BMI when it comes to specifying the effects of BMI on PCOS, 
or that the BMI risk alleles have pleiotropic effects on BMI as well as PCOS. The latter has been 
suggested for SNPs mapping to the FTO gene in association with obesity and type 2 diabetes 
mellitus in Asians [16,17].
 Previous studies observed association of risk-alleles mapping to the FTO and MC4R gene 
with PCOS and its phenotypic characteristics [18-23]. However, these studies did not include 
BMI-matched case-control sets and had relatively small sample sizes (number of cases ranging 
from 65 to 800 and less than 1000 controls). 
 Therefore, we studied twelve BMI-associated loci in BMI-matched case-control sets 
from two large university medical centers to determine the effect on PCOS-susceptibility 
independently of current BMI.
Materials and Methods
Ethics statement
All clinical investigations were conducted according to the guidelines in the Declaration of 
Helsinki. The study was approved by the medical ethics committee from the Erasmus MC 
University Medical Centre. Approval for the UK study was obtained from the North Thames 
Multicenter Research Ethics Committee [MREC/99/2/45]). All subjects provided fully written 
informed consent.
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Subjects
Independent northern European PCOS populations from the United Kingdom (UK) and the 
Netherlands were included in this study. The UK case-control set included a total of 1354 
women, of whom 563 were diagnosed with PCOS and 791 served as controls. The case-control 
set from the Netherlands consisted of 510 patients diagnosed with PCOS and 2720 control 
women from the general population. BMI levels between cases and controls in both studies 
were similar (P > 0.05). Patients in both cohorts were diagnosed according to 2003 Rotterdam 
criteria [24]. The controls from the UK were population-based and recruited as part of the UK 
Blood Services (UKBS) set up by the Wellcome Trust Case Control Consortium (WTCCC) [25]. 
Control women from the Netherlands were derived from the Rotterdam Study, a population-
based prospective cohort study [26]. In brief, this is a large population-based study of elderly 
subjects from a specific area near Rotterdam (Ommoord). All women aged 45 years or older 
at onset of menopause and with available DNA were included in the present analyses. These 
population-based control groups provided reference groups of allele frequencies which reflect 
the local general Northern European population, rather than being control groups wherein 
PCOS specifically was excluded. Patients and controls were of European descent.
Genotyping and quality control
Supplementary Table 1 summarizes the studied SNPs mapping to BMI-associated loci as 
identified by Frayling et al. [11], Loos et al. [13], Thorleifsson et al. [14] and Willer et al. [15]. 
These 12 loci were established as genome wide significant between the years 2007-2009 
during the first waves of GWAS and have been replicated across several ethnic populations 
ever since [27]. The studied SNPs were the lead SNPs mapping to the BMI-associated loci, 
as described in the aforementioned papers [11,13-15]. Genotyping was carried out using 
Taqman “on demand”-assays (Applied Biosystems, Warrington, UK). The genotyping success 
rate was > 95%. The Rotterdam Study controls were genotyped using the Illumina 550k array 
and imputed using HapMap2 CEU reference panel [28]. Genotypes of six of the SNPs were 
derived from this data: rs4074134 mapping to BDNF, rs7138803 mapping to FAIM2, rs7647305 
mapping to ETV5, rs10838738 mapping to MC4R, rs10913469 mapping to SEC16B, rs7498665 
mapping to SH2B1. SNP rs11084753 had an imputation quality of 94%, rs6548238 of 95% and 
all other SNPs had an imputation quality of > 99%. The other SNPs were genotyped using 
Taqman “on demand”-assays (Applied Biosystems, Warrington, UK). None of the SNPs deviated 
from Hardy-Weinberg equilibrium (HWE).
Statistical analysis and power calculation
Association analyses were initially carried out within each case-control set separately. The 
additive genetic model was tested using PLINK (v.1.07) [29] and IBM SPSS version 20 (IBM 
Statistical Package for the Sociological Sciences Inc., Chicago, USA). The combined effect of 
the BMI-increasing alleles in the two populations was evaluated using a fixed-effects meta-
analysis in GWAMA [30]for SNPs with heterogeneity (I2) less than 25%. When I2 exceeded 25%, 
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a random effect meta-analysis was performed using statistical software package R (http://
www.r-project.org) [31]. Using Genetic Power Calculator software we determined that with 
the sample size of the total case control set (cases: n=1073; controls: n=3511), we reached 
approximately 95% power to detect association of a risk allele of frequency ≥ 0.2 having an 
odds ratio of ≥ 1.3 and an alpha of 0.05 (http://pngu.mgh.harvard.edu/~purcell/gpc/) [32]. 
Since the genetic variants were selected and not randomly tested, we did not correct for 
multiple testing and a P < 0.05 was considered statistically significant.
 To test for the combined effect of all the BMI-associated alleles on PCOS susceptibility and 
to estimate the genetic risk of having PCOS for these women dependent on the number of BMI-
increasing alleles present, we calculated the Genetic Risk Score (GRS). The GRS was modeled 
as a continuous variable and the calculation was carried out using R (http://www.r-project.
org/) [31]. Using the GRS we assume that each SNP in the panel contributes equally to PCOS 
risk and that each individual allele has an equal and additive effect on risk. To obtain accurate 
counts of BMI-increasing alleles, only individuals with genotypes for at least 90% of SNPs (11 
out of 12) were included. Based on this criterion, a total of 1264 individuals, i.e., 512 cases 
and 752 controls, from the UK and 3150 individuals from the Netherlands, i.e. 502 cases and 
2648 controls, were included in the GRS-analysis. This method was described previously 
[33,34]. Missing genotypes were replaced with the average risk score for each SNP in the total 
population. The maximum attainable score was 24 BMI-increasing alleles (12 SNPs * 2 alleles). 
The reference group was defined as 12 to 13 BMI-increasing alleles, which was the mean 
number of BMI-increasing alleles present in the controls. Analyses were carried out within the 
separate case-control sets as well as in the combined set. Finally, we calculated the overall 
trend across the GRS-groups using the Kruskal Wallis trend test (IBM SPSS version 20).
Results
The UK cases had a mean BMI of 26.0 kg/m2 (± 10.9 SD) and the controls had a BMI of 
25.9 kg/m2 (± 4.57 SD), whereas the cases from the Netherlands had a median BMI of 26.4 kg/m2 
(IQR 22.4-31.7) and the controls had a BMI of 26.3 kg/m2 (IQR 23.97-29.1). Allele frequencies 
of the BMI-risk alleles in the cases and controls of both case-control sets are reported in 
supplementary Table 2. First, we tested whether carrying BMI-associated alleles influenced 
PCOS susceptibility in cases and controls who were of similar BMI (Table 1). SNP rs7498665 
mapping to the SH2B1 locus was significantly associated with a decreased risk of having PCOS 
(OR = 0.79; 95% CI 0.69-0.90, P = 0.001) in the case-control set from the Netherlands. No such 
association was evident in the case-control set from the UK (OR = 1.04; 95% CI 0.88-1.22, 
P = 0.64) or in the random effects meta-analysis. Moreover, none of the other SNPs was 
significantly associated with PCOS, neither in the separate UK and Dutch analysis nor in the 
meta-analysis. 
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To determine whether the overall burden of BMI-increasing alleles was associated with PCOS 
case-control status in these samples, a GRS was constructed (Figure 1, Table 2). The individuals 
carrying less than 8 BMI-associated alleles and individuals carrying over 18 BMI-associated 
alleles together account for a very small proportion of the total population, i.e. 2.6%. None of 
the GRS-groups was attributed more often to patients with PCOS compared with the reference 
GRS-group. Moreover, no overall trend in carrying an increasing number of BMI-associated 
alleles on PCOS susceptibility was observed neither for the total case-control set (P = 0.44), nor 
for the separate case-control sets from the UK (P = 0.97) or the Netherlands (P = 0.17).
Figure 1 | Combined impact of risk alleles on the risk of having PCOS compared to the reference risk 
group.
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Discussion
In this combined analysis including > 4,000 patients with PCOS and controls from the United 
Kingdom and the Netherlands, we observed no association of genetic BMI-risk loci with PCOS 
when contemporaneous BMI is similar in cases and controls.
 The last two years, genome wide association studies (GWAS) have emerged to identify 
genetic risk factors for PCOS. Two large studies identifying such PCOS-susceptibility loci in 
Han-Chinese patients have been published [35,36], while GWAS in patients from Northern 
European ancestry are in progress. In the current study, we observed no systematic effect 
of the BMI-associated alleles on PCOS susceptibility in our BMI-matched case-control set, 
indicating that BMI-associated alleles do not convey pleiotropic effects on PCOS risk. This 
infers that adjustment or matching for BMI will disentangle BMI-associated genetic signals 
to show up in PCOS GWAS and seems therefore not a genuine concern in the previous and 
upcoming GWASs in PCOS.
 Presence of an increasing number of BMI-raising alleles is associated with an increased 
genetic predisposition to obesity. To determine the overall burden of BMI-associated alleles on 
risk for PCOS we calculated a counted genetic risk score and compared PCOS risk across such 
BMI risk groups. By doing so, we assumed that each allele has an equal and additive effect on 
PCOS risk. In practice some SNPs will have stronger effects than others. However, when the ORs 
are small as they are in our study, using a counted genetic risk model is appropriate [33,37]. 
None of the GRS-groups was attributed more often to the patients diagnosed with PCOS 
than controls compared to the reference GRS-group. Moreover, no overall trend across the 
consecutive GRS groups was observed, strengthening the results from the allelic-association 
analysis that BMI-associated alleles seem not to have pleotropic effects on PCOS risk. Increased 
BMI levels and weight in PCOS seem to be mediated by other genetic factors determining 
an individual’s susceptibility to become obese or through modifying environmental effects. 
It has been shown that although women with PCOS reported a better, more healthy, dietary 
intake they seem to have an increased energy intake in combination with an increased sitting 
time without any discernible differences in total physical activity compared to women without 
PCOS [38]. Moreover, also in patients with PCOS, higher energy intake and glycaemic index 
and lower physical activity, as well as age, smoking, alcohol intake, occupation, education and 
country of birth, were independently associated with BMI [39].
 A potential limitation of the current study is that we matched BMI based on a single 
measurement. In general the BMI increases in men as well as in women throughout life. 
Therefore, a single BMI measurement may not be an appropriate proxy for lifetime BMI and 
might be a poor estimate of the long-standing effects of BMI on PCOS risk. However, since 
we observed no systematic effect of BMI-associated alleles on PCOS risk in our matched case-
control set, this seems not to have influenced our results tremendously. It has been previously 
observed that the association of genetic variants in FTO and MC4R with BMI and weight 
strengthen during childhood up to age 20 years and then become weaker with increasing age 
during adulthood [40]. Therefore, as has been suggested for phenotypes associated with type 
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2 diabetes mellitus [17], longitudinal studies are needed to adequately explore the complex 
and dynamic nature of BMI-associated alleles on cardiometabolic characteristics in PCOS.
 In conclusion, we have shown in two independent large PCOS case-control sets matched 
for BMI, that there is no systematic effect of BMI-associated alleles on PCOS risk suggesting that 
these alleles do not have a pleiotropic effect on PCOS susceptibility. Hence, adjusting for BMI 
in PCOS case-control GWAS studies should be an effective strategy for removing confounding 
effects of BMI on the association of other genetic variants and PCOS.
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Supplementary Tables
Supplementary Table 1 | Studied BMI-associated loci.
Nearest gene SNP Chromosome Position Paper in which the  
SNP was first cited
BDNF rs4074134 11 27603861 Thorleifsen et al.
FAIM2 rs7138803 12 48533735 Thorleifsen et al.
ETV5 rs7647305 3 187316984 Thorleifsen et al.
FTO rs9939609 16 52378028 Frayling et al.
GNPDA2 rs10938397 4 44877284 Willer et al.
KCTD15 rs11084753 19 39013977 Willer et al.
MC4R rs17782313 18 56002077 Willer et al.
MTCH2 rs10838738 11 47619625 Loos et al.
NEGR1 rs2815752 1 72585028 Willer et al.
SEC16B rs10913469 1 176180142 Thorleifsen et al.
SH2B1 rs7498665 16 28790742 Willer et al.
TMEM18 rs6548238 2 624905 Willer et al.
SNP, Single Nucleotide Polymorphism.
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Abstract
Context: Genome Wide Association Studies (GWAS) have revealed new susceptibility loci for 
Chinese patients with Polycystic Ovary Syndrome (PCOS). Because ethnic background adds to 
phenotypic diversities in PCOS, it seems plausible that genetic variants associated with PCOS 
act differently in various ethnic populations. 
Objective: We studied cross-ethnic effects of Chinese PCOS loci (ie, LHCGR, THADA, DENND1A, 
FSHR, c9orf3, YAP1, RAB5B/SUOX, HMGA2, TOX3, INSR, and SUMO1P) in patients of Northern 
European descent. 
Design: Genetic association study conducted at an University Medical Center.
Patients: Association was studied in 703 Dutch PCOS patients and 2164 Dutch controls. To 
assess the cross-ethnic effect, we performed a meta-analysis of the Dutch data combined 
with results of previously published studies in PCOS patients from China (n=2254) and the 
United States (n=2618) (US). Adjusted for multiple testing, a P value < 3.1 x 10-3 was considered 
statistically significant. 
Results: Meta-analysis of the Chinese, US, and Dutch data resulted 12 significant 
variants mapping to the YAP1 (P value = 1.0 x 10-9), RAB5B/SUOX (P value = 3.8 x 10-11), 
LHCGR (P value = 4.1 x 10-4), THADA (P value = 2.2x10-4 and P value =1.3x10-3), DENND1A 
(P value = 2.3x10-3 and P value = 2.5 x 10-3), FSHR (P value = 3.8 x 10-5 and P value = 3.6 x 10-4), 
c9orf3 (P value =2.0 x 10-6 and P value = 9.2 x 10-6), SUMO1P1 (P value = 2.3 x 10-3) loci with ORs 
ranging from 1.19 to 1.45 and 0.79 to 0.87.
Conclusions: Overall, we observed for 12 of 17 genetic variants mapping to the Chinese 
PCOS loci similar effect size and identical direction in PCOS patients from Northern European 
ancestry, indicating a common genetic risk profile for PCOS across populations. Therefore, it 
is expected that large GWAS in PCOS patients from Northern European ancestry will partly 
identify similar loci as the GWAS in Chinese PCOS patients.
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Introduction
Polycystic ovary syndrome (PCOS) is the most common endocrinopathy in women affecting 
approximately 6-10% of all reproductive-aged women. Patients with PCOS suffer from 
ovulatory dysfunction, have signs of hyperandrogenism and have polycystic morphology of 
the ovaries. Associated symptoms of PCOS include obesity, insulin resistance, dyslipidemia 
and type 2 diabetes leading to major health implications. It is a life-long condition with 
considerable variation of symptomatology between and within patients. PCOS itself and 
associated symptoms cluster in families [1]. Based on twin studies the heritability of PCOS is 
estimated to be around 65% [1]. Although, genetic variants in up to one hundred candidate 
genes have been found to be associated with PCOS in previous studies, the vast majority of 
these have not been replicated. Hitherto, only Genome Wide Association Studies (GWAS) 
of Han-Chinese PCOS patients have revealed new susceptibility loci for PCOS [2,3]. The top-
signals of a recent Korean GWAS in PCOS patients did not reach the genome wide significance 
(gws) threshold [4]. The first GWAS on PCOS was conducted in a Han-Chinese population and 
identified variants mapping to three loci (ie, 2p16.3, 2p21 and 9q33.3) [2]. 
 Subsequently, association of some of the variants in these susceptibility loci were confirmed 
in PCOS patients from the United States [5,6]. Recently, a second GWAS in a larger cohort of 
Han-Chinese PCOS patients discovered variants mapping to eight new risk loci (ie, 2p16.3, 
9q22.32, 11q22.1, 12q13.2, 12q14.3, 16q12.1, 19p13.3 and 20q13.2) for PCOS [3]. Among the 
genes located in these loci were the FSRH gene and the INSR gene which both have been 
previously associated with PCOS in candidate gene studies (5,7]. Following the GWAS by Shi 
et al. [3], fine-mapping of the 2p16.3 region in PCOS patients from the United States reported 
evidence of this region for association with PCOS [8]. This is in line with what we and others 
previously demonstrated [7,9]. Moreover, genetic variation in the FSHR gene has been found 
to predict ovulation after clomiphene citrate treatment in infertile women [10].
 It has been well established that ethnic background adds to the phenotypic diversities 
in PCOS patients [11-14]. Chinese patients with PCOS present themselves more often with 
an amenorrhea and hyperandrogenism compared with PCOS patients of Northern European 
ancestry [12]. Moreover, they seem to be at increased risk of metabolic complications in later 
life [12]. Differences in genetic risk profile might contribute to these phenotypic differences in 
PCOS patients from different ethnic populations. Thus, it seems plausible that genetic variants 
associated with PCOS act differently in diverse ethnic populations.
 Therefore, the aim of this study was to assess the association of genetic variants identified 
in the studies by Chen et al. [2] and Shi et al. [3] in our Dutch PCOS cases and controls from 
Northern European ancestry. We performed a meta-analysis of the Dutch data with the data 
from the two previously published US studies. Finally, to determine the cross-ethnic effects 
of the genetic variants, we conducted a meta-analysis with the Chinese, US, and Dutch data 
combined.
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Material and Methods
Subjects and phenotyping
All 703 Dutch PCOS patients of Northern European ancestry included in this study were 
recruited from a large University hospital in Rotterdam, the Netherlands. The patients visited 
the outpatient clinic and underwent a standardized physical examination and hormonal 
evaluation after an overnight fast. Clinical work-up included menstrual history as well as 
current cycle length, anthropometric measurements (height and weight) and calculation 
of body mass index (BMI) as weight in kilograms divided by the squared height in meters. 
Transvaginal ultrasonography was performed to assess ovarian volume and number of follicles 
in both ovaries. PCOS was diagnosed according to the 2003 Rotterdam consensus criteria [15]. 
In agreement with these criteria two of the following three criteria should be present: oligo-
ovulation and/or anovulation with gonadotropins levels within the normal limits, biochemical 
and/or clinical hyperandrogenism and polycystic morphology of the ovaries. Oligomenorrhea 
was defined as a cycle length over 35 days and amenorrhea as absence of menstrual bleeding. 
Biochemical hyperandrogenism was determined by calculation of the Free Androgen Index 
as: 100 x T (testosterone) (nmol/L) / SHBG (nmol/L). A Free Androgen Index exceeding 4.5 
was used as a cut-off. Clinical hirsutism was assessed using the modified Ferriman-Gallwey 
score and defined as a score of at least 8. Polycystic morphology of the ovaries was assessed 
by transvaginal ultrasound and defined as the presence of at least 12 follicles in one or 
both ovaries and/or increased ovarian volume > 10 ml. Exclusion criteria were presence of 
related disorders with similar presentations such as Cushing’s disease and congenital adrenal 
hyperplasia.
 Control women were recruited from a local general Dutch population of Northern 
European ancestry. The controls were drawn from the Rotterdam Study, a population-based 
prospective cohort study [16]. Briefly, it is a large population-based study of the elderly from 
an area near Rotterdam. All women of whom DNA was available, with an age of menarche 
between 10-17 years, age of menopause > 40 years and who had had at least two children 
were included. Data on menstrual cycle was available in only 20% of these women. Women 
who had reported an irregular menstrual cycle history were excluded. The included controls 
provide a reference group of the local general population rather than a control group in which 
PCOS was specifically excluded. This study was approved by the institutional medical ethical 
review board, and written informed consent was obtained from all participants. 
Genotyping and quality control
Genomic DNA was extracted from peripheral venous blood samples according to standard 
procedures. Genotyping of the cases was performed using the Illumina HumanHap 610K 
beadarray. Controls were genotyped using the Illumina Infinium HumanHap 550K beadarray. 
Imputation of the genome-wide genotyped data of both cases and controls on all autosomes 
was performed using the MACH algorithm (http://www.sph.umich.edu/csg/abecasis/MACH) 
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based on phased autosomal chromosomes of the HapMap CEU Phase II panel (release 
September 2006 build 126). The genotypes of the 17 single nucleotide polymorphisms (SNPs) 
associated with PCOS in the Chinese as identified by Chen et al and Shi et al. [2,3], mapping to 
the LHCGR, THADA, DENND1A, FSHR, c9orf3, YAP1, RAB5B/SUOX, HMGA2, TOX3, INSR, SUMO1P1 
loci were retrieved from this genome-wide imputed genotypes database. Imputation quality 
of rs2349415 was 0.86; the imputation quality of rs6022786 was 0.87, and the imputation 
quality of rs2272046 was 0.92. All other SNPs were imputed with a quality above 0.95. Northern 
European ancestry of cases and controls was determined by Principal Component Analysis. 
Statistical analysis and power calculation
Baseline characteristics of the PCOS cases are displayed as medians and interquartile ranges 
which were calculated using IBM SPSS Statistics version 20. To test for association with PCOS in 
our Northern European case-control sample we performed adjusted allelic association analysis 
using MACH2DAT software (http://www.sph.umich.edu/csg/abecasis/MaCH) implemented in 
BCSNPmax.
 The first four Principal Components retrieved from principal component analysis, were 
used to correct for potential population stratification. Because a high correlation (i.e. r2 = 0.826, 
D’ = 1) between rs10986105 and rs10818854 exist in the Caucasian population, we adjusted 
for 16 independent SNPs. A P value < 3.1 x 10-3 (0.05/16) was considered statistically significant. 
 Genetic Power Calculator package (http://pngu.mgh.harvard.edu/~purcell/gpc/) was 
used to calculate the power to detect an association between the tested SNPs and PCOS [17]. 
We assumed effect estimates similar to those observed in the Chinese sample and used allele 
frequencies from the Hapmap CEU cohort [18]. As indicated in Supplementary Table 1, the 
power to detect effects of similar magnitude to the Chinese PCOS case-control sample was 
limited. To improve the statistical power to detect effects, we performed a meta-analysis with 
previously published data. SNPs mapping to the THADA, DENND1A and LHCGR loci identified 
by Chen et al. [2] have been previously tested in the Northern European case-control samples 
[5,6,19,20]. The studies by Eriksen et al. [19] and Lerchbaum et al. [20] only reported allele 
frequencies and P values in their published data, and were therefore not included in the 
Northern European meta-analysis. The GWAS in Korean PCOS patients by Hwang et al. [4] 
also evaluated the significance of the previously identified Chinese associated variants in 
their population. They describe that six of the seven tested genetic variants, had a significant 
P values between 2 x 10-2 and 8 x 10-4 [4]. However, neither in their manuscript, nor in the 
supplementary data, they report more detailed information. Therefore, this data was not 
included in the meta-analysis. Supplementary Table 2 summarizes the SNPs identified by Chen 
et al. [2] and Shi et al. [3] and replicated by Goodarzi et al. [5], Welt et al. [6] as well as the 
current study. 
 To assess the cross-ethnic effects of the Chinese susceptibility genetic variants for PCOS, we 
performed a meta-analysis of the Dutch data combined with results of previously published 
studies in PCOS patients from China, that is, the previously published data by Chen et al. [2], Shi 
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et al. [3], and the data from the United States, the studies by Goodarzi et al. [5], Welt et al. [6]. 
A fixed effect meta-analysis was conducted using GWAMA, a software tool for meta-analysis 
[21] for SNPs with heterogeneity (I2) less than 25%. When I2 exceeded 25%, a random effect 
meta-analysis was performed using statistical software package R (http://www.r-project.org). 
Because the study by Shi et al. [3] is an extension of the study by Chen et al. [2], we included 
for the meta-analysis only the results of the discovery phase to avoid overlap of patients.
Results
Baseline characteristics of the PCOS patients from the Dutch data and the previously published 
studies from China and the United States [2,3,5,6] are displayed in Table 1. The allele frequencies 
of each SNP in the Chinese, US and Dutch control samples as well as the allele frequencies 
from the Hapmap CEU and CHB populations [22] are depicted in Table 2. The majority of the 
studied SNPs differ in allele frequency in individuals from Chinese ancestry compared with 
individuals included in the US and Dutch control-samples, which were of Northern European 
ancestry. Table 3 summarizes the results of the Dutch study, the results of the previously 
published Chinese and US studies as well as the results of the meta-analyses. The strongest 
PCOS association in the Dutch data was with rs1894116 mapping to the YAP1 locus (odds ratio 
[OR] = 1.37, P value = 1.85 x 10-3). SNP rs705702 mapping to the RAB5B/SUOX locus (OR = 1.21, 
P value = 4.31 x 10-3) was also associated with PCOS. However, most likely due to lack of power, 
this signal did not reach the threshold for significance. In the current study rs12468395 and 
rs12478601 mapping to the THADA locus, rs10986105 mapping to the DENND1A locus and 
rs4385527 mapping to the c9orf3 locus were nominally significantly associated with PCOS 
susceptibility. The magnitude of the effects as well as the direction of the effect of these five 
SNPs was similar to those observed in the GWAS on Chinese PCOS patients. 
 In the fixed effect meta-analysis of the Dutch data and the United States, the studies 
by Goodarzi et al, Welt et al, rs10818854 mapping to the DENND1A locus was significantly 
(OR = 1.53, P value = 1.68 x 10-8) associated with PCOS. However, heterogeneity of 0.82 
was present amongst these studies for this SNP (Supplementary Table 3). In the random 
effect meta-analysis rs10818854 was no longer significant (P value = 4.9 x 10-3). Two SNPs 
mapping to the THADA locus (ie, rs12468394 [OR = 0.87, P value = 1.01 x 10-5] and rs12478601 
[OR = 0.88, P value = 1.77 x 10-4], as well as rs10986105 mapping to the DENND1A locus 
[OR = 1.56, P value = 1.53 x 10-5]) were significantly associated with PCOS in the meta-analysis 
of the studies with samples from Northern European ancestry.
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Table 2 | Frequencies of risk alleles derived from the Hapmap CHB and Hapmap CEU as well as the 
allele frequencies control samples from the GWAS by Chen et al., the GWAS by Shi et al. and the current 
study.
Chinese population Northern European population
SNP Allele Hapmap CHB Chen et al. Shi et al. Hapmap CEU Dutch data
(n=90) (n=895) (n=2106) (n=90) (n=2164)
rs13405728 G 0.26 0.27 - 0.06 0.05
rs12468394 A 0.28 0.31 - 0.51 0.50
rs13429458 C 0.19 0.21 - 0.10 0.11
rs12478601 T 0.32 0.31 - 0.60 0.57
rs10818854 A 0.04 0.08 - 0.05 0.04
rs2479106 G 0.15 0.22 - 0.30 0.30
rs10986105 C 0.06 0.07 - 0.04 0.04
rs2268361 T 0.43 - 0.50 0.75 0.64
rs2349415 T 0.24 - 0.18 0.28 0.32
rs4385527 A 0.18 - 0.22 0.41 0.39
rs3802457 A 0.14 - 0.10 0.01 0.01
rs1894116 G 0.18 - 0.19 0.07 0.09
rs705702 G 0.30 - 0.25 0.28 0.30
rs2272046 C 0.08 - 0.09 0.03 0.03
rs4784165 G 0.30 - 0.33 0.24 0.25
rs2059807 G 0.33 - 0.30 0.64 0.61
rs6022786 A 0.35 - 0.34 0.43 0.42
SNP, single nucleotide polymorphism; NA, Not Available 
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Meta-analysis of the Dutch, US and Chinese data resulted in 12 significant variants: rs13405728 
(OR = 0.86, P value = 4.1x10-4) mapping to the LHCGR locus, rs12468394 (OR = 0.80, P value 
= 2.2x10-4) and rs12478601 (OR = 0.82, P value = 1.3x10-3) mapping to the THADA locus, 
rs10818854 (OR=1.45, P value = 2.3x10-3) and rs10986105 (OR = 1.54, P value = 2.5x10-3) 
mapping to the DENND1A locus, rs2268361 (OR = 0.87, P value = 3.8x10-5) and rs2349415 (OR 
= 1.24, P value = 3.6x10-4) mapping to the FSHR locus, rs4385527 (OR = 0.82, P value =2.0x10-6) 
and rs3802457 (OR = 0.70, P value = 9.2x10-6), mapping to the c9orf3 locus, rs1894116 (OR = 
1.32, P value = 1.0x10-9) mapping to the YAP1 locus and rs705702 (OR = 1.28, P value = 3.8x10-
11) mapping to the RAB5B/SUOX locus, rs6022786 (OR = 1.19, P value = 2.3x10-3) mapping to 
the SUMO1P1 locus.
Discussion
For 12 genetic variants, mapping to the LHCGR, THADA, DENND1A, FSHR, c9orf3, YAP1, RAB5B/
SUOX and SUMO1P1 loci, identified by GWAS in Chinese PCOS patients we observed similar 
effect sizes and identical direction in patients of Northern European ancestry from the 
Netherlands and the United States. Since the publication of the first GWAS in Han-Chinese 
PCOS patients by Chen et al. [2], several research groups aimed to replicate the three identified 
loci (ie, LHGCR, THADA and DENND1A) in PCOS patients from Northern European ancestry. 
Adequately powered studies succeeded in validating several of the identified variants [5,11], 
whereas others were not able to replicate any of the Chinese findings [19,20]. Shi et al revealed 
eight new risk for PCOS [3], which hitherto have not been assessed in PCOS patients from 
Northern European ancestry. This is the first study replicating the association of rs1894116 
mapping to the YAP1 locus with PCOS in a case-control set from Northern European ancestry. 
After identification by Shi et al. [3], this variant is replicated in an independent sample of Han-
Chinese PCOS patients [23]. The YAP1 gene encodes for the protein YAP1 (Yes-associated protein 
1) which is one of the transcriptional targets of the highly conserved Hippo pathway which 
controls organ size by regulating cell growth, proliferation and apoptosis [24]. Dysregulation 
of the Hippo pathway and overexpression of YAP resulted in tumor formation [25,26]. YAP1 
was also found to be expressed in porcine ovaries [27]. Because increased ovarian volume is 
an important clinical feature of PCOS, this might be regulated by the Hippo signaling pathway. 
However, translational studies are needed to confirm this hypothesis.
 Another important key feature of PCOS is ovulatory dysfunction. Factors that play key 
regulatory roles in follicular growth, ovulation and luteinization are the pituitary gonadotropins 
FSH and LH as well as their receptors, FSHR and LHCGR respectively. In this cross-ethnic 
assessment, we observed that genetic variants mapping to the FSHR were associated with 
PCOS. Genetic variation in the FSHR gene, encoding the FSH receptor, has been extensively 
studied in association with ovulatory dysfunction. Previously, a higher prevalence of genetic 
variants in the FSHR gene in PCOS patients from Italy and the United States has been described 
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[7,8]. Moreover, it has been shown in studies with infertile patients from various ethnic ancestry 
that variants mapping to the FSHR influence FSH levels and can even predict ovarian response 
after ovulation induction treatment [7,9,10,28,29].
 LHCGR encodes a G protein-coupled receptor for luteinizing hormone and human chorionic 
gonadotropin (hCG). In the ovary, LHCGR is expressed in granulosa cells at the later stages of 
pre-ovulatory follicles. Notably, the induction of LHCGR during granulosa cell differentiation 
allows the pre-ovulatory follicle to respond to the mid-cycle surge of luteinizing hormone, 
resulting in ovulation and release of the mature oocyte. In women, inactivating mutations of 
LHCGR are associated with increased luteinizing hormone, enlarged ovaries, oligomenorrhea, 
resistance to luteinizing hormone or HCG, and infertility [30]. In the current study, we were also 
able to relate genetic variants mapping to LHCGR to PCOS. Whether this gene, besides that 
it constitutes a risk allele for PCOS, shares a similar relationship with LH as well as androgen 
levels remains to be determined. Genetic variants mapping to LHCGR did not influence the 
characteristic clinical features, i.e. BMI, testosterone and homeostasis model assessment–
insulin resistance (HOMA-IR), of PCOS [2]. Hence, in contrast to variants mapping FSHR, this 
variant seems not to account for other clinical phenotypes frequently found in PCOS.
 Allele frequencies of the majority of risk alleles differ remarkably in the samples from 
Northern European ancestry compared with the sample from Asian ancestry. Previously, 
Ioannidis and colleagues [31] observed that genetic markers indeed vary in frequency across 
populations, however that their biological impact on the risk for common diseases may usually 
be consistent across these populations. Obviously, even if their biological impact on the risk 
is similar, larger samples sizes are needed when the allele frequency of the risk allele is low. 
We increased the power to detect associations by combining the results from US studies with 
the Dutch data and we confirmed the association of genetic variants mapping to THADA and 
DENND1A. In the cross-ethnic meta-analysis of the Chinese, US and Dutch data combined, 12 
out of the 17 genetic variants were associated with PCOS. Genetic variants mapping to the 
RAB5B/SUOX and YAP1 loci even reached the genome wide significant level. Another important 
issue when replicating GWAS findings from one population in other populations is dissimilarity 
of linkage disequilibrium (LD) across these populations. LD describes the correlation among 
neighboring alleles on the same chromosome [32]. It has been well established that these 
patterns of LD are different across populations [18,32]. The tested genetic variant will only 
give a significant association with the disease if it is strongly correlated with the functional 
genetic variant. When the functional genetic variant is located in another LD block because 
of population differences, it will not be detected with the tested variant. LD structure needs 
to be taken into account when studying association among different populations. However, 
while LD structure of the THADA locus is different for Northern Europeans compared with the 
Chinese, we were able replicate the Chinese finding. For the other loci the LD patterns were 
only slightly different.
 Obviously, besides genetic factors, also the potential influence of non-genetic factors, 
such as dietary intake and environmental factors like exogenously derived compounds, might 
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be involved in the etiology of PCOS. Is has been well established that over-nutrition leading 
to obesity aggravates reproductive as well as metabolic components of the PCOS phenotype 
[33]. Moreover, high intake of dietary advanced glycation end products may also contribute 
to the pathogenesis of PCOS (34). A potential exogenously derived compound is Bisphenol A, 
which has been found to be associated with androgen levels and insulin resistance in PCOS 
[35]. Evidently, these non-genetic factors differ between ethnicities and might also underlay 
diversities in phenotype.
 In this cross-ethnic assessment, we observed similar effect size and identical direction in 
PCOS patients from Northern European ancestry for 12 of the genetic variants mapping to 
the Chinese PCOS loci, indicating a common genetic risk profile for PCOS across populations. 
Because allele frequencies as well as phenotypic characteristics differ between PCOS patients 
from various ancestry, analyses in a large PCOS consortium, which we are conducting now, are 
needed to confirm and further explore ethnic-specific genetic profile. It is expected though, 
that large GWAS in PCOS patients from Northern European ancestry will at least partly identify 
similar loci as the GWAS in Chinese PCOS patients.
149Cross-ethnic meta-analysis in PCOS | 
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Abstract
Context: It has been well established that ethnicity is associated with the phenotype of 
Polycystic Ovary Syndrome (PCOS). However, self-reported ethnicity has been shown to be an 
inaccurate proxy for ethnic origin in other disease traits, and it is unclear how in PCOS patients 
self-reported ethnicity compares with a biological proxy such as genetic ancestry.
Objective: We analyzed the association of self-reported ethnicity in patients with PCOS to 
genetic ancestry based on genome-wide array data. Moreover, we determined which of these 
classifications better predicts the variability in endocrine and metabolic characteristics of 
PCOS better.
Patients: 1499 Dutch PCOS patients from the Netherlands, comprised of 11 self-reported 
ethnic groups of European, African, American and Asian descent were genotyped with the 
Illumina 610K Quad BeadChip and merged with the Illumina data available from HGDP-CEPH 
reference panel including 53 worldwide populations for ancestry inference.
Main outcome measures: Algorithms for inferring genetic relationships among individuals, 
including Multi-Dimensional-Scaling (MDS) and ADMIXTURE, were applied to describe and 
recover the genetic ancestry for each individual. Regression analysis was used to determine 
the best predictor for the variability in PCOS phenotypic and sub-phenotypic characteristics.
Results: The association between self-reported ethnicity and genetic ancestry as derived 
from genome-wide data was moderate, i.e. Cramer’s V = 0.77. For amenorrhea, total follicle 
count, BMI, SHBG, DHEAS and insulin, mainly genetic ancestry clusters ended up in the final 
models (P value < 0.004), indicating that they explain a larger proportion of variability of these 
PCOS characteristics compared to self-reported ethnic background. Especially the variability 
of insulin levels seems predominantly influenced by genetic ancestry (hypergeometric 
probability 0.02).
Conclusions: Self-reported ancestry is not a perfect proxy for genetic ancestry in patients 
with PCOS, emphasizing that by using genetic ancestry instead of self-reported ethnicity 
PCOS-relevant misclassification can be avoided. Moreover, as genetic ancestry explained a 
larger proportion of phenotypic variability associated with PCOS than self-reported ethnicity, 
future studies should also focus on genetic ancestry verification of PCOS patients for research 
questions, treatment as well as preventive strategies in these women. 
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Introduction
Polycystic Ovary Syndrome (PCOS) is the most common endocrine disorder in women of 
reproductive age [1]. The broad spectrum of symptoms of PCOS encompasses reproductive 
endocrine as well as metabolic features [2,3]. Reproductive characteristics include anovulation, 
hyperandrogenism and polycystic ovarian morphology. Patients with PCOS also suffer 
from obesity, dyslipidemia and insulin resistance. Moreover, they have an increased risk of 
developing type 2 diabetes mellitus and cardiovascular disease later in life. 
 It has been well established that ethnic origin influences the variability of the phenotype 
[4,5]. For instance, Mexican American patients suffer more often from insulin resistance and 
have higher BMI levels compared to European American patients with PCOS [6]. A higher 
prevalence of hirsutism was observed among PCOS patients from the Middle East compared 
to those of European ancestry [7]. Asian PCOS patients have more often insulin resistance than 
European PCOS patients but seem less likely to become obese than European PCOS patients 
and European American PCOS patients [6,8]. However, another study observed a higher 
incidence of increased BM and waist circumference in Chinese patients with PCOS compared 
to European patients [9]. African American and Hispanic patients with PCOS have elevated 
BMI levels and an increased waist circumference compared to European and Asian patients 
[10,11]. Because of such observations, it has been previously suggested that there is need 
for development of ethnicity-specific guidelines for identifying anthropometric thresholds for 
appropriate screening, diagnosis and treatment in high-risk ethnic groups [4,5]. However, the 
definition of ethnicity is complex including non-genetic elements such as diet, language and 
other cultural elements as well as elements that are expected to have a genetic component 
such as bio-geographic origin (i.e. genetic ancestry) or the genetic background in general, 
which may or may not affect the variability of the PCOS phenotype including sub-phenotypes 
[10,12,13].
 Usually in medical studies, including those on PCOS, ethnicity is assessed by self-reported 
data. However, self-reported ethnicity can be biased and does not necessarily capture all 
existing population substructure [14,15]. For instance, we have previously shown that a set 
of 10 ancestry informative markers is effective to map phenotypic differences in anovulatory 
patients at a continental level [13]. However, a more accurate resolution of the geographic 
ancestry of the patients would be desirable. Moreover, one of the proposed future directions 
for research during the consensus meeting on women’s health aspects of PCOS was the role 
of genetic and environmental factors in explaining differences in PCOS incidence as well as in 
PCOS associated characteristics among different populations [8].
 In the current study, we determine genetic ancestry of a multi-ethnic set of PCOS 
patients by means of high-resolution genome-wide microarray analysis and by using a 
worldwide reference dataset (HGDP-CEPH) – overall 152,375 independent single nucleotide 
polymorphisms (SNPs). We applied two clustering algorithms on the genome-wide SNP data 
and correlated self-reported ethnicity with derived genetic ancestry. Moreover, we compared 
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PCOS-associated sub-phenotypic differences among the various groups as defined by self-
reported ethnicity as well as by genetic ancestry. Finally, we determined whether classification 
based on self-reported data or genetic ancestry explains more variation in endocrine and 
metabolic characteristics of PCOS patients.
Materials and Methods
PCOS diagnosis and phenotyping
All patients with PCOS included in this study were recruited from a large University hospital 
in Rotterdam, the Netherlands. The patients underwent a standardized physical examination 
and hormonal evaluation after an overnight fast. Clinical work-up included menstrual 
history as well as current cycle length, anthropometric measurements (height and weight) 
and calculation of body mass index (BMI) as weight in kilograms divided by squared height 
in meters. Self-reported ethnicity and country of birth were registered prior to the clinical 
investigation via a questionnaire. This information was verified by the research investigator 
at the day of investigation. Transvaginal ultrasonography was performed to assess ovarian 
volume and number of follicles in both ovaries. 
 PCOS was diagnosed according to the 2003 Rotterdam consensus criteria. In agreement 
with these criteria two of the following three criteria should be present: oligo-ovulation and/
or anovulation with gonadotropins levels within the normal limits, biochemical and/or clinical 
hyperandrogenism and polycystic morphology of the ovaries (PCOM). Oligomenorrhea was 
defined as a cycle length over 35 days and amenorrhea as absence of menstrual bleeding. 
Biochemical hyperandrogenism was determined by calculation of the Free Androgen Index 
(FAI) as: 100 x [T (nmol/L) / SHBG (nmol/L)]. A FAI exceeding 4.5 was used as a cut-off. Clinical 
hirsutism was assessed using the modified Ferriman-Gallwey score and defined as an FG-score 
of at least 8. PCOM was assessed by transvaginal ultrasound and defined as the presence of 
at least 12 follicles in one or both ovaries and/or increased ovarian volume > 10 ml. Exclusion 
criteria were presence of related disorders with similar presentations such as Cushing’s disease 
and congenital adrenal hyperplasia. This study was approved by the institutional medical 
ethical review board, and written informed consent was obtained from all patients.
Hormone assays
Blood samples were drawn after an overnight fast, before 10.00 am on the day of clinical 
examination and processed within 2h after withdrawal. Until assayed, serum was stored 
at -20° C. Serum levels of SHBG, androstenedione, insulin and DHEAS were measured by 
immunoluminometric assay (Immulite® platform, Siemens Diagnostic Products Corporation 
(DPC), Los Angeles, CA). Testosterone was determined by radioimmunoassay (RIA) (Siemens 
DPC, Los Angeles, CA). DHEA was measured using RIA (Diagnostic Systems Laboratories, 
Webster, TX). Glucose levels were measured using a Hitachi 917 analyzer (Roche Diagnostics, 
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Almere, The Netherlands). Intra- and interassay coefficients of variation (CV) were less than 4 
and 5% for SHBG, less than 8 and 11% for androstenedione, less than 6 and 8% for insulin, less 
than 9 and 11% DHEAS, and, less than 3 and 5% for testosterone.
Genome-wide data and quality control
Genomic DNA was extracted from peripheral venous blood samples according to standard 
procedures. Each patient with PCOS was genotyped with the Illumina HumanHap 610K 
beadarray. SNPs with more than 5% of missing genotypes were excluded. Subsequently, we 
pruned for linkage disequilibrium (LD) by means of ascertaining markers that showed low 
LD at a distance of < 500 kb using the plink software [16] option plink --indep 50 5 2. This 
command prunes based on the variance inflation factor (VIF). The VIF is 1/(1-r2) where r2 is the 
multiple correlation coefficient for a SNP being regressed on all other SNPs simultaneously. A 
VIF of 1 would imply that the SNP is completely independent of all other SNPs. The parameters 
for --indep are: window size in SNPs, i.e. 50, the number of SNPs to shift the window at each 
step, i.e. 5, and the VIF threshold, i.e. 2. 
 In total, 166,194 Linkage Disequilibrium-pruned autosomal SNPs passed these quality 
steps and were included for further analysis. We included genome-wide data of 938 samples 
of CEPH’s Human Genetic Diversity Cell Line Panel (HGDP-CEPH) from 53 populations with 
known bio-geographic ancestry as a reference [17]. After merging with the data publicly 
available for the HGDP-CEPH samples, a total number of 152,375 autosomal SNPs was used for 
the analyses.
Statistical analysis
Genetic ancestry
In order to determine the genetic ancestry of patients with PCOS based on the genome-wide 
SNP data, two different analyses were performed. The first method was algorithm ancestry 
based [18]. Plink software was used to compute an Identical by State (IBS) matrix between 
all the individuals. The cmdscale transformation function in R software [19] was used to 
iteratively perform a classical Multi-Dimensional Scaling (MDS) with the IBS distance matrix 
of the HGDP-CEPH panel and each patient independently, retaining the first 10 dimensions. 
These dimensions were then used in the MCLUST software implemented in R [19] to define 
groups of individuals by fitting multivariate normal distributions on the proposed dimensions 
(Supplementary Figure 1). MCLUST has been previously used (http://www.maths.bris.
ac.uk/~madjl/finestructure/Lawson2012-GeneticSimilarityClustering.pdf) in the output of 
other multivariate techniques [20].
 The second analysis of genetic ancestry was model-based ancestry estimation [18] and 
attempted to estimate ancestry proportions of each individual from a set of putative ancestral 
populations. ADMIXTURE software was used with the complete dataset setting the number 
of clusters (K) from 1 to 12 [18]. The best K was estimated by the cross-error estimation 
implemented in the ADMIXTURE software. For the best K a ten times rerun was performed. In 
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order to get a categorical classification of the PCOS individuals, each patient was assigned to 
the cluster with the highest proportion of admixture.
 Genetic ancestry assignations were compared to self-reported ethnicity using the 
Cramer’s V-statistic in R [19]. In order to quantify the cluster diversity within each self-reported 
population, we computed the entropy of each population i estimated as [21].
∑
=
−=
K
k
ikiki ppH
1
)log(
Where pik is the proportion of individuals of population i that are assigned to cluster k. The value 
of entropy ranges from 0, which indicates no cluster diversity within i (i.e. all the individuals of 
a self-reported population belongs to the same cluster), to the log(K), which is the maximum 
value of diversity.
Association of PCOS phenotypic characteristics with ethnicity and genetic ancestry
Analysis of covariance adjusted for age was used to test for significant differences between the 
PCOS phenotypic characteristics of the ethnic subgroups based on genetic data. Chi-square 
test was used to test for differences of categorical variables. Variables were checked for normal 
distributions with the one-sample Kolmogorov-Smirnov test and log- or square-transformation 
were applied. Extreme outliers were excluded. Patients using oral contraceptives or other 
hormonal medication were excluded from the phenotypic analyses.
 To determine which of the two ethnicity assignations, i.e. assignation based on self-
reported data versus assignation based on genome-wide array data, explains the largest 
variability in phenotypical characteristics of PCOS, we computed a step-wise forward linear 
regression model for continuous variables and a step-wise forward logistic regression model 
for categorical variables. Age, all self-reported ethnicity clusters and all genetic ancestry 
clusters based on MCLUST cluster algorithm were included as independent variables in the 
model. The PCOS characteristics were included as dependent variables. Adjusted for multiple 
testing, a p-value of < 0.004 (0.05/12 variables) was considered to be statistically significant. 
If predominantly genetic clusters will end up in the final models, one can state that genetic 
clusters explain a larger proportion of variability compared to self-reported ethnicity.
 Subsequently, using multivariate hypergeometric distribution, we calculated the 
probability of finding, at random, an equal or larger number of genetic clusters assuming a 
similar number of significant observations as resulted from the regression analysis. A one-
tailed p-value < 0.025 is considered significant. Finally, a combined p-value was computed 
with the Fishers’ method [22].
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Results
All patients with PCOS were classified according to their self-reported ethnic origin: 66.7% 
(n=1000) Europeans, 8.8% (n=132) Turkish, 3.7% (n=55) Moroccan, 3.2% (n=48) Caribbean, 
2.9% (n=44) Surinam Creole, 5.5% (n=83) Surinam Hindustani, 3.7% (n=55) Sub-Saharan 
Africans, 2.0% (n=30) Central-East Asians, 1.2% (n=18) Middle East, 0.9% (n=14) South 
Americans, and 1.3% (n=20) admixed. Countries of birth accompanying the self-reported 
ethnic origin are listed in Supplementary Table 1.
Genetic clustering: MCLUST
The first two dimensions of the 1499 patients computed by classical MDS analysis controlling 
for the HGDP-CEPH samples are plotted in Figure 1. In the first cluster analysis, we applied the 
MCLUST cluster algorithm to the first 10 dimensions of the MDS. This resulted in identification 
of 8 clusters based on the genomic data (Table 1). Cluster 1 comprises primarily self-reported 
European patients (90%, n=900). Most self-reported Turkish patients (n=124, 93.9%) are 
allocated to cluster 2, whereas most self-reported patients from Morocco (n=52, 94.5%) are 
assigned to cluster 5. Self-reported Surinam Creole patients are distributed over cluster 6 
(n=18, 40.9%) and cluster 8 (n=17, 38.6%). Cluster 6 includes the majority of self-reported 
Surinam Hindustani patients with PCOS (n=76, 91.6%), whereas most of the self-reported 
Caribbean patients (n=41, 85.4%) and of the self-reported Sub-Sahara African patients (n=40, 
72.7%) are allocated to cluster 8. Cluster 7 includes the majority of self-reported Central-East 
Asian patients (n=23, 76.7%). Cluster 4, and to a lesser extent cluster 3, include patients from 
nearly all self-reported ethnicities. Comparison of self-reported ethnicity with the genetic 
ancestry assignations as derived from MDS and MCLUST resulted in a Cramer’s V of 0.77, 
indicating a moderate association between the self-reported ethnicity and genetic ancestry. 
Patients self-reported from the Middle East, the Surinam Creoles and those of admixed self-
reported ethnicity showed the highest measure of genomic diversity as indicated by the high 
entropy values (entropy = 0.60, 0.51 and 0.45 respectively), which may be expected given their 
group definition.
Genetic clustering: ADMIXTURE
For the second cluster analysis, we used the cluster algorithm implemented in ADMIXTURE to 
estimate the genetic ancestry proportions of each individual according to K putative ancestral 
populations. By performing a cross-validation error analysis, we observed that at K=10 the 
cross-validation error was the smallest indicating that K = 10 reflects the most statistically 
supported number of ancestral populations (Supplementary Figure 2). Individual ancestry as 
estimated by ADMIXTURE using K = 10 is plotted in Figure 2. Patients were assigned to one of 
the clusters based on the highest proportion of detected ancestry. None of the patients were 
assigned to cluster 1 or cluster 8 (Table 2). Almost all self-reported Turkish patients (n=128, 
97.0%) are allocated to cluster 2. All self-reported Moroccan patients, except for one (n=54, 
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98.2%) are gathered in cluster 3 and nearly all self-reported Surinam Hindustani are in cluster 
4 (n=78, 94.0%). Cluster 5 is a mix of self-reported Caribbean, Surinam Creole and Sub Saharan 
Africans. Only one patient, a self-reported Turkish, was assigned to cluster 6. Self-reported 
Central-East Asians are primarily assigned to cluster 7 (n=23, 76.7%). Cluster 10 encompassed 
almost all self-reported European patients (n=987, 98.7%). However, this cluster also includes 
patients from all other self-reported ethnicities. The association of the self-reported ethnicity 
and the genetic ancestry assignations as derived from ADMIXTURE was with 0.77 (Cramer’s V) 
the same as obtained when comparing self-reported ethnicity with genetic ancestry derived 
from MDS/MCLUST indicating a moderate association. As expected and as noted in the MDS/
MCLUST analysis, the self-reported Surinam Creole, the admixed and self-reported Middle East 
group also in the ADMIXTURE analysis showed the highest degree of genetic diversity based 
on the entropy values (entropy = 0.43; 0.53 and 0.37, respectively), whereas the self-reported 
Europeans and Turkish patients were both genetically very homogeneous as reflected by low 
entropy values (entropy = 0.02 and 0.07, within both groups respectively).
PCOS phenotype, self-reported ethnicity, and genetic ancestry
Then, we determined whether self-reported ethnicity or genetic ancestry explained a larger 
proportion of variability of different PCOS characteristics. Besides age, the 11 self-reported 
ethnicities and the 8 genetic ancestry clusters obtained via MDS/MCLUST analysis were 
included as independent variables in the regression models. Table 3 and Figure 3 display 
the statistically significant results. For seven PCOS associated characteristics (amenorrhea, 
TFC, BMI, FAI, SHBG, DHEAS, and insulin) we revealed significant effects for at least one 
genetic cluster, while significant effects of self-reported ethnicities were seen in only four 
of these PCOS characteristics(amenorrhea, FAI, SHBG, and adion). For three characteristics 
(amenorrhea, FAI, and SHBG) we observed significant effects for more genetic clusters than 
for self-reported ethnicities, respectively. For two characteristics (BMI, insulin) only genetic 
clusters but no self-reported ethnicity revealed significant effects. Variability of adion was 
significantly influenced by age and one self-reported ethnicity. Notably and not unexpected, 
age had a significant effects on all characteristics except on insulin. For three characteristics 
(waist, LH, and testosterone) it was the only significant finding. Overall, predominantly genetic 
ancestry clusters ended up in the final models, indicating that they explain a larger proportion 
of variability of the PCOS characteristics compared to self-reported ethnicity. To add statistical 
value to these findings, we calculated per characteristics the probability of finding, at random, 
an equal or larger number of genetic clusters as observed in the regression analysis using 
multivariate hypergeometric distribution. For insulin, the probability of randomly selecting at 
least four genetic clusters was significant (P value = 0.02). The hypergeometric probability for 
the other characteristics revealed no significant results (P value > 0.05). Although, generally 
spoken, genetic ancestry clusters predominantly ended up in the final models, combining all 
the probabilities resulted in an overall non-significant P value of 0.09.
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Table 2 | Comparison of self-reported ethnic origin and assigned clusters based on ADMIXTURE 
clustering algorithm with k = 10. 
Self-reported ethnicity Sample 
size (n)
Genetic clusters and percentage (%) of  
individuals assigned to the clusters based on  
ADMIXTURE clustering algorithm
Entropy
2 3 4 5 6 7 9 10
Sub-Saharan African 55 7.2 1.8 0 72.7 0 0 0 18.2 0.35
Caribbean 48 0 0 0 85.4 0 0 0 14.6 0.18
Surinam Creole 44 0 0 40.9 50.0 0 6.8 0 2.2 0.43
Central-East Asian 30 3.3 0 16.7 0 0 76.7 0 3.3 0.32
Surinam Hindustani 83 0 0 94.0 0 0 0 0 6.0 0.10
European 1000 0.07 0 0.1 0.03 0 0.2 0 98.7 0.02
Turkey 132 97.0 0 0 0 0.8 0 0 2.3 0.07
Morocco 55 0 98.2 0 0 0 0 0 1.8 0.04
Middle East 18 72.2 5.5 5.5 0 0 0 0 16.7 0.37
South American 14 0 0 0 7.1 0 0 28.6 64.3 0.36
Admixed 20 5.0 0 5.0 20.0 0 5.0 5.0 60.0 0.53
Individuals are assigned to the cluster with the highest proportion of genetic ancestry. None of the individuals were assigned 
to genetic cluster 1 and genetic cluster 8. Percentages indicate the proportion of individuals from each self-reported ethnic 
group present in the genetic clusters. Each row sums up to 100%. Entropy is a measure of genetic diversity. The value of 
entropy ranges from 0, which indicates no diversity or genetically similar, to the log(K), which is the maximum value of 
diversity. n, number
163Genetic ancestry in PCOS | 
7
Table 3 | Step-wise forward regression model to determine which self-reported clusters or genetic 
clusters are responsible for variability in phenotypic characteristics.
Predictors beta s.e. P value
Amenorrhea Age -0.087 0.013 < 0.0001
Genetic cluster 4 0.960 0.295 0.001
Genetic cluster 2 0.745 0.222 0.001
Morocco 1.384 0.416 0.001
PCOM - - - -
TFC Age -0.008 0.002 < 0.0001
Genetic cluster 8 0.10 0.115 < 0.0001
BMI Genetic cluster 8 -0.004 0.001 < 0.0001
Genetic cluster 5 -0.003 0.001 < 0.0001
Waist Age 0.001 < 0.000 0.003
LH Age -0.005 0.002 0.004
Testosterone Age -0.007 0.002 < 0.0001
FAI Age -0.01 0.002 < 0.0001
Genetic cluster 2 0.22 0.03 < 0.0001
Genetic cluster 6 0.22 0.04 < 0.0001
Genetic cluster 8 0.19 0.04 < 0.0001
Central East Asian 0.20 0.07 0.002
SHBG Age 0.006 0.001 < 0.0001
Genetic cluster 2 -0.17 0.02 < 0.0001
Hindustani -0.18 0.03 < 0.0001
Genetic cluster 5 -0.19 0.04 < 0.0001
Genetic cluster 8 -0.13 0.03 < 0.0001
Central East Asian -0.20 0.05 < 0.0001
Genetic cluster 4 -0.08 0.03 0.003
Adion Age -0.006 0.001 < 0.0001
Turkey 0.08 0.018 < 0.0001
DHEAS Age -0.03 0.003 < 0.0001
Genetic cluster 8 -0.17 0.06 0.004
Insulin Genetic cluster 6 0.33 0.04 < 0.0001
Genetic cluster 8 0.17 0.03 < 0.0001
Genetic cluster 5 0.15 0.05 0.002
Genetic cluster 2 0.10 0.03 0.002
PCOM, polycystic Ovarian Morphology; TFC, Total Follicle Count; BMI, Body mass Index; LH, Luteinizing Hormone; FAI, Free 
Androgen Index; SHBG, Sex-Hormone Binding; Adion, Androstenedione; DHEAS, Dehydroepiandrosterone-sulphate.
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Figure 3 | Distribution of genetic versus self-reported significant clusters resulted from the regression 
analysis per PCOS characteristics.
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The number of significant clusters resulted from the regression analysis with a maximum of 19 (11 self-reported ethnic 
clusters and 8 genetic ancestry clusters) is plotted on the Y-axis. The PCOS characteristics are listed on the X-axis. TFC, total 
follicle count; BMI, Body Mass Index; FAI, Free Androgen Index; SHBG, Sex Hormone Binding Globulin; Adion, Androstenedione; 
DHEAS, Dehydroepiandrosterone. * Hypergeometric probability.
Discussion
Usually, ethnicity is assessed by self-reported data and used as a proxy for genetic ancestry. 
Probably, because self-reported ethnicity is easily accessible via questionnaires or interviews, 
or medical records. However, disparity regarding the degree to which genetic variation 
correlates with self-reported ethnicity has been reported [14,23-25]. In general, self-reported 
ethnic background emphasizes the geographic region of origin of an individual [24]. Moreover, 
ethnicity also takes into consideration cultural tradition, language, diet, common history 
and religion among other non-biological factors [26,27], while genetic variation and genetic 
ancestry solely refer to the biological parts of a person’s origin and can be used to describe the 
bio-geographic ancestry. Moreover, it is not uncommon for individuals to change ethnicities 
over their own life-course or during that of their direct or distant biological ancestors [28], 
which can cause discrepancy between a person’s bio-geographic origin and his/her ethnicity. 
Therefore, the use of self-reported ethnicity in biomedical research in principle can lead to 
misclassifications, biases, and thereby hindering reproducibility between studies [15,29,30]. In 
addition, errors incurred by using self-reported ethnicity rather than genetic ancestry might 
produce significant false-positive associations in large studies because of slight differences in 
genetic ancestry between cases and controls [23,31].
 In this study we therefore estimated the ancestral composition based on genome-wide 
genetic data of a multi-ethnic population of patients diagnosed with PCOS, related this 
genetic ancestral composition to phenotypic characteristics of PCOS, and compared that to 
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the impact of self-reported ethnicity. As may be expected, we observed that self-reported 
ethnicity and genetic ancestry are different in some patients with PCOS. This discrepancy is 
mostly pronounced in the admixed population, the self-reported Surinam Creoles and the 
patients from self-reported Middle East, as indicated by differences in entropy scores. On the 
contrary, the self-reported ethnicity does seem a relative good proxy for genetic ancestry 
in self-reported European patients, self-reported Surinam Hindustani, self-reported Turkish 
patients and self-reported Moroccan patients. Over 90% of the patients in each of these 
self-reported ethnicities end up together in a genetic ancestry cluster. Hence, for some self-
reported ethnicities the disparity between self-reported ethnicity and genetic ancestry is 
larger than for others. 
 Hitherto, phenotypic differences among patients with PCOS have been only described 
based on self-reported ethnic assignations, while in this study we test the effect of genetic 
ancestry on PCOS characteristics and compare these data with the effect of ethnicity. As 
stated, self-reported ethnicity reflects the sociocultural practices shared among population 
subgroups, which may or may not include a common genetic origin [32]. If we would have 
merely found self-reported clusters in the final regression models, one would state that 
ethnic-specific environmental (sociocultural) factors, determine the variability in PCOS 
characteristics. In general, we observed that genetic ancestry explains a larger proportion of 
variability in the phenotypic characteristics of PCOS compared with self-reported ethnicity 
insinuating that genetic ancestry is a better predictor for phenotypic variability in PCOS. This 
was in particular the case for insulin levels, which variability was solely determined by genetic 
ancestry cluster. This highlights the importance of taking genetic factors into account when 
assessing variability in the PCOS characteristics. Whether this observation supports genetics 
of PCOS is difficult to disentangle, since it is expected that environmental factors which are 
relevant for the PCOS phenotype also covariate with genetic ancestry. Diet as well as the level 
of physical activity differ across ethnic populations and influence the characteristics of PCOS 
[33]. Moreover, it has been suggested that differences in dyslipidemia in PCOS patients of 
diverse ethnic and geographical backgrounds are not only explained by variations in body 
weight, but also genetic and environmental factors, such as diet and activity level, likely 
contribute to these differences [34]. However, studies combining environmental factors and 
genetic ancestry instead of self-reported ethnicity are lacking [3]. Therefore, challenges for 
future studies are incorporation of these environmental and sociocultural factors as well as the 
genetic factors to explain ethnic variances.
 Obviously, also in the light of upcoming GWASs, the results of our study are of interest. 
The potential confounding effect of genetic population substructure on the interpretation 
of disease association studies has been well established [23,35]. Our results indicate that 
this is also an issue in PCOS, stressing the importance of using genetic ancestry to correct 
for population admixture in genetic studies in patients with PCOS. Although we were able to 
include a very large study population, the majority of these patients were of European descent 
providing power-limitations on non-Europeans. Increasing the number of non-European 
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individuals would increase power and might even identify larger and additional phenotypic 
differences.
 In conclusion, this study indicates that genetic ancestry inferred from genome-wide data 
is a better predictor for variability of the PCOS phenotype compared to self-reported ethnicity. 
By using genetic ancestry instead of self-reported ethnicity misclassification based on family 
records or in admixed individuals can be avoided. Therefore, genetic ancestry inferred from 
genome-wide data should be recommended for the exact determination of bio-geographic 
origin. Moreover, as genetic ancestry explained a larger proportion of phenotypic variability 
associated with PCOS than self-reported ethnicity, future studies should also focus on genetic 
ancestry verification of PCOS patients for research questions, treatment as well as preventive 
strategies in these women.
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Supplementary Figure 2 | Cross-validation error (CV) estimates of the cluster analysis using 
ADMIXTURE software.
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The cross-validation error at K = 10 was with 0.424 the smallest, indicating that this is the most sensible model.
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Supplementary Table 1 | Self-reported ethnicity and country of birth of all included PCOS patients.
Ethnic origin Country of Birth
Sub Saharan African Angola (n=2), Cabo Verde (n=9), Congo (n=2), Eritrea (n=1), Ghana (n=2), Guinea 
(n=1), Mali (n=1), Mozambique (n=1), Nigeria (n=2), Sao Tome (n=1), Sierra Leone 
(n=3), Sudan (n=2), Somalia (n=5), South Africa (n=2), the Netherlands (n=21)
Caribbean Antilles (n=3), Aruba (n=8), Curacao (n= 34), St Maarten (n=1), Dominicans’ Rep (n=1), 
St Kitts (n=1)
Surinam Creole Surinam (n=44)
Central East Asia Afghanistan (n=2), China (n=3), Filipinas (n=5), Hong Kong (n=2), Indonesia (n=7), 
Malaysia (n=1), Singapore (n=1), Sri Lanka (n=2), Vietnam (n=2), South Korea (n=1), 
the Netherlands (n=4)
Surinam Hindustani Afghanistan (n=1), India (n=3), Mauritius (n=1), Pakistan (n=11), Suriname (n=45), Sri 
Lanka (n=1), the Netherlands (n=21)
European Afghanistan (n=1), Armenia (n=2), Belgium (n=2), Bosnia (n=4), Bulgaria (n=1), 
Brazil* (n=1), Canada(n=3), Germany (n=5), England (n=3), France (n=4), Georgia 
(n=1), Greece (n=2), Hungary (n=2), Kosovo (n=1), Lithuania (n=1), the Netherlands 
(n=937), Norway (n=1), Ukraine (n=1), Poland (n=7), Portugal (n=4), Romania (n=3), 
Russia (n=2), Serbia (n=2), Slovakia (n=1), Spain (n=2), Yugoslavia (n=1), Swiss (n=3), 
USA (n=2)
Turkey Turkey (n=90), Germany (n=2), Netherlands (n=40)
Morocco Morocco (n=51), Nederland (n=4)
Middle East Yemen (n=1), Azerbaijan (n=1), Iraq (n=7), Iran (n=3), Israel(n=2), Lebanon (n=1), Syria 
(n=1), Emirates (n=1), Pakistan (n=1)
South America Argentina (n=1), Brazil (n=3), Chili (n=1), Colombia (n=2), Costa Rica (n=1), Ecuador 
(n=1), Mexico (n=2), Peru (n=1), Venezuela (n=2)
Admixed America (n=1), Colombia (n=1), the Netherlands (n=14), Surinam (n=3)

Chapter 8
General Discussion
174 | Chapter 8
More than 105 million women aged 15-49 years have been diagnosed with polycystic ovary 
syndrome (PCOS) worldwide [1]. As stated, the estimated prevalence of PCOS varies between 
varies between 5-15%, thereby being the most common endocrine disorder in women of 
reproductive age [2,3]. Moreover, the economic burden of the disorder is considerable; the 
healthcare costs are estimated to be over $ 4 billion in the United States annually [1]. The 
introduction of the additional phenotypes as defined by the Rotterdam criteria [4,5] has 
increased the phenotypic heterogeneity as well as the prevalence of the syndrome remarkably 
[6]. The broad diversity of the phenotype emphasizes the need for individual health-risk 
estimation for a patient with PCOS and her family members in order to provide appropriate 
clinical care. As stated, the phenotypic characteristics determining PCOS result from a complex 
interaction between genetic and environmental factors. The focus of this thesis was to identify 
some of these genetic variants and assess how they might determine PCOS susceptibility. 
Moreover, we aimed to determine which patients, based on specific phenotypical PCOS 
characteristics, had the highest risk of developing long-term health complications. The 
current chapter places these results in a broader context, discusses the potential implications 
of phenotypic and genetic interaction for clinical practice and suggests future directions for 
research.
Phenotypic and genetic heterogeneity of PCOS
PCOS has been widely acknowledged as having adverse reproductive as well as metabolic 
implications resulting in a broad spectrum of signs and symptoms including ovulatory 
dysfunction, hyperandrogenism, polycystic ovarian morphology (PCOM), obesity, insulin 
resistance, dyslipidemia, type 2 diabetes mellitus and possibly cardiovascular disease. These 
individual phenotypic symptoms as well as combinations of these characteristics determine 
the disease, seem to predict variability in treatment outcome and development of long-
term health sequelae. Genetic factors are partly responsible for the diversity of phenotypic 
characteristics accompanying PCOS and might also have a role in predicting treatment 
outcome and development of long-term health sequelae.
Ovulatory dysfunction
Menstrual cycle irregularities resulting in oligo- or anovulatory subfertility are one of the 
keyfeatures of PCOS [4,5]. In case PCOS patients would like to conceive, they have to undergo 
ovulation induction treatment. Most of the existing ovulation induction protocols are not 
very much patient-tailored. Nevertheless, oligo-ovulatory patients with PCOS have a more 
favourable response to ovulation induction treatment using clomiphene citrate compared to 
anovulatory PCOS patients [7]. In addition, elevated androgen levels and BMI in PCOS patients 
are associated with clomiphene resistance after ovulation induction treatment [8]. 
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 Genetic variants mapping to the Follicle-Stimulating Hormone Receptor (FSHR) gene and 
the Luteinizing Hormone/Choriogonadotropin Receptor (LHCR) gene have been observed 
to be associated with PCOS in candidate gene studies in patients from Northern European 
descent [9,10] and the GWASs in Han-Chinese patients [11,12]. This suggest that these variants 
play a role in the etiology of PCOS regardless of ethnicity. Moreover, PCOS patients carrying 
the Ser680 allele in the FSHR gene were more often clomiphene citrate resistant than non-
carriers [13,14]. Hence, apart from BMI and serum androgen concentrations, the genetically 
determined sensitivity of the FSH receptor seems to be an important factor too. This implies 
that genetic data might have a role in further optimizing the existing patient-tailored strategies 
in ovulation induction treatment in PCOS. 
Hyperandrogenism
Hyperandrogenism is considered to play a central role in the etiology of PCOS [15]. One of 
the factors influencing hyperandrogenism is ethnic origin (for review see [16]). Although 
patients from the Middle East and those of Mediterranean origin had lower testosterone levels 
compared to PCOS patients from Northern European descent, they were more often hirsute 
[17]. In contrast, East Asian patients were less hirsute compared to Europeans, despite having 
similar androgen concentrations [18]. Such observations suggest interacting genetic factors 
to influence PCOS phenotype heterogeneity.
 Although the ovaries are the principal source of androgen excess in patients with PCOS, 
the adrenal gland also contributes to the observed hyperandrogenism [19]. Apart from ethnic 
variation, elevated testosterone as well as DHEAS levels are present in patients with PCOS 
as well as their brothers and sisters, suggesting that hyperandrogenemia is a genetic trait 
[20-22]. In general, candidate gene studies as well as GWASs hitherto have not resulted in 
identification of PCOS susceptibility genes that are directly involved in synthesis and action of 
androgens. However, genetic variants in these genes have been observed to modify the sub-
phenotypic characteristics of PCOS. For example, genetic variants mapping to Cytochrome 
P450-C17 (CYP17) and 11-beta hydroxysteroid dehydrogenase (HSD11B1) were not associated 
with PCOS, nor with the quantitative traits characteristic of PCOS [23]. While genetic variants 
mapping to the CYP19 gene [24-26], SULT2A1 gene [27,28], SHBG gene (for a review see [29,30]) 
and the [CAG] Variable Number of Tandem Repeats (VNTR) in the Androgen Receptor (AR) 
gene [31] do not constitute discernible risk alleles for PCOS, they do affect androgen levels 
in patients with PCOS. Moreover, also genetic variants mapping to genes not directly linked 
to androgen synthesis were found to modulate androgen levels in PCOS patients. Thyroid 
Associated Protein (THADA) is one of the PCOS susceptibility loci identified in the first Chinese 
GWAS [11] and encodes thyroid adenoma-associated protein, which is expressed in pancreas, 
adrenal medulla, thyroid, adrenal cortex, testis, thymus, small intestine, and stomach. 
Chromosomal aberrations of the genomic region containing THADA have been observed in 
benign thyroid adenomas, but are also associated with androgen levels in Han-Chinese and 
Northern-European patients with PCOS [32,33].
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 The treatment of hyperandrogenism is challenging. Main treatments are aiming 
to decrease the free androgen levels by inhibition of ovarian steroid production and 
simultaneously increase SHBG levels by using the oral contraceptive pill (OCP). The use of 
OCP has been proven to influence the PCOS phenotype [34]. Unfortunately, not all patients 
have an improvement of their hirsutism to a similar extent. Since genetic variations mapping 
to genes involved in androgen synthesis and action have been observed to modify the 
hyperandrogenic phenotype, it is plausible that these variants might also influence response 
treatment or even provide potential new drug targets. Studies addressing the effects of 
genetic variants mapping to genes involved in the synthesis and action of sex steroids in terms 
of response to OCP, observed no association [35,36]. However, these studies are small and 
probably underpowered to detect the subtle effect of common variants. As far as ovulation 
induction is concerned, hyperandrogenism in terms of free androgen levels seems to be 
the most prominent predictor of the outcome of ovulation induction treatment [37]. Since 
genetic variants mapping to genes which are involved in the regulation of the steroidogenesis 
or encode the androgen receptor seem important in determining the androgen levels, these 
genetic variants might add to the improvement of ovulation induction outcome strategies. 
Literature addressing this issue is lacking and further investigation of the clinical applicability 
of the modifiers of the hyperandrogenic phenotype is needed. 
 Finally, although literature is inconsistent in terms of efficiency of treatment with 
corticosteroids in PCOS [38], in case of elevated adrenal androgens in PCOS treatment 
focussing on reducing the adrenal component might have benefits [39]. 
Polycystic ovarian morphology
The most discussed feature of PCOS is the polycystic ovarian morphology (PCOM). PCOM 
seems not to be associated with metabolic health implications [40]. However, in contrast to 
hyperandrogenemia, PCOM seems fairly constant across ethnicities [41,42]. Genetic studies 
focussing on PCOM are lacking. Hence, PCOM constitutes a kind of epiphenomenon rather 
than a causal factor. Indeed the fact that ageing in patients having PCOS is similarly associated 
with a loss of follicles, and subsequently the disappearance of PCOM, suggests that similar 
genetic factors govern these processes in PCOS patients compared to normal healthy ageing 
women [43].
Obesity
The relation between elevated BMI-levels and PCOS is obvious considering the fact that the 
majority of patients with PCOS suffer from obesity [44]. However, whether obese patients are 
predisposed to PCOS or whether they are obese because of their PCOS status, is subject to 
a continuous debate [45]. The co-occurrence of PCOS and obesity suggests the possibility 
of shared genetic susceptibility. Our study showed that, when matching for BMI, genetic 
variants mapping to well-known BMI-increasing loci are not associated with PCOS suggesting 
that that these BMI-associated risk alleles do not convey pleiotropic effects on PCOS risk. The 
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most extensively studied BMI-associated SNPs in relation to PCOS map to the Fat mass and 
Obesity-associated (FTO) gene. The majority of these studies suggest that BMI-associated 
alleles mapping to the FTO gene do not play a role in PCOS susceptibility, but that they do 
influence the metabolic profile of PCOS patients of Northern European descent [46-49]. 
Current evidence points in the direction that obesity is a modifying rather than a causal factor 
for PCOS. Indeed, it has been shown that the incidence of PCOS amongst different BMI groups 
was quite similar [50]. Hence, it seems that obesity aggravates the reproductive and metabolic 
phenotype of PCOS [51,52]. As a consequence it should not become a necessary prerequisite 
for the diagnosis of PCOS. Moreover, appropriate first line intervention for patients with PCOS 
during their reproductive age is lifestyle modification [53]. Dietary changes, increased exercise 
and weight loss have been shown to decrease adipose tissue and improve insulin sensitivity 
as well as reproductive function in PCOS indicating that overweight or obesity indeed seems 
to constitute modifiers of the phenotype instead of being causally involved in PCOS [54-56]. 
Insulin resistance and type 2 diabetes mellitus
PCOS is associated with insulin resistance leading to hyperinsulinemia, independent of BMI-
levels [57,58]. Patients with PCOS seem to have a higher risk of developing gestational diabetes 
[59,60]. Hindustani patients with PCOS have more often insulin resistance than patients from 
other ethnic backgrounds [16,42]. Hyperandrogenism is a predictor for insulin resistance and 
type 2 diabetes mellitus as well [61,62]. Patients with PCOS and also their family members are 
at an increased risk of developing type 2 diabetes mellitus [57,59,60,63-65]. 
 The major defect in insulin action in PCOS seems to be a post-binding defect in the early 
steps of insulin signal transduction and appears to be secondary to increased inhibitory 
serine phosphorylation of the insulin receptor (INSR) and insulin receptor substrate 1 (IRS-1) 
(for review see [66]). Genetic variants mapping to the INSR gene were associated with PCOS 
in Han-Chinese patients using GWAS [12] as well as patients of Northern European descent 
using candidate gene analysis [67,68]. Moreover, genetic ancestry compared to self-reported 
ethnicity explains a large part of the variability in insulin levels suggesting that the genetic 
factors play an important role, as we have shown. Genetic variants mapping to the HMGA2 
and THADA loci, both identified in the GWASs in Han-Chinese PCOS patients [11,12], were also 
observed to be associated with type 2 diabetes in GWAS [69,70]. Genetic variants mapping to 
THADA were also associated with PCOS susceptibility in Northern European patients [71,72].
 Considering that type 2 diabetes mellitus seems to strike stronger in mothers of patients 
with PCOS, it would be of interest to see whether genetic variants mapping to THADA and 
HMGA2 influence this elevated mortality risk. Moreover, if long-term follow-up studies in 
patients with PCOS confirm this burden of insulin resistance and type 2 diabetes mellitus, 
treatment with metformin might be effective in prevention of these long-term adverse health 
implications. Treatment with metformin has not proven its efficacy in improving outcome 
of ovulation induction treatment [73], however, it seems effective in decreasing insulin and 
androgen levels [74]. 
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Albeit not included in the diagnostic criteria for PCOS, insulin resistance seems to play an 
important role in the pathogenesis of the syndrome from clinical as well as genetic point of 
view. 
Cardiovascular disease
It has been established that risk factors for cardiovascular events, including insulin resistance, 
dyslipidemia, increased carotid intima-media thickness and subclinical cardiovascular disease 
(CVD), are more often present in patients with PCOS compared to controls, independently 
of BMI [52,75-78]. Hyperandrogenism seems an important predictor for an adverse 
cardiometabolic profile. Although the increased mortality in mothers might be a proxy for 
an increased mortality risk in their PCOS daughters, there is need for prospective follow-up 
studies which associate these CVD predictors in PCOS with hard endpoints, such as stroke 
and coronary heart disease as well as with CVD mortality rates in women with PCOS. Future 
research should therefore also focus on the role of genetic factors determining the androgen 
levels and their contribution to CVD morbidity and mortality in PCOS women. Indeed, recently 
it has been shown that aromatase is a novel endocrine factor predictive of CVD mortality 
among postmenopausal women. These authors suggest that extremes of aromatase activity 
determined through genetic factors might underlie CVD [79]. In this light, larger sufficiently 
powered studies assessing the role of genetic variation in aromatase activity in women with 
PCOS are needed.
 Remarkably, despite the considerable adverse health implications accompanying PCOS, 
no guideline for screening and treatment of these adverse implications in PCOS exists in the 
Netherlands. PCOS guidelines from Australia and the United States recommend that patients 
with PCOS should be routinely screened for type 2 diabetes mellitus and cardiovascular 
disease at an early age and on a regular basis [80,81]. Recommendations in terms of the exact 
age at which the first screening should take place or the frequency of screening, has not yet 
been determined. Early identification of high-risk patients enables appropriate preventive 
screening and early treatment of adverse complications. Moreover, since the diagnostic 
process accounts for only a minor part of the total healthcare costs for PCOS, screening and 
early treatment will most likely reduce these healthcare costs [1,82]. 
 However, until prospective follow-up studies have associated the presence of CVD 
predictors in PCOS with cardiovascular events, all patients with PCOS should be monitored 
similarly. Moreover, to provide the appropriate care, a PCOS guideline in the Netherlands is 
needed.
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Perspectives for research in PCOS
Future research at the Erasmus MC University Medical Centre Rotterdam
All patients with PCOS described in this thesis underwent a similar screening at the outpatient 
clinic of the Erasmus MC University Medical Centre according to a standardized protocol. 
The inclusion of these patients is an ongoing effort. Of the large majority of these patients, 
also DNA samples are available. This multi-ethnic, carefully phenotyped cohort of patients 
diagnosed with PCOS provides a great opportunity to further explore the pathogenesis of 
PCOS and the mechanisms of its phenotypic heterogeneity. 
 Currently, we have initiated a worldwide collaboration of research groups focussing on 
identifying genetic factors in the pathogenesis of PCOS. This PCOS Genetics Consortium 
consists of research groups from the Netherlands, the United States, the United Kingdom, 
Austria, Estonia, Germany, Switzerland, Poland and Iceland. Establishing such a consortium has 
the advantage of increasing the power to detect subtle genetic effects of common and rare 
variants and, as such, increasing the probability of identifying genetic variants associated with 
PCOS. It is expected that this will lead to discoveries of new PCOS susceptibility loci. Further 
genetic research should also focus on genome-wide genetic association of quantitative traits, 
such as testosterone levels, to provide insight in the driving underlying biological mechanisms 
of these individual phenotypes.
 Moreover, we are embarking on the prospective long-term follow up of patients who have 
been diagnosed with PCOS at our clinic and who have reached perimenopausal age. During 
this first follow-up visit, hard endpoints of cardiovascular disease in terms of mortality or 
cardiovascular events, have probably not yet occurred considering the relatively young age of 
the patients. Eventually, by monitoring surrogate markers determining cardiovascular health 
over time, we will be able to associate these markers to cardiovascular events. Because of the 
multi-ethnic nature of the patient population visiting our outpatient clinic, we are also able to 
assess ethnic differences in the development of cardiovascular disease.
Advances in genetics
New technologies, such as whole exome sequencing and whole genome sequencing, have 
advanced research potentials in genetics even further. The development of these next 
generation sequencing (NGS) methods has resulted in a better gene-coverage and enables 
genotyping of rare variants [83]. It is expected that these approaches will also find their way 
into the genetic research in PCOS [30]. Obviously, identifying the SNPs which are associated 
with a certain disease is only the beginning. DNA is transcribed to mRNA, which is translated 
to polypeptide chains, which are folded into protein. The term functional genomics is used 
to describe combining different approaches to understand the relationship between the 
genome, including genetic variants, and the phenotype. One of these approaches is measuring 
expression of genes. Alterations in gene-expression levels could influence phenotypic 
variation and susceptibility to disease. Gene-expression is detected by using microarrays 
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and the correlation between SNPs and gene-expression can be studied [84]. Subsequently, 
to study the effect on cellular level, this specific gene could be knocked out in target tissue. 
Over the past few decades, several animal models, i.e., mice, rats, sheep and rhesus monkeys, 
have been developed in an attempt to understand the potential contribution of exposure to 
excess steroids on the development of PCOS [85]. Especially, mouse models have the benefit 
of knocking in/out genes for addressing functionality of specific genes [85].
 In addition, a few studies addressing differences in DNA methylation profiles between 
patients with PCOS and controls have been published [86-89]. Epigenetic changes refer to 
the changes in the genome without changes in DNA sequence. These changes are inheritable 
through mitosis or meiosis and lead to phenotypic variability. Although the published studies 
so far have included small sample sizes, methods for genome-wide DNA methylation analysis 
at a single base pair resolution are evolving quickly [90]. Therefore, it will soon be more feasible, 
also in PCOS, to carry out studies with sufficiently large sample sizes, in different tissue types 
and in a genome-wide manner [30].
Non-genetic influences on the PCOS phenotype
PCOS has a substantial heritability, indicating that up to 65% of the risk for PCOS is explained 
by genetic factors [91]. Therefore, the genetic approach on which this thesis focusses, will not 
completely explain the pathogenesis of PCOS. Non-genetic factors, for example environmental 
factors such as the use of OCPs, nutrition and exogenously derived compounds as bisphenol 
A, might influence also the PCOS phenotype and require further investigation. Also, the 
phenotype of PCOS is significantly affected by whether the patients arise from a referral 
population or through unselected screening, likely reflecting the degree of patient concern 
and awareness and access to healthcare [92].
Conclusions and final remarks
It seems as though genetic variations mapping to genes involved in androgen synthesis and 
action, are modifying the PCOS phenotype instead of constituting PCOS risk alleles, whereas 
genes involved in ovulatory dysfunction and insulin signalling or related to type 2 diabetes 
mellitus are associated with PCOS risk. The GWASs in Han-Chinese patients with PCOS have 
also been successful in identifying PCOS susceptibility genes involved in unexpected and 
unknown biological pathways, such as calcium signalling and endocytosis. It is expected that, 
despite large phenotypic differences between patients from various ethnic origins, GWASs 
across different ethnicities will reveal at least partly similar PCOS susceptibility loci. Both 
phenotypic characteristics as well as genetic factors seem to have a role in treatment outcome 
and long-term health sequelae in PCOS. Obviously, the interaction between these phenotypic 
and genetic factors is complex and integrating these factors in so-called personalized medicine 
in terms of treatment and risk prediction will be a challenge for future studies. 
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Summary
The Polycystic Ovary Syndrome (PCOS) is the most common endocrine disorder in women 
of reproductive age. PCOS has reproductive as well metabolic symptomatology and is 
considered to be a complex genetic disease. During reproductive age, key features include 
oligomenorrhea or amenorrhea, hirsutism or hyperandrogenism and polycystic ovarian 
morphology. Later in life, adverse metabolic implications, such as obesity, insulin resistance, 
type 2 diabetes and cardiovascular disease, become more prominent. In this thesis, we aimed 
to identify genetic factors for PCOS susceptibility using a candidate-gene approach and 
a hypothesis-free genome-wide approach. Moreover, we have identified several high-risk 
groups for long-term health implications within the broad phenotype of PCOS. 
 Chapter 1 provides a general introduction describing the diagnostic criteria of PCOS, its 
phenotypic heterogeneity and complex genetic background.
 The variability of the phenotype of PCOS seems to represent variability in the long-term 
health implications of the syndrome. In chapter 2 the cardiometabolic profile of 2,278 carefully 
phenotyped patients with PCOS from two University Hospitals was analyzed. Hyperandrogenic 
patients had besides their elevated androgen levels, an increased waist circumference and 
more often obesity and overweight, insulin resistance as well as the metabolic syndrome 
compared to patients with non-hyperandrogenic PCOS. Overall, no differences were observed 
between the endocrine profiles of the component hyperandrogenic PCOS phenotypes. 
Current efforts to monitor patients with PCOS prospectively to obtain these hard endpoint 
data, such as cardiovascular events and excess mortality later in life, need approximately 25 
more years of follow-up. Therefore, in chapter 3, we made use of the heritable nature of the 
syndrome by performing a reverse parent-offspring study and determined all-cause mortality 
in parents of patients with PCOS using Standardized Mortality Rate analysis. Mothers above 
age 60 years had a significant excess mortality compared to the general Dutch population. 
Moreover, diabetic mothers of patients with PCOS had a two times higher mortality risk 
compared to patients with type 2 diabetes who were not selected through PCOS. No excess 
mortality among fathers was observed. The severe excess mortality justifies active screening 
of the mothers of PCOS patients to ensure that good preventive and therapeutic measures are 
taken timely. 
 Chapter 4 includes the results of three candidate gene analyses which aimed to identify 
PCOS susceptibility genes. For this approach, candidate genes were chosen based on prior 
knowledge of the function of the gene and its potential biological mechanisms underlying 
the disease. Since PCOS is associated with insulin resistance, genes involved in the insulin 
signalling pathway seem obvious PCOS candidate genes. In chapter 4.1, a thorough evaluation 
of nearly 300 genetic variants in 39 genes which are involved in the insulin signalling pathway 
was performed. At the discovery stage, 4 SNPs mapping to the insulin receptor gene (INSR) 
showed significant association with PCOS. One SNP, rs2252673, was associated with PCOS in 
the replication cohort, also after adjusting for BMI. This implies that the insulin receptor is 
involved in the etiology of PCOS. 
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Not only the ovary, but also the adrenal gland contributes to the androgen excess in PCOS, as 
reflected by elevated DHEAS levels. Chapter 4.2 concerns the possible mechanisms behind 
the heritability of DHEAS levels in PCOS patients and studies the genetic variations of the 
key enzymes regulating the level of DHEA sulfation. Although the candidate-gene study was 
appropriately powered, genetic variants mapping to the SULT2A1, PAPSS2 and STS genes were 
not associated with PCOS predisposition or with the clinical signs of PCOS. SNP rs2910397 
mapping to SULT2A1 was associated with a decrease in the DHEAS to DHEA ratio. Because 
PCOS is a complex genetic disorder, interaction of several genetic variants in genes encoding 
enzymes in the steroidogenesis might contribute to the variation in adrenal androgen levels 
in PCOS. 
 The third candidate-gene study studied BMI-associated risk alleles in association with 
PCOS. The relation between obesity and PCOS clearly exists. Obesity is a highly heritable 
trait and genome-wide association studies (GWASs) investigating BMI-loci have been very 
successful. Chapter 4.3 describes a combined analysis of over 4,000 BMI-matched individuals 
from the United Kingdom and the Netherlands. We observed no association with PCOS of 
BMI risk alleles mapping to BDNF, FAIM2, ETV5, FTO, GNPDA2, KCTD15, MC4R, MTCH2, NEGR1, 
SEC16B, SH2B1, and TMEM18. This suggests that there is no systematic effect of BMI-associated 
alleles on PCOS risk independent of BMI, suggesting that these alleles do not have a pleiotropic 
effect on PCOS susceptibility. Moreover, adjusting for BMI in PCOS case-control GWAS studies 
should be an effective strategy for removing confounding effects of BMI on the association of 
other genetic variants and PCOS.
 Obviously, candidate-gene selection is limited by incomplete knowledge of the 
pathophysiology of PCOS. By performing a hypothesis-free GWAS, one can overcome this 
limitation. Hitherto, two GWASs in Han-Chinese patients and one in Korean patients with PCOS 
have been published. Chapter 5 reports the preliminary results of a GWAS in patients with 
PCOS of Northern European ancestry. In GWASs > 1,000,000 common genetic variants (SNPs) 
are tested for an association with the disease without a prior knowledge about the potential 
effect of the variants or genes on the disease. Although this Northern European GWAS in 
patients with PCOS has revealed a number of new potentially interesting PCOS-associated 
loci, no genome-wide significant SNPs were detected. The strongest PCOS-associated SNP 
was rs11681377 on chromosome 2. However, this result should be interpreted with care. It is 
crucial that these variants are replicated in large independent samples of patients with PCOS 
and controls. The lack of power seems to be underlying the negative results of this GWAS. To 
overcome this issue, meta-analyses in a large consortium are crucial.
 Since it has been well established that ethnic background adds to phenotypic diversities in 
PCOS, it seems plausible that genetic variants associated with PCOS act differently in various 
ethnic populations. Chapter 6 describes a cross-ethnic meta-analysis of susceptibility loci for 
Han-Chinese PCOS patients in patients of Northern European descent. We studied the effects 
of genetic variants identified in Han-Chinese GWASs mapping to the LHCGR, THADA, DENND1A, 
FSHR, c9orf3, YAP1, RAB5B/SUOX, HMGA2, TOX3, INSR, SUMO1P1 loci in patients of Northern 
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European ancestry and assessed the cross-ethnic effect of the SNPs. Overall, we observed for 
12 out of 17 tested genetic variants mapping to the Chinese PCOS loci similar effect size and 
identical direction in PCOS patients of Northern European ancestry. Two variants even reached 
genome-wide significance level. This indicates a common genetic risk profile for PCOS across 
populations. Hence, it is expected that upcoming large GWASs in PCOS patients from Northern 
European ancestry will partly identify similar loci as the GWAS in Chinese PCOS patients.
 Usually in medical studies, including those on PCOS, ethnicity is assessed by self-reported 
data, either via interviews or obtained from medical records. Chapter 7 concludes that 
self-reported ethnicity is not a perfect proxy for genetic ancestry in patients with PCOS. To 
avoid false-positive associations because of misclassification, it is therefore advised to use 
genetic ancestry to correct for population admixture in genetic studies in patients with PCOS. 
Moreover, overall, a larger proportion of variation in phenotypic characteristics of PCOS is 
explained by genetic ancestry. This seems especially the case with insulin resistance.
 Finally, Chapter 8 places the results described in this thesis in wider context and discusses 
to which extent genetic studies in PCOS have contributed to unraveling its underlying 
mechanisms. Moreover it discusses potential implications for clinical practice and suggests 
future directions for research.
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Samenvatting
Het Polycysteus Ovarium Syndroom (PCOS) is de meest voorkomende endocriene (hormonale) 
aandoening bij vrouwen in de reproductieve (vruchtbare) levensfase. PCOS is een complex 
genetische aandoening. Bij complex genetische aandoeningen zijn genetische variaties 
betrokken bij het ontstaan van het ziektebeeld. Tijdens de reproductieve levensfase wordt 
PCOS gekenmerkt door anovulatie (het uitblijven van de eisprong), hyperandrogenisme 
(verhoogde waarden van mannelijk hormoon in het bloed) of hirsutisme (overbeharing) en 
polycysteuze ovaria (de aanwezigheid van veel kleine eiblaasjes in de eierstokken). Dit leidt bij 
het merendeel van de patiënten tot vruchtbaarheidsproblemen. Later in hun leven hebben zij 
een grotere kans op het ontwikkelen van insuline resistentie (ongevoeligheid voor insuline), 
type 2 diabetes mellitus (ouderdomssuikerziekte), en mogelijk ook hart- en vaatziekten. 
Het doel van dit proefschrift was het identificeren van genetische variaties die een rol spelen 
bij het ontstaan van PCOS. Ook worden voorspellers op het ontwikkelen van de lange termijn 
complicaties van PCOS beschreven. 
 Hoofdstuk 1 beschrijft de criteria op basis waarvan de diagnose PCOS gesteld wordt. Ook 
zijn mogelijke onderliggende biologische mechanismen van het ziektebeeld kort besproken. 
Verder is uitgelegd wat genetische variaties zijn en hoe deze het ontstaan van ziekten 
kunnen beïnvloeden. De meest voorkomende genetische variatie is het zogenaamde Single 
Nucleotide Polymorfisme (SNP), een enkelvoudige base-verandering in het DNA. Wanneer 
bepaalde SNPs vaker voorkomen bij patiënten dan bij individuen uit de algemene populatie, 
lijken deze geassocieerd met het ziektebeeld. 
 De aanwezigheid van specifieke symptomen van PCOS in de reproductieve levensfase lijken 
geassocieerd te zijn met een grotere kans op het ontstaan van complicaties op latere leeftijd. 
In hoofdstuk 2 is geanalyseerd of de aanwezigheid van hyperandrogenisme gerelateerd 
is aan een ongunstig metabool profiel. In totaal zijn 2278 patiënten uit twee academische 
ziekenhuizen geïncludeerd in deze studie. PCOS patiënten met hyperandrogenisme hadden 
inderdaad een meer ongunstig metabole uitkomst. Naast de hogere androgeen waarden 
hadden zij een grotere middelomtrek, een hogere Body Mass Index (BMI) en hogere insuline 
waarden. Bovendien vonden we – in vergelijking met PCOS patienten zonder hyper-
androgenisme – vaker overgewicht, insulineresistentie en het metabool syndroom (i.e. een 
combinatie van insulineresistentie, overgewicht, hoge bloeddruk, en verhoogd cholesterol). 
PCOS patiënten met hyperandrogenisme lijken dus een hoger risico te hebben op het ontstaan 
van lange termijn complicaties dan PCOS patiënten met normale androgeen waarden. 
Momenteel worden de patiënten prospectief vervolgd om te kunnen vaststellen of deze 
complicaties, zoals type 2 diabetes mellitus, hart- en vaatziekten en misschien zelfs mortaliteit, 
ook daadwerkelijk vaker optreden. Echter, om hier met zekerheid uitspraken over te kunnen 
doen, is nog jaren van vervolgonderzoek nodig. Om toch nu al meer inzicht te verkrijgen in 
het optreden van deze lange termijn complicaties, is in hoofdstuk 3 gebruik gemaakt van 
de erfelijke aard van het ziektebeeld. Middels een zogenoemde ‘reversed parent-offspring’ 
192 | Chapter 9
analyse hebben we de sterfte van ouders van PCOS patiënten geïnventariseerd. Moeders 
die ouder dan 60 jaar waren, lieten een significant grotere sterfte zien in vergelijking met de 
sterfte in de algemene Nederlandse bevolking. Bovendien hadden de moeders die leden aan 
type 2 diabetes mellitus een twee keer zo hoog sterfterisico dan vrouwen met type 2 diabetes 
uit de algemene – dus niet via PCOS geselecteerde - populatie. Deze ernstige oversterfte 
rechtvaardigt screening van de moeders van PCOS patiënten zodat de juiste preventieve en 
therapeutische maatregelen tijdig genomen kunnen worden.
 Hoofdstuk 4 beschrijft een drietal kandidaat-gen studies. Bij kandidaat-gen onderzoek 
worden genen geselecteerd die mogelijk een rol kunnen spelen bij het ontstaan van PCOS. 
Deze selectie wordt gebaseerd op reeds aanwezige kennis over het ziektebeeld. Vervolgens 
wordt getest of genetische variaties (SNPs) in deze genen vaker voorkomen bij PCOS patiënten 
dan bij controle-vrouwen uit de algemene populatie. Wanneer dit het geval is, lijken deze 
variaties dus een rol te spelen bij het ontstaan van PCOS. 
 Aangezien patiënten met PCOS vaker ongevoelig zijn voor insuline, zijn genen betrokken 
in de insuline signaaltransductie route voor de hand liggende kandidaat-genen voor PCOS. Bij 
signaaltransductie wordt een signaal (zoals verhoging van de insuline spiegels in het bloed na 
het eten van een maaltijd) herkend door de cel en dit heeft specifieke veranderingen in die 
cel tot gevolg (zoals stimulatie van de glucose opname in bijvoorbeeld de spieren). Wanneer 
de insuline signaaltransductie niet naar behoren functioneert, zou dat insuline resistentie en 
hogere insuline waarden in het bloed, zoals bij PCOS het geval is, kunnen verklaren. Hoofdstuk 
4.1 laat zien dat een SNP in de insuline receptor inderdaad vaker voorkomt bij patiënten 
met PCOS dan bij de controlegroep. Dit was niet het geval voor andere bekende genetische 
variaties die betrokken zijn bij de insuline signaaltransductie. De aangetoonde associatie is 
een sterke aanwijzing dat de insuline receptor betrokken is bij de etiologie van PCOS.
 Bij PCOS is er niet alleen sprake van een verhoogde androgeen productie vanuit het 
ovarium, maar er is ook een toegenomen androgeen productie vanuit de bijnier. PCOS 
patiënten en hun familieleden hebben verhoogde DHEAS waarden in het bloed. DHEAS 
wordt exclusief door de bijnier geproduceerd en kan worden omgezet in DHEA. DHEA is een 
voorloper van de actieve mannelijke hormonen in het bloed, zoals testosteron. In hoofdstuk 
4.2 is getest of variaties in genen die belangrijk zijn voor de omzetting van DHEAS naar DHEA 
en andersom (namelijk SULT2A1, PAPSS2 en STS), vaker voorkomen bij PCOS patiënten dan bij 
de controlegroep. Ook is de associatie van deze genetische variaties met de variabiliteit van 
de androgeen waarden bij PCOS patiënten bestudeerd. Er werd geen associatie gevonden 
tussen de genetische variaties in SULT2A1, PAPSS2 en STS en de aanwezigheid van PCOS. SNP 
rs2910397 in SULT2A1 was geassocieerd met een lagere DHEAS/DHEA ratio, maar beïnvloedde 
het androgene fenotype van PCOS niet. Aangezien PCOS een complex genetische aandoening 
is, lijkt het waarschijnlijk dat een interactie tussen verscheidene genetische varianten in genen 
die belangrijk zijn bij de productie van androgenen kan bijdragen aan de variatie in androgeen 
waarden in PCOS.
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De derde kandidaat-gen studie richt zich op genetische variaties die geassocieerd zijn met 
BMI. Grote genetische studies in de algemene bevolking hebben veel BMI-geassocieerde 
genetische variaties geïdentificeerd. Omdat het merendeel van de patiënten met PCOS 
overgewicht heeft, is het aannemelijk dat deze BMI-geassocieerde genetische variaties vaker 
voorkomen bij patiënten met PCOS. Eerdere studies hebben aangetoond dat dit het geval 
lijkt. Echter, na correctie voor het verschil in BMI tussen de PCOS patiënten en controlegroep, 
lijkt deze associatie te verdwijnen. Hoofdstuk 4.3 beschrijft een gecombineerde analyse 
van ruim 4.000 PCOS patiënten en controles uit Nederland en het Verenigd Koninkrijk. De 
patiënten en controlegroep hadden een vergelijkbaar BMI om te voorkomen dat het verschil 
in BMI de resultaten zou beïnvloeden. De bestudeerde BMI-geassocieerde genetische variaties 
kwamen net zo vaak voor in beide groepen. Dit suggereert dat deze genetische variaties niet 
geassocieerd zijn met PCOS wanneer er rekening wordt gehouden met BMI. 
 Vanzelfsprekend wordt kandidaat-gen selectie beperkt door de onvolledige kennis van 
de onderliggende biologische mechanismes van PCOS. Bij een hypothese-vrije genoomwijde 
associatie studie (GWAS) is dit niet het geval. Tot nu toe zijn er twee GWASs in PCOS patiënten van 
Chinese afkomst verschenen en één GWAS in Koreaanse patiënten. Hoofdstuk 5 rapporteert 
de voorlopige resultaten van de GWAS studie in PCOS patiënten van Europese afkomst. In 
een GWAS worden meer dan 1.000.000 veelvoorkomende genetische variaties in het humane 
DNA getest in associatie met het ziektebeeld, zonder dat er op voorhand een hypothese is 
over mogelijke effecten van deze genetische variaties of genen op het ziektebeeld. Hoewel 
er geen genoomwijd significant geassocieerde SNPs werden gevonden, waren er wel een 
aantal SNPs suggestief voor associatie met PCOS. SNP rs11681377 op chromosoom 2 was 
het sterkst geassocieerd met PCOS. Echter, alvorens harde conclusies te kunnen trekken uit 
deze voorlopige resultaten is het van wezenlijk belang om deze SNPs in een groter cohort te 
repliceren. Zeer waarschijnlijk zijn grotere aantallen patiënten nodig om de kleine effecten 
van SNPs te kunnen signaleren in deze GWAS setting. Daarom is samenwerking binnen een 
groot PCOS consortium essentieel. 
 De etnische achtergrond van patiënten is van invloed op de ernst van de PCOS symptomen. 
PCOS patiënten van mediterrane afkomst hebben vaker hirsutisme dan Europese patiënten. 
Patiënten van Hindoestaanse afkomst hebben frequenter insuline resistentie dan patiënten 
van andere etnische achtergronden. Het lijkt daarom plausibel dat genetische variaties die met 
PCOS geassocieerd zijn, een verschillend effect kunnen hebben op het fenotype van patiënten 
van verschillende etnische afkomst. In hoofdstuk 6 worden de effecten van de genetische 
varianten die geïdentificeerd zijn in de GWAS in Chinese patiënten, bestudeerd in een groep 
patiënten met PCOS van Europese afkomst. Deze gecombineerde analyse laat zien dat 12 van 
de 17 geteste genetische varianten een effect van dezelfde grootte en in dezelfde richting 
hebben als in de Chinese studie. Dit duidt op een gemeenschappelijk genetisch risicoprofiel 
voor PCOS patiënten van verschillende etnische achtergrond. Het is dan ook de verwachting 
dat de grote PCOS GWAS in patiënten van Europese afkomst voor een deel dezelfde gebieden 
zal identificeren als de GWASs in Chinese PCOS patiënten hebben gedaan.
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Voor de bepaling van de etnische achtergrond van patiënten worden in medische studies 
meestal anamnestisch verkregen gegevens of gegevens uit het medisch dossier gebruikt. 
Hoofdstuk 7 laat zien dat de zelf-gerapporteerde etnische achtergrond geen perfecte maat is 
voor de genetische etnische afkomst van de patiënten met PCOS. Misclassificatie op basis van 
zelf-gerapporteerde etniciteit kan tot vals-positieve associaties leiden. Om deze vals-positieve 
associaties te voorkomen, zou het gebruik van de genetisch etnische afkomst de voorkeur 
hebben. Bovendien bepaalt deze genetische afkomst een groter deel van de variatie in de 
uiterlijke kenmerken van PCOS. Dit lijkt met name bij insulineresistentie het geval.
 Tenslotte plaatst hoofdstuk 8 de beschreven resultaten uit dit proefschrift in breder 
perspectief en bediscussieert het hoe genetische studies hebben bijgedragen aan het 
ontrafelen van onderliggende biologische mechanismen van PCOS. Ook worden mogelijke 
implicaties voor de klinische praktijk besproken en richtingen voor vervolgonderzoek 
gesuggereerd.
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11β-HSD 11β-hydroxysteroid 
dehydrogenase 
3β-HSD 3β-hydroxysteroid 
dehydrogenase 
Adion Androstenedione
AE Androgen Excess
AES Androgen Excess and PCOS 
Society
AMH Anti-Müllerian Hormone 
ASRM American Society of 
Reproductive Medicine
BMI Body Mass Index
BP Blood Pressure
Chr Chromosome
CI Confidence Interval
CVD Cardiovascular Disease
CVRF Cardiovascular Risk Factors 
DHEA Dehydroepiandrosterone
DHEAS Dehydroepiandrosterone-sulfate
DM2 Type 2 Diabetes Mellitus
DNA DeoxyriboNucleic Acid
E2 Estradiol
ESHRE European Society of 
Reproductive Medicine
FAI Free Androgen Index
FG Ferriman Gallway Score
FSH Follicle-stimulating Hormone
GnRH Gonadotropin-Releasing 
Hormone
GRS Genetic Risk Score
GSK-3b glycogen synthase kinase 3b 
GWAS Genome-Wide Association Study 
gws genome-wide significant
h2 Heritability
HA Hyperandrogenemia
HDL High Density Lipoprotein
HOMA Homeostasis Model Assessment 
I2 Heterogeneity
IQR Interquartile Range
IR Insulin Resistance
LC-MS/MS Liquid Chromatography–Tandem 
Mass Spectrometry
LD Linkage Disequilibrium
LDL Low Density Lipoprotein
LH Luteinizing Hormone 
MAF Minor Allele Frequency
MBS Metabolic Syndrome
n number
NA not available
NGS Next Generation Sequencing
NIH National Institutes of Health
NTR Netherlands Twin Registry
OCP Oral Contraceptive Pill
OD Ovulatory Dysfunction
OR Odds Ratio
P P-value
PCOM Polycystic Ovarian Morphology
PCOS Polycystic Ovary Syndrome
PYRS Person Years
QQ-plot Quantile Quantile plot
RIA Radio-Immuno Assay
RNA RiboNucleic Acid 
RR Relative Risk
SHBG Sex-Hormone Binding Globulin 
SMR Standardized Mortality Ratio 
SNP Single Nucleotide Polymorphism
T testosterone
TC Total Cholesterol
TG triglycerides 
UK United Kingdom
US United States of America
VNTR Variable Number of Tandem 
Repeats
WC Waist Circumference
WHR Waist-Hip Ratio
ZODIAC Zwolle Outpatient Diabetes 
Project Integrating Available 
Care 
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List of gene name abbreviations
ACTR2 Actin-Related protein 2 
homolog
AR Androgen Receptor
BDNF brain-derived neurotrophic 
factor
C14orf177 chromosome 14 open reading 
frame 177
C14orf64 chromosome 14 open reading 
frame 64
C15orf54 chromosome 15 open reading 
frame 54
C9orf3 chromosome 9 open reading 
frame 3
CAPZA3 capping protein (actin 
filament) muscle Z-line, alpha 3
CHRM2 cholinergic receptor, 
muscarinic 2
CYP17 cytochrome P450, family 17 
CYP19 cytochrome P450, family 19 
CYP3A7 cytochrome P450, family 3, 
subfamily A, polypeptide 7
DEK DEK oncogene
DENND1A DENN domain-containing 
protein 1A
DPP10 dipeptidyl-peptidase 10
DRD2 dopamine receptor D2
EML6 echinoderm microtubule 
associated protein like 6
ETV5 ets variant 5
FAIM2 Fas apoptotic inhibitory 
molecule 2
FBN3 fibrillin 
FSHR follicle-stimulating hormone 
receptor
FTO fat mass and obesity associated
GATA4 GATA binding protein 4
GNPDA2 glucosamine-6-phosphate 
deaminase 2
GTF2A1L general transcription factor IIA, 
1-like
HMGA2 high mobility group AT-hook 2
HSD11B1 11-beta hydroxysteroid 
dehydrogenase 
ID4 inhibitor of DNA binding 4, 
dominant negative helix-loop-
helix protein
INSR Insulin receptor
IRS2 insulin receptor substrate 2
IYD iodotyrosine deiodinase
KCTD15 potassium channel 
tetramerization domain 
containing 15
LHCGR luteinizing hormone / 
choriogonadotropin receptor
MC4R melanocortin 4 receptor
MKX mohawk homeobox
MTCH2 mitochondrial carrier 2
NEGR1 neuronal growth regulator 1
OLFML2B olfactomedin-like 2B
PAPSS2 3-phosphoadenosine 
5-phospho sulfate synthase 
isoform 2 
PPP1R14C protein phosphatase 1, 
regulatory (inhibitor) subunit 
14C
RAB1A Ras-related in Brain type 1A 
RAB5B RAB5B, member RAS oncogene 
family
RBFOX1 RNA binding protein, fox-1 
homolog (C. elegans) 1
RPL7P6 ribosomal protein L7 
pseudogene 6
SEC16B SEC16 homolog B (S. cerevisiae)
SH2B1 SH2B adaptor protein 1
SHBG Sex Hormone Binding Globulin
STS steroid sulfatase 
SULT2A1 sulfotransferase 2A1
SUMO1P1 SUMO1 pseudogene 1
SUOX sulfite oxidase
THADA thyroid adenoma associated
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THBS1 thrombospondin 1
TMEM18 transmembrane protein 18
TMPRSS5 transmembrane protease, 
serine 5
TOX3 TOX high mobility group box 
family member 3
YAP1 Yes-associated protein 1
ZNF217 zinc finger protein 217
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consortium. Ik wil je voor alle steun de afgelopen jaren heel hartelijk bedanken. Ik had me 
geen betere promotor kunnen wensen!
Geachte professor Uitterlinden, beste André, vanaf het begin bent u betrokken geweest bij 
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komt kijken bij internationale samenwerking, hebben mij veel geleerd. Na de maandelijkse 
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prettige samenwerking en uw motiverende en stimulerende interesse zijn heel waardevol 
voor mij geweest. Ik ben dan ook heel dankbaar dat ook u mijn promotor bent.
Beste dr. Stolk, beste Lisette, geen héééééle lange mails meer, het is klaar! Toen ik begon 
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altijd tijd maakte als ik – al dan niet in combinatie met plink, putty, R, metal, BCSNPmax of 
GRIMP – vastliep. Wat was het leuk om David en jullie op komst zijnde kleine in de 3D sneak 
preview te zien! Ik ben heel blij dat je mijn copromotor bent!
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nemen in de leescommissie. Beste professor De Jong, wat heb ik ongelofelijk veel van u geleerd 
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I also like to thank the other members of my committee. Dear professor Franks, thank you for 
coming to the Netherlands to be part of my committee, I very much appreciate that. Dear 
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interesse in en meedenken over mijn projecten, ik heb dat altijd zeer gewaardeerd! Fijn dat u 
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Beste co-auteurs, bedankt voor de fijne samenwerking en alle hulp en waardevolle feedback 
op de artikelen in dit proefschrift. Dear co-authors, thank you so much for contributing to 
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collaboration.
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Esther, Godfried, Pauline, Berthe, Jenny, Hjalmar, Elisabeth, Nicole, Sofie, Jolanda, Lizka, 
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Dat gezamenlijke artikel gaat er zeker komen! Remko, Beate, Simone, Kris en anderen van 
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onmisbaar tijdens mijn promotietraject! Bedankt!
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Dear members of the genetic work discussion group, thank you for your feedback during the 
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want to thank you for all your help with the genetic ancestry paper. 
Dear members of the PCOS genetics consortium, I’m very excited that the consortium is really 
coming together! Thank you so much for your collaboration. I feel privileged to be part of this 
consortium and I can’t wait for the first results.
En natuurlijk verdienen mijn collega’s uit Utrecht een plek in dit dankwoord. Lieve Femi, 
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Lieve Sharon, Lindy, Annelinde, Mariëlle, Olivier en Wendy, wat was Hs508 een geweldige 
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weet eigenlijk wel zeker!) dat het blijft lukken om elkaar regelmatig te zien en bij te praten. 
En natuurlijk wil ik andere alle (oud)-mede-onderzoekers – Nicole, Melek, Evelyne, Kim, Emilie, 
Bas, Marit, Jennifer, Leonie, Ruben, Sam, Hein, Robbert, Annelien, Nienke, Manon, Babette, 
John, Marieke, Zoe, Averil, Nina, Pauline, Charlotte, Irene, Caroline, Jinke, Sylvia, Claudia, 
Jashvant, Babs, Marijana, Sabine, Anke, Amber, Chantal, Sevilay, Maria, Matthijs, Sarah en 
Fatima… de lijst wordt steeds langer – heel erg bedanken voor jullie interesse en natuurlijk 
ook de gezellige koffies, lunches en borrels. Succes met jullie onderzoek en carrière. Lieve 
Christine, die gezellige etentjes (Istanbul, Rotterdam, Delft, Eindhoven de gekste, Ede?) 
houden we erin! Jeroen, mede-kantoortuin-genoot, hoe moet dat straks met het gat in mijn 
ontwikkeling? Enne, vanaf nu valt de plant onder jouw verantwoordelijkheid!
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Lieve Wendy, onze promotietrajecten zijn heel erg gelijk opgegaan. En hoe leuk is het dat we 
nu vlak na elkaar promoveren en met de opleiding starten. Ik wil je bedanken voor je steun, 
betrokkenheid en de gezelligheid! Begonnen als collega’s, geëindigd als vrienden, beter kan 
niet. Ik ben heel blij dat je straks als paranimf naast me staat. 
Om op het werk goed te kunnen presteren, is ontspanning met familie en vrienden natuurlijk 
belangrijk. Indirect hebben zij dan ook zeker bijgedragen aan dit proefschrift. Lieve Mirjam, 
Jennifer, Denise, Petra, Ellen, Vanessa en Robbert, wat ooit begonnen is als samen korfballen, 
is uitgegroeid tot vriendschap. En ook al zien we elkaar niet meer iedere week (en eigenlijk 
gewoon veel te weinig!!), ik hecht heel veel waarde aan onze vriendschap. Lieve Debby, ik heb 
je gemist bij het fietsen afgelopen jaar, maar gelukkig zijn daar etentjes en drankjes drinken 
voor in de plaats gekomen. Misschien minder sportief, maar net zo gezellig! Lieve Karin, 
wanneer gaat er gekookt worden in je nieuwe keuken? Lieve Irene, jammer dat je er niet bij 
kunt zijn vandaag, maar we kletsen snel bij. Leo, Nathalie en Michael, er zit weer een soort van 
regelmaat in onze dates! Ik zou het heel leuk vinden als we dat vol kunnen houden.
Lieve Jo en Ray, de weekendjes weg, etentjes, tochten met de racefiets of mountainbike en 
natuurlijk de geweldige reizen samen zijn een feestje! Ik ben heel blij met jullie! Wanneer gaan 
we weer?
Lieve familie Verheezen – Van der Kruk, vanaf het eerste moment dat ik bij jullie over de vloer 
kwam heb ik me helemaal thuis gevoeld. Ik kan me geen fijnere schoonfamilie wensen! Lieve 
Laris, wat leuk om er een schoon-nicht (bestaat dat?) bij te hebben!! Heel fijn dat je lekker in 
Delft blijft wonen! Lieve Nika en Senne, komen jullie snel weer logeren?
Ik ken maar weinig families die waterpistool-gevechten houden en ieder jaar dezelfde 
sinterklaas foto maken… wat is het boffen dat ik nu juist zo’n familie getroffen heb! Lieve Dick 
en Anja, Marc en Nienke, Leanne en Jeroen, lieve tante Hilly en Leo: met elkaar meeleven is 
als vanzelfsprekend, en dat is heel bijzonder en waardevol. Lieve Frans en Marian, we fietsen 
snel weer langs!
Lieve Karin, zus en paranimf, ik denk nog vaak terug aan onze Malawi reis, wat was dat 
geweldig om samen meegemaakt te hebben. Werk, studie, korfbal en nog veel meer, het is 
ongelofelijk hoe jij alle ballen in de lucht weet te houden en steeds nieuwe uitdagingen ziet. 
Ik ben hartstikke trots op je en ben heel blij dat je als paranimf naast me staat. Lieve Marcel, 
hoe jij al je bezigheden weet te combineren zonder iets half te doen (zouden jullie daarom zo 
goed bij elkaar passen?), vind ik ongelofelijk knap. En je staat altijd klaar wanneer dat nodig is, 
je bent een top zwager!
Lieve pap en mam, dank voor jullie onvoorwaardelijke steun, meeleven en meedenken. Ik kan 
altijd bij jullie terecht en zonder jullie was ik niet geweest wie ik nu ben. Hou van jullie!
Lieve Amanda, soms weet je meteen dat iets goed zit. Wat vullen we elkaar goed aan en wat 
hebben we het leuk! Op naar nog heel veel meer mooie jaren samen! x
Yvonne
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